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Abstract 
 
The immunosuppressive molecule PD-L1 is upregulated in many cancers 
and contributes to evasion of the host immune system. Recent clinical trials 
of immunotherapies in cancer using antibodies targeting PD-L1 and its 
receptor PD-1 have led to promising responses in a subset of patients. These 
results emphasise the pressing need for biomarkers of patient response and 
means to increase the number of patients that benefit from these 
immunotherapies. One potential biomarker is PD-L1 on tumour cells, 
although the relative importance of the tumour microenvironment and cell-
intrinsic signalling in the regulation of PD-L1 expression remains unclear. The 
use of physiological, genetically engineered mouse models (GEMMs) of 
human cancer may accelerate the preclinical development of 
immunotherapies targeting complex cancer-host interactions and improve our 
understanding of the regulation of PD-L1 in cancer. 
 
Here, we discover that widely used, autochthonous GEMMs of Ras-driven 
lung cancer are poorly immunogenic and refractory to immunotherapies, 
questioning their disease-relevance and suitability for the preclinical study of 
immunotherapies in their current form. In addition, we investigate the 
molecular basis of tumour cell PD-L1 expression in lung cancer. We report 
that oncogenic RAS signalling is sufficient to upregulate tumour cell PD-L1 
expression. Mechanistically, RAS signalling increases PD-L1 mRNA stability 
by modulating the AU-rich element-binding protein tristetraprolin (TTP). TTP 
negatively regulates PD-L1 expression through AU-rich elements in the 
3’UTR of PD-L1 mRNA. In human and mouse lung cancer, TTP expression is 
reduced and its restoration in tumour cells enhances anti-tumour immunity. 
Our findings have implications for the interpretation of tumour PD-L1 
expression as a biomarker for patient response to immunotherapies, and 
suggest a role for oncogenic RAS signalling in immune evasion. 
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1 Chapter 1. Introduction 
 
1.1 Overview 
 
An emerging hallmark of cancer is successful evasion of the host immune 
system (Hanahan and Weinberg, 2011). Fundamentally, cancer immunology 
is defined by our understanding of the process of cancer 
immunosurveillance; the detection and elimination of malignant cells by the 
immune system. This concept was first proposed in the 1950s (Burnet, 
1957)(Thomas, 1959). Historically, the concept of host immunity as an 
extrinsic tumour suppressor has been controversial. We now have 
overwhelming evidence that cancer immunosurveillance occurs in mice and 
humans, but is inevitably countered by a fraction of tumour cells through 
innate and evolved subversion strategies, resulting in cancer. 
 
At this time, there is a renewed interest in the field of cancer immunology and 
a collective realisation that there is considerable therapeutic potential in re-
establishing anti-tumour immunity. Genetically engineered mouse models 
(GEMMs) have been instrumental in the renaissance of the cancer 
immunosurveillance hypothesis and are an invaluable tool for studying 
reciprocal interactions between the host and cancer cells (Dunn et al., 2002). 
Studies in genetically engineered mice have elaborated the function of 
several immune checkpoint molecules, the general function of which is to 
maintain homeostasis and prevent autoimmunity following stimulation of an 
immune response. However, these immune system checkpoints are often 
dysregulated and exploited in cancer to avoid immune destruction. Recently, 
there has been an emphasis on targeting these molecules with antibodies in 
cancer to block inhibitory signalling from immune checkpoint pathways. Such 
immunotherapy approaches are often referred to as immune checkpoint 
blockade (ICB).  
 
Chapter 1. Introduction 
 22 
An important value of stimulating an anti-tumour immune response is that the 
immune system can co-evolve with the tumour, and the resulting regressions 
can be durable, giving immunotherapies a unique advantage over 
chemotherapies and targeted therapies. Indeed, there have been striking 
anti-tumour responses reported from clinical trials of immune checkpoint 
blockade in multiple tumour types, including in some of the most difficult to 
treat and deadly cancers such as non-small cell lung cancer (NSCLC) and 
metastatic melanoma. Currently, only a small fraction of cancer patients 
respond to these immunotherapies, making patient stratification using reliable 
biomarkers crucial.  
 
Programmed death-1 ligand-1 (PD-L1, also known as B7-H1 or CD274) is a 
notable immune checkpoint molecule that has been successfully targeted in 
the clinic, and will be the major focus of this thesis. Although PD-L1 is known 
to be upregulated in many cancers, the regulation of the expression of this 
molecule remains poorly defined. Currently, there is increasing interest in 
PD-L1 as a biomarker for response to immunotherapies and so the need to 
further understand the regulation of this molecule is greater than ever. 
 
1.2 Immune checkpoints 
 
1.2.1 Co-signalling 
 
An adaptive immune response requires antigen-specific T cell receptor (TCR) 
or B cell receptor (BCR) engagement by their cognate antigens. However, 
this alone is not sufficient to stimulate lymphocyte effector function. Co-
signalling in parallel with TCR or BCR signalling adds an extra-level of control 
to the adaptive immune response, making the decision to react context-
dependent. Co-signalling is not antigen specific and can activate, or inhibit, 
lymphocyte activity; so-called co-stimulation or co-inhibition, respectively. 
Collectively, this relates to the two-signal model that was first proposed by 
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Bretscher and Cohn in 1970. Here, signal one refers to the antigen-specific 
activation through the TCR or BCR, and signal two refers to input derived 
from co-stimulatory molecules. Given the dual dependence on context and 
cognate antigen, the two-signal system can prevent chronic and self-
destructive activation of adaptive immunity. This is especially important in 
regulating the response to antigens that persist for long periods of time. 
Hence, co-stimulation or co-inhibition is implicated in disease situations such 
as chronic infection, auto-immunity and cancer. Since cancer cells do not 
express co-stimulatory molecules and thus cannot provide co-stimulation 
themselves (with the possible exception of some lymphomas), anti-tumour 
adaptive immune responses first require priming by antigen-presenting cells 
(APCs). This occurs through a process called cross-presentation, whereby 
APCs present antigens not expressed by the APC itself, but acquired through 
phagocytosis or endocytosis. The immunological synapse between the T cell 
and APC represents the interface between the innate and adaptive immune 
system (Figure 1.1). 
 
Formal proof of the two-signal model came from work by Jenkins and others 
demonstrating that TCR stimulation alone led to T cell unresponsiveness, but 
stimulation with an anti-CD28 antibody could lead to T cell activation, even in 
the absence of accessory cells (Jenkins et al., 1988; Jenkins et al., 1991). 
Presently, co-signalling through CD28 is the most extensively studied 
example of co-stimulation. CD28 on T cells can interact with CD80 (B7.1) or 
CD86 (B7.2) on APCs (Figure 1.1). Only MHC-antigen engagement with the 
TCR in combination with CD28 co-signalling will initiate T cell activation.  
 
One mechanism of terminating or dampening the resulting immune response 
against a specific antigen operates through the immunosuppressive molecule 
cytotoxic T-lymphocyte-associated protein-4 (CTLA-4). CTLA-4 was the first 
described example of a co-inhibitory molecule. CTLA-4 exerts its negative 
functions on T cell activity by competing with CD28 for binding to CD80/CD86 
(Walunas et al., 1994). In addition, CTLA-4 engagement appears to reverse 
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TCR and CD28-mediated T cell activation through the recruitment of 
phosphatases including PP2A and possibly SHP-2 (Chuang et al., 2000; 
Marengere, 1997). Importantly, the “off” signal from CTLA-4 appears to be 
dominant, as CTLA-4’s binding affinity for CD80 is much higher than that of 
the activating ligand, CD28 (Linsley, 1995; vanderMerwe et al., 1997). 
Indeed, the powerful inhibitory effect of CTLA-4 function was functionally 
demonstrated in Ctla-4 KO mice. Within 3-4 weeks from birth, Ctla-4-deficient 
mice die from a severe inflammatory disorder related to excessive 
lymphoproliferation (Tivol et al., 1995; Waterhouse et al., 1995).  
 
 
 
Figure 1.1 Co-signalling in T cell activation 
Common co-stimulatory and co-inhibitory signals in the regulation of a T cell 
response. Co-stimulatory molecules are in green and co-inhibitory molecules 
are in red. The APC presents a processed antigen peptide via MHC class II. 
In all situations depicted, signal one is present, but the presence or absence 
of signal two ultimately determines T cell activity. The PD-1/PD-L1 interaction 
is also functional in tumour cells, as the tumour cell can present antigens via 
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MHC class I. Only in the CD80-CD28 engagement situation presented does 
productive T cell activation take place. In the case of CTLA-4, CD28 is 
outcompeted by CTLA-4 for CD80 or CD86 binding.  
APC, antigen presenting cell. MHCII, major histocompatibility complex class 
II. TCR, T cell receptor. 
 
1.2.2  PD-1 biology 
 
After the initial discovery of CTLA-4 as an immune checkpoint molecule, the 
search began for related co-inhibitory molecules within the immunoglobulin 
superfamily. The Honjo group first identified programmed death-1 (PD-1) in 
1992 in a T cell hybridoma undergoing cell death induced by acute 
stimulation with PMA and ionomycin (Ishida et al., 1992). PD-1 is a 
membrane-bound receptor of the CD28 superfamily and harbours an internal 
immunoreceptor tyrosine inhibitory motif (ITIM) and an immunoreceptor 
tyrosine switch motif (ITSM). Reminiscent of CTLA-4, PD-1 engagement by 
its ligand PD-L1, has an immunosuppressive effect on T cell activity 
(Freeman et al., 2000). In an analogous fashion, PD-1 is upregulated on T 
cells following activation and thus serves to inhibit excessive or inappropriate 
activation of the immune system. Mechanistically, PD-1 receptor engagement 
leads to activation of the phosphatase SHP-2, which binds to the ITSM of 
PD-1 and suppresses the activation of Akt downstream of CD28 and PI3K 
signalling (Chemnitz et al., 2004; Parry et al., 2005) (Figure 1.2). This 
culminates in reduced T cell proliferation, reduced cytokine synthesis and 
changes in T cell metabolism involving reductions in glycolytic capacity. 
Surprisingly, PD-1 expression has recently been described on a minor subset 
of melanoma cells in mice and human tumours (Kleffel et al., 2015). Here, 
PD-1 expression was found to promote tumorigenesis even in the absence of 
adaptive immunity, apparently involving cell-intrinsic stimulation of the mTOR 
pathway and upregulation of S6 phosphorylation following PD-L1 
engagement. The starkly opposing effects of PD-1 activation on cell 
proliferation in melanoma cells and T cells warrants further investigation, but 
may involve tissue-specific differences in the role of SHP-2. 
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1.2.3 PD-L1 biology 
 
The primary ligand for PD-1, programmed death-1 ligand-1 (PD-L1) was 
discovered in 2000 (Freeman et al., 2000). PD-L1 is a member of the B7 
superfamily of proteins, and was first identified as a PD-1 ligand by database 
searching for B7-related proteins, due to the structural similarities between 
CTLA-4 and PD-1. However, unlike CD80, CD86 and CD28, PD-L1 is 
expressed on non-lymphoid tissues as well as haematopoietic cells. 
Specifically, PD-L1 is expressed on T and B cells, APCs such as dendritic 
cells and macrophages, as well as heart, pancreas (β cells), lung, kidney, 
vascular endothelium, corneal endothelium and placental tissues, and in a 
multitude of cancers (Keir et al., 2008). Crucially, PD-L1 expression on non-
lymphoid tissues allows for peripheral control of T cell activity, preventing 
autoimmune mediated tissue damage. This is a key difference to the 
checkpoint mediated by CTLA-4, which exercises control at the earlier stage 
of T cell priming. In support of this, Pd-1-deficient mice have a milder 
phenotype and live significantly longer than Ctla-4-deficient mice (Nishimura 
et al., 1998; Nishimura et al., 1999). However, there are reports that PD-1 
signalling can also determine the initial fate decisions of CD8 T cells in some 
contexts (Goldberg et al., 2007), but is unlikely to be as critical as CTLA-4 at 
this early stage. 
 
Since the discovery of PD-L1 in 2000, a second ligand for PD-1 has been 
identified, PD-L2 (Latchman et al., 2001), which has a more restricted tissue 
expression than PD-L1 as it is predominantly expressed by dendritic cells. 
Although IFN-γ induces expression of both PD-1 ligands, PD-L2 is more 
potently induced in response to IL-4 and GM-CSF, indicating significant 
differences in regulation of gene expression (Topalian et al., 2015). 
Presently, the function of PD-L2 is poorly understood. However, not 
dissimilar to PD-L1, PD-L2 seems to be directly involved in inhibiting T cell 
activation through ligation of PD-1 (Latchman et al., 2001). Although PD-L2 is 
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upregulated in several cancers (notably B cell lymphomas), these tend to be 
cases where there have been amplifications or genetic rearrangements of the 
genetic locus encoding both PD-L1 and PD-L2, as these genes are in very 
close proximity. Indeed, they are likely to have arisen from a gene duplication 
event. Therefore, it is difficult to conclude whether PD-L2 alone plays a 
significant role in cancer progression. 
 
The generation of the first PD-L1 knock-out (KO) mice by Arlene Sharpe and 
colleagues provided definitive insights into the function of PD-L1 in vivo 
(Latchman et al., 2004). PD-L1-deficient mice displayed more robust CD4 
and CD8 T cell responses, indicating that PD-L1 served as a negative 
regulator of the adaptive immune response. This evidence was consistent 
with the phenotype of PD-1 KO mice, which have enhanced CD8 T cell 
autoreactivity (Keir et al., 2007). Moreover, expression of PD-1 and PD-L1 on 
T and B cells is closely linked to stimulation. Thus, activation-induced 
expression allows the PD-1 pathway to function as a rapid homeostatic 
mechanism for limiting autoimmunity. Testing the potential therapeutic value 
of reversing PD-1 signalling was not initially performed in the context of 
cancer, but in chronic infection. Pivotal experiments from Rafi Ahmed and 
colleagues revealed that administration of anti-PD-L1 antibodies to mice 
suffering from chronic lymphocytic choriomeningitis virus (LCMV) infections 
significantly reduced viral load by re-stimulating the exhausted anti-viral T cell 
population (Barber et al., 2006).  
 
Surprisingly, in addition to its conventional role of signalling through PD-1, 
PD-L1 has been shown to signal internally into the cell expressing PD-L1. 
This unconventional, reverse signalling through PD-L1 requires PD-L1 
binding to CD80 (Butte et al., 2007). Sophisticated genetic experiments 
revealed that T cells deficient for CD28 and CTLA-4 were still functionally 
inhibited by CD80, whereas CD28, CTLA-4, PD-L1 triple-deficient T cells 
were unaffected. The molecular nature of the resulting signal remains 
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unclear, as the short cytoplasmic tail of PD-L1 does not contain known motifs 
for downstream signal transduction. 
 
Crucially, PD-L1 expression on the surface of tumour cells can prevent anti-
tumour immunity by decreasing T cell effector function and T cell proliferation 
(Blank et al., 2004; Freeman et al., 2000), as well as promoting anti-tumour T 
cell apoptosis (Dong et al., 2002), at least partly through reduced expression 
of the anti-apoptotic protein Bcl-xL (Parry et al., 2005)(Figure 1.2). 
Interestingly, PD-1 has apparently opposing effects on regulatory T cells (T 
regs). PD-1 activation promotes the development or induction of Tregs, which 
seems to depend on the downregulation of the PI3K-AKT-mTOR pathway by 
PD-1 (Francisco et al., 2009) (Figure 1.2). This is consistent with the high 
level of PD-L1 expression commonly found on Treg populations. 
 
 
 
Figure 1.2 Attenuation of anti-tumour T cell effector function through 
PD-1 signalling 
Engagement of the TCR by the MHC in complex with cognate antigen 
stimulates the tyrosine kinase Lck. This process also requires 
dephosphorylation of Lck at inhibitory sites by CD45 at the cell membrane. 
Activated Lck phosphorylates tyrosines on CD3 chains. Phosphorylated CD3 
ζ serve as docking sites for the tyrosine kinase ZAP70. Once activated, 
ZAP70 phosphorylates the transmembrane signalling scaffold protein LAT. 
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LAT subsequently recruits several downstream adaptor proteins and 
promotes RAS activation and PI3K activation. PI3K signalling is also 
activated by co-stimulatory signals emanating from CD28. PD-1 signalling is 
activated via interaction with PD-L1 expressed on tumour cells. PD-1 
signalling counters PI3K and thus AKT signalling stimulated by TCR 
engagement. Mechanistically, this operates through phosphatase SHP-2 
(and possibly SHP-1), which binds to the cytoplasmic tail of PD-1 in the 
ITSM. Overall, this contributes to the reduction in the synthesis of effector 
cytokines by CD8 T cells such as IFN-γ, and reductions in T cell survival 
signals (Bcl-xL expression is downregulated), T cell proliferation and glucose 
metabolism. In contrast, rare melanoma cells expressing PD-1 may have 
enhanced tumorigenic potential through increased activation of mTOR 
activity through PD-1 signalling.  
 
1.3 RAS signalling pathway 
 
1.3.1 RAS biology and cancer 
 
RAS proteins are a superfamily of GTP-binding proteins that are central to 
the molecular control of cell proliferation and survival. RAS protein activity 
governs cellular responses to extracellular signals such as growth factors. 
Approximately 20 % of all cancers have mutations in RAS proteins (HRAS, 
NRAS or KRAS), and many more dysregulate RAS signalling through 
mutations in signalling proteins upstream or downstream of RAS (Downward, 
2003). The discovery of Ras proteins arose from work on viruses able to 
initiate cancer in rodents. Thus, the name Ras originates from rat sarcoma 
virus (Malumbres and Barbacid, 2003). RAS is a GTPase; it cycles from its 
biologically active GTP-bound state to the inactive GDP-bound form. Since 
the intrinsic GTPase activity of RAS is low, GTPase activating proteins 
(GAPs) accelerate the catalytic hydrolysis of GTP to GDP by RAS, such as 
neurofibromin 1 (NF1) (Trahey and Mccormick, 1987). Conversely, RAS 
guanine nucleotide exchange factors (GEFs) promote the timely release of 
GDP and exchange for GTP, such as son of sevenless (SOS) (Downward et 
al., 1990b; Wolfman and Macara, 1990). Oncogenic RAS mutant proteins 
(with point mutations invariably occurring in codons 12, 13 and 61) have 
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compromised GTPase activity and thus are unable to normally revert to the 
inactive GDP-bound form. Therefore, oncogenic RAS mutants are considered 
to be constitutively active. A corollary is that cells harbouring mutant RAS no 
longer depend on growth factor stimulation for RAS activity, promoting 
uncontrolled and inappropriate cell proliferation and cancer. 
 
Activated RAS binds to effector proteins at the plasma membrane including 
RAF proteins (Moodie et al., 1993; Vojtek et al., 1993; Warne et al., 1993), 
Ral-GEF proteins and the p110 catalytic subunits of phosphatidylinositol-
kinases (PI3Ks) (Downward, 2003; Rodriguezviciana et al., 1994), with the 
notable exception of the p110β isoform of PI3K (Fritsch et al., 2013). The 
association with the plasma membrane is required for activity of downstream 
kinases such as RAF (Leevers et al., 1994). Once activated, these kinases 
can amplify the initial signal from RAS by activating many substrates and 
therefore facilitate the control of complex cellular processes such as cell 
division and growth. Specifically, downstream of A, B and C-RAF are 
mitogen-activated kinase/ERK kinase 1 (MEK1) and MEK2, which can in turn 
phosphorylate the serine/threonine kinases extracellular-regulated kinase 1 
(ERK1) and ERK2. This evolutionarily conserved, three-tier mitogen-
activated protein kinase (MAPK) cascade eventually leads to the 
phosphorylation and activation of transcription factors and cell cycle 
regulators. In parallel, RAS directly regulates the enzymatic activity of PI3Ks, 
which are lipid kinases (Vanhaesebroeck et al., 2010). Through conversion of 
the substrate phosphatidylinositol-4,5-bisphosphate (PIP2) to 
phosphatidylinositol-3,4,5-trisphosphate (PIP3) by phosphorylation, PI3Ks 
are able to recruit and activate several effector proteins that bind PIP3 
through their pleckstrin homology domains, including the kinase AKT 
(Downward, 2003). 
 
Pharmacological inhibitors of mutant RAS would have obvious therapeutic 
value in many cancers, however attempts to find effective RAS inhibitors has 
proved difficult. For example, farnesyltransferase inhibitors prevent 
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farnesylation of the C-terminus of RAS, and in doing so; prevent the proper 
localisation of RAS to the plasma membrane (Kohl et al., 1995). Also of note 
are recently developed small molecules able to react with the cysteine 
residue in RASG12C mutant proteins can inhibit oncogenic RAS signalling and 
have shown promising selectivity for mutant RAS (Ostrem et al., 2013); 
however, both of these classes of agents are yet to prove their worth in a 
clinical setting. On the other hand, there has been a very productive 
campaign to develop potent small molecule inhibitors of RAS effector 
proteins (generally kinases), including MEK, ERK and AKT. Inhibitors of 
MEK1/2 and PI3K will be used extensively in the work presented in this 
thesis. In addition, upstream growth factor receptor tyrosine kinases, such as 
epidermal growth factor receptor (EGFR), are amenable to small molecule 
inhibition or antibody-mediated inhibition, as they are cell membrane 
proteins.  
 
1.3.2 RAS and p38 signalling 
 
Another class of related MAPKs are the stress-activated kinases including c-
Jun N-terminal kinases (JNKs) and p38. In normal cells, the p38 pathway is 
involved in mediating cellular responses to cellular stresses, cytokines and 
inflammatory cues such as lipopolysaccharide (LPS). In an analogous 
manner to the RAS/MEK/ERK signalling module, p38 MAPK is activated 
through phosphorylation by protein kinases MEKK3 and MEKK6. In 
mammals, four isoforms of p38 exist: p38α, p38β, p38γ and p38δ.  
 
In the context of transformation, the p38 pathway has been shown to have 
tumour suppressive properties (Dolado et al., 2007). For example p38α 
deletion sensitised mice to KRAS-driven lung cancer (Ventura et al., 2007). 
p38 is activated by oncogenic RAS signalling, eventually leading to 
oncogene-induced senescence (Xu et al., 2014b). It seems that p38α, p38γ 
and p38δ (but not p38β) are critical for this process, (Kwong et al., 2013; 
Kwong et al., 2009). Oncogene-induced senescence is dependent on 
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MEKK3/6, which is activated downstream of MEK/ERK signalling (Wang et 
al., 2002). In parallel, p38δ is activated transcriptionally by AP-1 and Ets 
transcription factors following activation of oncogenic RAS (Kwong et al., 
2013). Although the exact nature of the signal downstream of oncogenic 
RAS/MEK/ERK that leads to p38 activation remains unclear, it is likely that 
MEK/ERK-induced accumulation of reactive oxygen species (ROS) and/or 
DNA damage play a key role (Dolado et al., 2007; Nicke et al., 2005). 
Although the accumulation of ROS and DNA damage are often linked, they 
both seem capable of independently activating p38 signalling (Xu et al., 
2014b). Using an RNA-interference approach to identify novel regulators of 
RAS-induced growth arrest, Nicke and colleagues identified MINK to be a 
crucial component in the signalling network activating the senescence 
program (Nicke et al., 2005). Activation of p38 by MINK appeared to be 
dependent on ROS accumulation, which was associated with oncogenic 
levels of MEK activity. ROS can also activate p38 signalling through 
apoptosis signal-regulating kinase 1 (ASK1), in a mechanism involving the 
dissociation of thioredoxin from ASK1 under oxidative conditions (Saitoh et 
al., 1998) (Figure 1.3). Indeed, ROS-mediated ASK1 activation appears to be 
critical in TLR4-mediated responses to LPS in APCs, which depends on p38. 
These data suggest a significant functional role for this pathway in the 
biology of non-transformed cells (Matsuzawa et al., 2005). Interestingly, TNF 
can also engage the p38 pathway in a mechanism involving the induction of 
ROS and homo-oligomerisation of ASK1.  
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Figure 1.3 A model for the activation of p38 signalling by ROS 
Activation of oncogenic RAS signalling leads to increased levels of 
intracellular reactive oxygen species (ROS) and DNA damage. The resulting 
oxidative state may be reversed with NADPH reserves in the cell (not 
shown). ROS accumulation can also be stimulated in normal antigen 
presenting cells through exposure to TNF-α. Through a redox-sensitive, N-
terminal interaction with ASK1, the reduced form of thioredoxin inhibits ASK1 
activity. Once oxidised by oxygen radicals, thioredoxin releases ASK1, which 
can then homo-oligomerise and activate downstream kinases MEKK3/6 and 
the p38 pathway. Collectively, this process is known to contribute to 
oncogene-induced senescence (Xu et al., 2014b). 
 
1.4 Lung cancer and mouse models of the disease 
 
The major focus of this thesis is the molecular biology of lung cancer. Lung 
cancer is the largest cause of cancer related death in the UK and worldwide 
(Swanton and Govindan, 2016). There are two broad histological subtypes of 
lung cancer, non-small cell lung cancer (NSCLC) and small-cell lung cancer 
(SCLC). NSCLC makes up the majority of lung cancer cases (around 85 % of 
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cases), and is further subdivided into adenocarcinoma and squamous-cell 
carcinoma (Herbst et al. 2008). The most significant environmental risk factor 
is tobacco smoking, relating to 85-90% of all lung cancer cases (Meuwissen 
and Berns, 2005; Swanton and Govindan, 2016). Smoking is especially 
associated with a high frequency of mutations in KRAS (20-30 % of lung 
adenocarcinomas) (Slebos et al., 1990). Mutations in RAS in lung cancer 
often result from G-T transversions, which is a hallmark of mutagenesis 
caused by carcinogens found in tobacco smoke. Also contributing to lung 
cancer progression is the frequent loss of the tumour suppressor TP53, 
which is mutated in about 40-50 % of all NSCLCs and 91 % or 92 % of lung 
squamous-cell or small-cell carcinomas, respectively (Swanton and 
Govindan, 2016). 
 
Mouse models of human cancer have been used to understand the basic 
biology of cancer and cancer therapy, and therefore have potential to help 
discover improved cancer treatment, improved biomarkers and diagnosis and 
prevention of cancer and understand drug resistance mechanisms (Frese 
and Tuveson, 2007). Early models of lung cancer relied on carcinogen-
induced models (Balmain and Pragnell, 1983). For example, experiments by 
Balmain and Pragnell in 1983 showed that DNA from mouse skin carcinomas 
was able to transform 3T3 fibroblasts; crucially, the transforming DNA was 
found to contain the H-Ras oncogene. More controlled genetically engineered 
mouse models of cancer followed. Notably, the development of the latent 
KrasG12D allele mouse (or Kras LA mouse) was the first demonstration that 
spontaneous recombination of oncogenic Kras could lead to early onset lung 
cancer in mice (Johnson et al., 2001). Tumorigenesis was accelerated when 
the KrasLA mice were crossed onto a strain deficient in the tumour 
suppressor Trp53. Subsequently, significant advances in mouse genetics, 
notably from the Tyler Jacks laboratory, led to the development of more 
sophisticated models of RAS-driven lung cancer, where the expression of the 
oncogene can be controlled in a temporal and spatial (tissue-specific) 
manner; so called conditional mouse models. By nasal instillation of 
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adenoviral Cre recombinase, tissue-specific recombination of the Kras LoxP-
Stop-LoxP-G12D (or, Kras LSL-G12D) allele was achieved in the lung 
epithelium, leading to pre-neoplastic lesions (Tuveson et al., 2004). In this 
system, the bacteriophage LoxP sites flank the genetic element that will be 
excised after the expression of the LoxP-specific bacterial recombinase Cre. 
However, in cases where the LoxP sequences are running in opposite 
orientations, rather than deletion of the intervening sequence, there is an 
inversion event. Oncogenes can be expressed after the removal of 
transcriptional and translational stop sequences flanked by LoxP sites (LSL 
cassette), or an essential exon or entire gene can be removed when flanked 
by LoxP sites (flanked by LoxP; “floxed”). The Cre-LoxP system is now used 
extensively in cancer and many other areas of biology involving genetic 
manipulation of model systems. A major advantage of conditional mouse 
models is the ability to activate or inactivate genes in adult mice, which would 
have resulted in embryonic lethality or severe developmental defects if 
initiated constitutively. Using this system, tissue-specific recombination was 
used to concomitantly activate oncogenic RAS signalling and delete Trp53 in 
the lung epithelium with adenoviral Cre in KrasLSL-G12D/+; Trp53 flox/flox 
mice (DuPage et al., 2009a). This mouse model of lung cancer, referred to as 
the KP mouse, recapitulates many histopathological features of the human 
disease, including the adenoma to adenocarcinoma histological transition 
and, although rare in this model, metastasis to lymph nodes (DuPage et al., 
2009a). Adenoviral or lentiviral delivery of Cre allows for the tissue-specific 
and sporadic initiation of lung cancer in this model without detailed 
knowledge of the cell-of origin for the disease. Furthermore, the viral delivery 
component allows for the incorporation of other genetic elements into the 
tumour-initiating cells such as short hairpin RNAs (shRNAs) or cDNAs. This 
system is rarely “leaky” (i.e. unwanted expression of the transgene) unlike 
models using inducible Cre recombinases, as gene expression is tightly 
controlled by viral infection. Finally, another advantage of this conditional 
model is that Kras is expressed from its endogenous locus and therefore at 
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physiological levels. However, infection of other non-epithelial tissues in the 
lung is likely to occur, with as yet unknown effects on tumour progression. 
 
1.5 Cancer immunology 
 
1.5.1 An overview of cancer immunology 
 
It is well accepted that tumours initiated by viruses are less common in 
immunocompetent individuals. In the context of cancer without viral aetiology, 
the existence of cancer immunosurveillance has remained contentious. 
However, a substantial body of clinical evidence has accumulated in favour 
of this concept. For example, patients who undergo immunosuppressive 
therapy as part of organ transplantation have developed melanoma clonally 
derived from the donor organ, suggesting occult cancer cells are kept in 
check by the immune system until transplanted into an immunosuppressed 
recipient (Strauss and Thomas, 2010). Secondly, paraneoplastic syndrome is 
an autoimmune condition associated with the aberrant recognition of normal 
tissues as tumour by the immune system, owing to the expression of 
common targeted antigens (Albert and Darnell, 2004). Moreover, there have 
been reports of spontaneous tumour regressions. Rare spontaneous 
melanoma regressions have been linked with concomitant incidence of 
vitiligo (loss of skin pigment, which can be caused by autoimmune 
destruction of melanocytes), implying immune system involvement (Smith 
and Stehlin, 1965). In line with this, there is consensus that lymphocyte 
infiltration in diverse tumour types is linked with improved prognosis (Denkert, 
2010; Halama et al., 2011; Hiraoka et al., 2006). In a landmark paper, the 
density of tumour-infiltrating lymphocytes in colorectal cancer was shown to 
be a powerful prognostic factor and even outperformed classical histological 
grading (Galon et al., 2006). Quantitative analysis of the immune contexture 
of the tumour microenvironment for prognosis is now commonly referred to 
as the tumour “immunoscore”. 
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The recent explosion in the number of reported clinical successes of cancer 
immunotherapies has finally silenced critics of the cancer 
immunosurveillance hypothesis, and will be discussed in detail in later 
sections. 
 
1.5.2 Genetically engineered mouse models in cancer immunology 
 
Despite clinical indications, the cancer immunosurveillance hypothesis fell 
out of favour within the scientific community due to the lack of direct 
experimental evidence from animal models. For example, there was little 
difference in carcinogen-induced tumorigenesis in nu/nu athymic mice 
compared with immunocompetent mice (Stutman, 1974). A caveat to these 
experiments is that Stutman used a strain background that was exceptionally 
prone to carcinogen-induced tumorigenesis, perhaps masking small 
differences in tumour incidence. More importantly, it developed that nude 
mice still posses some functional αβ T cells and a repertoire of 
extrathymically derived lymphocytes such as NK and γδ T cells (Dunn et al., 
2002). Mice mutant for the recombination activating genes 1 and 2 (Rag1-/- 
and Rag2-/-, respectively) necessary for V(D)J rearrangement, allowed for 
complete elimination of NKT, B and T cells (Shinkai et al., 1992). The use of 
the more profoundly immunocompromised Rag-deficient mice was 
instrumental in re-establishing the immunosurveillence hypothesis 
(Shankaran et al., 2001), and is still invaluable today in modelling cancer in 
the absence of adaptive immunity. Rag-null mice were revealed to be more 
susceptible to carcinogen-induced and spontaneous tumours. It has since 
emerged that innate immunity can generate independent anti-tumour 
responses (Beatty et al., 2011) and pro-tumorigenic roles (Lujambio et al., 
2013), revealing added layers of complexity that cannot be fully explored in 
such models. 
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Robert Schreiber’s lab has made extensive use of the Rag-deficient and 
other immunodeficient mouse models to demonstrate that there is selection 
against immunogenic cancer clones; a phenomenon dubbed “cancer 
immunoediting” (Shankaran et al., 2001). In a landmark study, they observed 
that tumours arising in Rag2-/- hosts could be rejected when transplanted 
into syngeneic immune competent mice, whereas tumours transplanted from 
wild-type mice grew comparably, suggesting that tumours from Rag 2-/- 
hosts are more immunogenic (or “un-edited) (Shankaran et al., 2001). Finally, 
they demonstrated that tumour rejection was CD4+ and CD8+ T cell-
dependent, showing that these lymphocytes not only protect against 
immunogenic tumours in situ, but also sculpt the immunogenicity of these 
tumours by selection. Collectively, Schreiber’s work provided a model for 
dynamic tumour-host interactions and immunoediting processes dubbed the 
“three Es”; that is, tumour elimination, equilibrium and escape (Dunn et al., 
2002). 
 
11 years later, Schreiber and colleagues asked which antigens trigger tumour 
rejection. Using a similar system of transplanting mutationally complex 
tumours induced by the carcinogen methylcholanthrene, they carried out 
exon capture and deep sequencing of cDNA from immunogenic clones 
generated in Rag 2-/- hosts to identify antigens necessary and sufficient for 
tumour rejection (Matsushita et al., 2012). Computational prediction 
algorithms for strong MHC class I binders identified a mutant form of 
spectrin-β2 as a candidate neo-antigen strongly represented on the tumour 
cell surface. Its antigenicity was later confirmed by conventional expression 
cloning techniques. This study provides a rationale for personalized 
immunotherapies, where prominent neo-antigens are identified and may be 
re-targeted by vaccination strategies, especially in tumour types with high 
mutational load such as smoking-related lung cancer (Matsushita et al., 
2012). However, there is a possibility that immunogenic passenger mutations 
may be easily lost by selection. In related work, Willimsky and Blankenstein 
asked whether such selection exists when the driving oncogene is the major 
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tumour antigen (Willimsky and Blankenstein, 2005). Making use of a mouse 
model of spontaneously arising cancer driven by randomly activated 
expression of SV40 Large T antigen, they found that immunoediting did not 
occur in this context, as there is an absolute requirement to retain the 
oncogene for tumour maintenance. Rather, tumours arising in immune 
competent hosts initially triggered a T cell and humoral immune response, 
but this was eventually overcome by induced T cell tolerance, associated 
with TGFβ-induced cytotoxic T lymphocyte anergy. 
 
Tyler Jacks and colleagues recently addressed a similar question using a 
GEMM of oncogenic Kras-driven sarcomagenesis (DuPage et al., 2012). 
They investigated whether immunoediting of potent neo-antigens occurred in 
the context of spontaneously arising tumours. The neo-antigens were not 
required to maintain tumourigenesis in this case.  To this end, they utilised 
lentiviral delivery of Cre recombinase (“Lenti-x” vector) to initiate oncogenic 
Kras activation and concomitant deletion of Trp53, or lentiviral particles 
expressing both Cre and luciferase linked to three distinct model 
immunogenic peptides (“Lenti-LucOS”). They could follow neo-antigen 
expression in vivo by detecting luciferase activity. Interestingly, they 
observed increased latency in the progression of Lenti-x tumours in the 
immunocompetent hosts compared to Rag2-/- hosts. This immune-related 
tumour suppression was not apparent in the context of transplantation of fully 
developed Lenti-x tumours, which were established with similar efficiencies in 
wild-type and Rag2-/- recipients. As expected, growth of immunogenic Lenti-
LucOS tumours was initially inhibited in wild-type mice relative to Lenti-x 
tumours. Interestingly, the authors found that the engineered neo-antigens 
were eventually silenced in progressively growing sarcomas. The 
immunoediting process was dependent on T cells and/or the reduced 
presentation of tumour antigens by surviving tumour cells. 
 
In further work, DuPage et al demonstrated that a similar experiment 
performed in the lung epithelium gives quite different results, revealing key 
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tissue specific differences (DuPage et al., 2011). In a Kras-driven, Trp53-null 
NSCLC mouse model (DuPage et al., 2009b), immunogenic (“Lenti-LucOS”) 
tumours again grew slower in wild-type hosts than Rag2-/- hosts, but this 
time retained antigen expression (as determined by luciferase expression). 
Instead, they observed immune tolerance associated with tumour-specific 
CD8+ T cell PD-1 expression, influx of regulatory T cells and an anergic 
phenotype in anti-tumour CD8+ T cell population, characterised by 
downregulation of IFN-γ and TNF-α. These tissue-dependent differences 
may reflect the different levels of immune regulation in muscle and lung 
parenchyma, potentially caused by their disparate exposures to 
environmental pathogens, microbiota and debris. This raises an interesting 
point; what mechanisms of immune suppression are at play at metastatic 
sites? How the resident immune-compartment influences where tumour cells 
seed, and how the mechanisms of tumour immune escape are adapted for 
the new microenvironment are intriguing questions to be addressed. 
 
Experiments in mouse models using potent, model tumour neo-antigens 
universally expressed by every cell does not reliably mimic the 
heterogeneous and clonal nature of cancer (de Bruin et al., 2014; Gerlinger 
et al., 2012). Accurately modelling polyclonal cancer immune responses in 
GEMMs of lung cancer requires intrinsically high somatic mutation rates 
similar to those found in humans. Comprehensive sequencing efforts have 
addressed the mutational burden of tumours derived from different mouse 
models of lung cancer. Tyler Jacks and colleagues found a very low somatic 
point mutation rate in tumours derived from a mouse model of small-cell lung 
cancer driven by the loss of Rb and Trp53 tumour suppressors (McFadden et 
al., 2014a). Concordantly, in the Kras-driven mouse model of NSCLC, a 
comparably low point mutation rate was found in lung tumours in the absence 
of tobacco carcinogens (6 non-synonymous mutations on average), but this 
was considerably higher in tumours initiated with the carcinogens urethane or 
methyl-nitrosourea (MNU) (192 non-synonymous mutations on average in 
MNU-initiated tumours) (Westcott et al., 2015b). These data highlight 
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important discrepancies in predicted neo-antigen burden between GEMM 
and human tumours. However, GEMMs have key advantages over classical 
syngeneic transplantation models in the study of cancer-immune interactions: 
(1) GEMM tumours arise more slowly, allowing for co-evolution of the host 
immune system and tumour, (2) GEMM tumours arise at the orthotopic site, 
allowing accurate modelling of the microenvironment, whereas tumour 
transplants are often subcutaneous, (3) some transplanted tumour cells 
inevitably undergo cell death during the process of injection, which might act 
as an anti-tumour vaccine and have a significant impact on anti-tumour 
immunity. 
 
1.5.3 Immunogenic cell death 
 
An important question related to the broad effects of anticancer drugs is the 
contribution of the immune system to the anti-tumour response. Seminal 
work from the Zitvogel and Kroemer labs have revealed that certain 
anticancer drugs can lead to an immunogenic cell death (ICD) programme, 
which requires at least three molecular characteristics: (1) cell surface 
exposure of calreticulin (Obeid et al., 2007), (2) active release of ATP 
(Michaud et al., 2011), and (3) passive release of high-mobility group protein 
1 (HMGB1) (Galluzzi et al., 2012). These damage-associated molecular 
patterns have been shown to be necessary for the induction of adaptive 
immunity against cancer cells in mouse tumour transplantation experiments 
(Apetoh et al., 2007; Michaud et al., 2011; Obeid et al., 2007). However, ICD-
inducing drugs are mechanistically and structurally diverse, leading to 
confusion as to the precise signalling mechanisms driving these processes. 
However, it is now clear that endoplasmic reticulum (ER) stress and the 
accumulation of reactive oxygen species are important factors (Garg et al., 
2012). For example, chemotherapies inducing hyperploidy have been shown 
to induce ER-stress and promote calreticulin exposure at the cell membrane 
(Senovilla et al., 2012). This process underlies immune selection against 
polyploid cancer cell clones in mouse models. It seems that the activation of 
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dendritic cells and subsequent instigation of adaptive immune memory 
against the tumour is better achieved by inducing ICD than the release of 
intracellular antigens from dying tumour cells alone. This process has been 
called in situ vaccination (Galluzzi et al., 2012).  
 
For example, in syngeneic tumour transplant experiments, immunogenic 
anthracycline chemotherapy treatment of tumour-bearing mice stimulates the 
ATP-dependent recruitment of CD11c+CD11b+Ly6Chigh cells to the tumour-
bed, which are able to engulf dying tumour cell debris and contribute to the 
anti-tumour T cell response (Ma et al., 2013). Furthermore, in a GEMM of 
lung adenocarcinoma, oxaliplatin and cyclophosphamide treatment 
sensitised ICB-refractory tumours to PD-1 and CTLA-4 combination blockade 
through a mechanism involving drug-induced innate immune responses 
depending on TLR4, and infiltration of CD8+ T cells into lung tumours 
(Pfirschke et al., 2016). 
 
Although the characteristics of ICD were initially identified in the unnatural 
context of tumour cell transplantation, patients carrying defective alleles of 
receptors for extracellular ATP or HMGB1 have been found to be poor 
responders to some ICD-inducing chemotherapies, suggesting these findings 
have clinical relevance (Apetoh et al., 2007; Ghiringhelli et al., 2009). In 
contrast to the above observations, a study from de Visser and colleagues 
using the ICD-inducers doxorubicin and oxaliplatin to treat breast cancer in 
an autochthonous GEMM, showed that survival in treated Rag 2+/- mice was 
not significantly different from Rag 2-/- mice (Ciampricotti et al., 2012; 
Zitvogel and Kroemer, 2012a). These findings highlight the controversies in 
this field of research and further illustrate important differences between 
GEMMs and tumour transplantation models. It is possible that results from de 
Visser and colleagues could indicate profound tumour-mediated immune 
suppression. Whether combining chemotherapy with immune checkpoint 
blockade would significantly change the outcome in this context remains to 
be tested. 
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Targeted therapies and chemotherapies are commonly derived from a cell 
autonomous perspective, and how they impinge on the tumour 
microenvironment is often overlooked. What is clear is that the chronic 
selection pressure exerted by such agents will lead to Darwinian selection for 
resistant clones, resulting in acquired resistance. Conversely, the concept of 
in situ vaccination by cytotoxic agents in conjunction with immunomodulatory 
drugs is an attractive alternative for several reasons. The growing class of 
ICD inducers only need to be used in short bursts for anti-tumour vaccination, 
making both acquired resistance and long-term dose-related toxicity less 
likely. It can be envisaged that serial in situ vaccination by ICD-inducers will 
re-prime the adaptive immune system against immunoedited subclones. An 
improved understanding of how targeted therapies and chemotherapies 
affect the reciprocal signalling between the immune system and tumour in 
clinically relevant GEMMs, and how to combat adaptive mechanisms of 
tumour-mediated immune suppression may present opportunities for durable 
therapeutic responses in cancer (Galluzzi et al., 2015). 
 
1.6 Cancer immunotherapy 
 
1.6.1 Clinical data for immune checkpoint blockade 
 
Perhaps the first recorded clinical use of cancer immunotherapy was by the 
New York surgeon William Coley in the late 19th century. He noted that 
Streptococcus pyrogenes skin infections occurred in sarcoma patients with 
unexpected tumour regression, and subsequently treated patients with an 
inactivated bacterial concoction (“Coley’s toxins”), with some success (Nauts 
et al., 1953). In an analogous manner, administration of Bacillus Calmette-
Guerin (BCG) is still used as a component of standard therapy for bladder 
cancer (Herr et al., 1995).  
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Intriguingly, several clinical case studies lend support for the idea that the 
immune system can contribute to the efficacy of classical cancer treatments 
such as radiotherapy. Patients receiving radiotherapy very occasionally 
experience spontaneous regressions of distant, non-radiated lesions; this 
rare phenomenon is called the abscopal effect. Presently, there is mounting 
evidence that the abscopal effect is in fact mediated by a systemic immune 
response. For example, a patient presenting with metastatic melanoma 
experienced tumour regression at distant sites after receiving radiotherapy 
and anti-CTLA-4 immunotherapy (Postow et al., 2012). The anti-tumour 
response clearly correlated with markers of increased systemic immune 
reactivity to the melanoma tumour-associated antigen NY-ESO-1. 
 
Steven Rosenberg pioneered some of the first successful, controlled cancer 
immunotherapy trials in human patients (Rosenberg, 2014). In 1985, a 
fraction of patients with metastatic disease responded durably to high-dose 
recombinant IL-2 therapy, a cytokine involved in promoting T cell proliferation 
(Rosenberg et al., 1985). These were among the trial results that eventually 
led to the FDA-approval of IL-2 for patients with metastatic renal cancer in 
1992. However, severe adverse effects and treatment related deaths were 
observed, often relating to capillary leak syndrome and excessive fluid 
retention in visceral organs. Nonetheless, these reports provided some of the 
first clinical evidence supporting immune modulation for anti-cancer therapy 
in humans. 
 
The discovery of IL-2 and its ability to promote the long-term survival of T 
cells in culture simultaneously ignited interest in the related field of adoptive 
cell therapies (ACT). Early ACT for cancer treatment involved re-infusion of 
expanded anti-tumour T cells. However, the discouragingly poor success 
rates of these approaches in early trails meant that ACT technologies did not 
really progress until relatively recently. The clinical approval of a novel cancer 
immunotherapy Sipuleucel-T reinvigorated research into ACT for cancer. 
Sipuleucel-T therapy involves the re-infusion of autologous APCs incubated 
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with prostate-specific antigen and GM-CSF ex vivo. Clinical trials revealed a 
significant but modest mean overall survival benefit of about four months for 
men with metastatic, castration-resistant, prostate cancer receiving 
Sipuleucel-T over placebo (Kantoff et al., 2010). Presently, there is growing 
enthusiasm over treatments based on infusion of cancer patients with 
genetically engineered T cells with chimeric antigen receptors (CAR-T cells) 
that can specifically identify and eliminate haematological cancers, and more 
recently, solid cancers (Rosenberg and Restifo, 2015). 
 
Seminal preclinical work by Allison and colleagues validated the immune 
checkpoint molecule CTLA-4 as a viable therapeutic target. Administration of 
anti-CTLA-4 antibodies caused regressions of established subcutaneous 
tumours (Leach et al., 1996). Some antibody-treated mice remained tumour-
free for long periods of time, and moreover, were more resistant to tumour re-
challenge, implying induction of immunological memory. These preclinical 
data were followed by major successes in early clinical trials with ipilimumab, 
the human anti-CTLA-4 antibody from Bristol-Myers Squibb (Hodi et al., 
2010; Phan et al., 2003; Yang et al., 2007). Remarkably, a subset of 
melanoma patients treated with ipilimumab experienced complete 
regressions and have remained disease-free for over 10 years (Sharma and 
Allison, 2015). 
 
Topalian and colleagues grasped the attention of the cancer research 
community with a landmark phase I clinical study demonstrating durable and 
profound tumour regressions in multiple human cancers using an anti-PD-1 
antibody (Topalian et al., 2012). Notably, NSCLC was among the 
malignancies that showed promising responses to anti PD-1 ICB, a cancer 
that has hitherto been considered poorly immunogenic. The distinct biology 
of the PD-1 and CTLA-4 checkpoints in regulating T cell function, and the 
clinical successes of these ICB agents as monotherapies, provided sufficient 
rationale for their combination. As expected, the first trial of nivolumab (anti-
PD-1) and ipilimumab (anti-CTLA-4) in combination revealed increased 
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toxicity compared with either monotherapy, but the combination also 
achieved greater overall survival benefit in patients with previously untreated 
melanoma over single agent therapy (Larkin et al., 2015b; Postow et al., 
2015). Notably, as a single agent nivolumab is clearly superior to ipilimumab, 
even in cases were tumours were classified as PD-L1 negative. 
 
1.6.2 Correlates of cancer immunotherapy response 
 
The mechanistic understanding of how cancer immunotherapies work is 
currently lagging behind the clinical progress. Next-generation sequencing 
(NGS) of tumour specimens has suggested that the tumour mutational load is 
the best molecular correlate for immunotherapy success, but its value as a 
biomarker for response is perhaps limited. Melanoma response to anti-CTLA-
4 therapy with ipilimumab significantly correlated with mutational burden 
(Snyder et al., 2014), and similar findings have been reported for lung 
adenocarcinoma (Rizvi et al., 2015b). Using whole-exome sequencing and 
bioinformatics analyses in NSCLC patients treated with pembrolizumab, the 
authors demonstrated sensitivity to PD-1 blockade was significantly 
correlated with non-synonymous mutational burden and the corresponding 
predicted neo-antigen burden. More support for this link came from evidence 
that patients with mismatch repair-deficient colorectal tumours (and thus 
higher somatic mutation rate) had a significantly higher response rate to 
pembrolizumab than mismatch repair-proficient colorectal tumours (Le et al., 
2015). Further work in this field has revealed that lung tumours with lower 
clonal heterogeneity tend to respond better to PD-1 ICB than tumours with a 
more complex and branched sub-clonal architecture (McGranahan et al., 
2016). Interestingly, the authors revealed a tendency for tumours with low 
clonal neo-antigen complexity to express higher levels of PD-L1 mRNA, 
perhaps reflecting increased targeting by anti-tumour T cells. However, 
precisely why tumours with lower tumour heterogeneity respond better to PD-
1 ICB remains unclear. Until recently, most of the cancer immunotherapy 
field has been focussed on anti-tumour CD8 T cell responses, but tumour-
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specific CD4+ T cells have now been described in human melanoma, and 
their therapeutic efficacy in adoptive cell transfer for treatment of epithelial 
cancers has been vindicated (Linnemann et al., 2015; Tran et al., 2014).  
 
Finally, two reports using similar approaches to determine tumour-rejection 
antigens revealed that tailored peptide vaccines can induce significant anti-
tumour activity (Gubin et al., 2014; Yadav et al., 2014). Both studies used a 
combination of RNA sequencing and MHC binding prediction algorithms to 
predict mutant antigens likely to be presented by MHC class I on tumour 
cells. Peptide vaccines based on validated tumour neo-antigens were 
effective when co-administered with imm unostimulatory adjuvants in both 
studies, using distinct syngeneic tumour models. Gubin et al went on to show 
that anti-PD-1 and anti-CTLA-4 therapy is associated with phenotypic 
changes in tumour-antigen-specific CD8+ T cells in mice. Specifically, 
following ICB, antigen-specific CD8+ T cells expressed more effector 
cytokines and granzyme B (especially after anti-CTLA-4 therapy), and 
showed decreased expression of immunosuppressive molecules such as 
lymphocyte-activation gene 3 (LAG-3) and T cell immunoglobulin and mucin 
protein 3 (TIM-3). Collectively, these data highlight the potential therapeutic 
value of combining peptide vaccines with ICB, and demonstrate that 
alterations in the phenotype of pre-existing anti-tumour immune cells 
contribute to the anti-tumour effects of ICB. 
 
Collectively, these results imply that genomic instability, a hallmark of cancer, 
could be a potential weakness for cancer cells, ultimately compromising 
immune evasion (Hanahan and Weinberg, 2011). From the perspective of 
cancer immunology, rather than mutations in driving oncogenes, passenger 
mutations in innocuous proteins may in fact be cancer’s therapeutic 
vulnerability. Increasingly personalised medicine involving comprehensive 
NGS and profiling of active immune checkpoints will clearly be required to 
adopt the most effective immunotherapy combinations. These results also 
raise the following question: can some forms of chemotherapy increase the 
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number of tumour mutations and thus, with careful scheduling, work 
synergistically in combination with ICB? 
 
1.6.3 PD-L1 expression as a biomarker for sensitivity to PD-1/PD-L1 
immune checkpoint blockade 
 
Only a fraction of patients currently respond to immune checkpoint blockade, 
presenting a major clinical challenge. Reliable biomarkers of patient 
response are urgently needed to maximise the number of patients that can 
benefit form these therapies and simultaneously reduce the huge cost of 
clinical failure with these expensive antibody therapeutics. To date, no 
conclusive evidence has been put forward for a molecular target to serve as 
an appropriate biomarker. In stark contrast to targeted therapies, knowledge 
of the driving oncogene does not seem to provide much prognostic value in 
this context.  
 
However, tumour PD-L1 expression and tumour-proximal stromal/immune 
cell PD-L1 expression have been shown to correlate with response to ICB 
targeting the PD-1 pathway, but remains contentious. In an early study of the 
response to PD-1 ICB in NSCLC, melanoma, renal cell carcinoma, colorectal 
cancer and prostate cancer response, PD-L1 positive tumours had a 
significantly better response rate than PD-L1 negative tumours; objective 
responses were 9/25 for PD-L1 positive and 0/17 for PD-L1 negative tumours 
(Topalian et al., 2012). These data are concordant with a recent phase I 
study of pembrolizumab in NSCLC patients, where PD-L1 expression in over 
50 % of tumour-cells was significantly correlated with improved drug efficacy 
(Garon et al., 2015). In contrast, large-scale clinical trials of nivolumab in 
NSCLC have revealed that tumour PD-L1 expression on tumour cells is 
correlated with therapy response in non-squamous, but not the squamous 
subtype of NSCLC (Borghaei et al., 2015; Brahmer et al., 2015). Crucially, 
the Brahmer and Borghaei studies both used the same PD-L1 detection 
antibody and scoring criteria to determine tumour PD-L1 positivity, 
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suggesting that their results may reflect genuine biological differences 
between these histological tumour types, rather than trivial technical 
differences. Interestingly, Borghaei et al demonstrated that patients with 
tumours harbouring mutations in KRAS responded better on nivolumab than 
KRAS wild-type patients. One speculative explanation for increased efficacy 
of PD-1 pathway ICB in KRAS mutant tumours is that KRAS mutations are 
more prevalent in smokers, which are known to have a higher tumour 
mutational burden. However, there is evidence that KRAS and EGFR mutant 
(but not ALK mutant) NSCLCs have a significantly higher frequency of 
tumour PD-L1 positivity when compared with triple-negative cases (EGFR P 
< 0.001, KRAS P = 0.02, ALK P = 0.06) (D'Incecco et al., 2015). These data 
are supported by the observation that a higher proportion of patients with 
KRAS mutant NSCLC had >50 % PD-L1 expressing tumour-cells when 
compared with KRAS wild-type tumours (Garon et al., 2015). That is, 42.2 % 
of patients with KRAS mutations and 26.8 % of patients deemed KRAS wild-
type had tumours with at least 50 % of tumour-cells expressing PD-L1. In 
contrast, no clear distinction was seen for mutations in other common drivers 
such as EGFR and ALK. 
 
Recently, five independent reports published in the same issue of Nature 
comprehensively profiled the mechanisms governing responses to PD-1 and 
CTLA-4 ICB in humans and mice. Herbst and colleagues performed a phase 
I clinical trial with the Genentech anti-PD-L1 monoclonal antibody 
MPDL3280A for the treatment of multiple malignancies (Herbst et al., 2014). 
Notably, 21 % of NSCLC patients responded to this therapy, with a higher 
proportion of responders being smokers than never-smokers. Significantly, 
the presence of PD-L1-positive tumour infiltrating immune cells was a strong 
positive predictor of response, whereas tumour-cell PD-L1 expression was 
not. Tumours undergoing treatment-related regressions appeared to have 
large increases in tumour immune infiltrates and increased PD-L1 expression 
on tumour cells and infiltrating immune cells, possibly reflecting high levels of 
IFN-γ in the tumour bed. Genentech also trialled their PD-L1 antibody in 
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patients with urothelial bladder cancer, and had comparable results; high PD-
L1 expression on tumour-infiltrating immune cells was the clearest positive 
predictor of therapy response (Powles et al., 2014). The authors also noted 
that the promising responses they obtained with PD-L1 ICB in this cancer 
might reflect its high mutation rate. In melanoma, response to the anti-PD-1 
antibody pembrolizumab (Merck) was associated with the presence of PD-1-
postive immune cells at the tumour margin (Tumeh et al., 2014).  
 
Interestingly, anti-tumour responses following pembrolizumab dosing were 
associated with tumour-proximal T cell clonal expansion and increased 
clonality, which was determined by NGS of TCRs expressed by tumour-
infiltrating lymphocytes (Gubin et al., 2014). This effect might reflect the 
expansion of anti-tumour T cell clones. Remarkably, using responder 
characteristics from their discovery patient cohort (including the IHC-based 
assessment of tumour-proximal CD8, PD-1 and PD-L1 expression and T cell 
density and distribution), Ribas and colleagues successfully predicted 
response to pembolizumab in 13/15 melanoma patients, emphasising the 
clinical significance of their findings. Taken together, these reports 
demonstrate that the efficacy of ICB depends on whether there is a 
significant pre-existing anti-tumour T cell response, and whether the given 
checkpoint is currently functional in the tumour. 
 
Differences in the interpretation of PD-L1 expression on tumour cells or 
tumour-infiltrating immune cells as a biomarker for PD-1 pathway blockade 
likely arise from several factors including: (1) different antibodies used to 
detect PD-L1, (2) different quantification methods and thresholds between 
studies to define a “PD-L1 positive” tumour, (3) tumour PD-L1 expression is 
likely to be heterogeneous and not reliably represented by single region 
biopsies, (4) PD-L1 expression is highly dynamic, so precisely when the 
biopsy is taken is critical, and (5) PD-L1 expression can be determined by 
cell-intrinsic signalling, which may be independent of tumour cell 
immunogenicity. In summary, this field would benefit from standardising 
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methods to detect and interpret tumour PD-L1 expression in patients. 
Examples of these confounding factors are depicted in Figure 1.4. 
 
 
 
Figure 1.4 Tumour PD-L1 expression as a biomarker for 
immunotherapy response 
Clinically demonstrated associations between tumour PD-L1 expression and 
response to PD-1/PD-L1 pathway blockade in NSCLC. (1) Tumour cell PD-L1 
expression, governed by cell-extrinsic cues such as inflammation in the 
tumour-microenvironment and thus likely reflects the immunogenicity of the 
tumour (Borghaei et al., 2015; Garon et al., 2015; Topalian et al., 2012). (2) 
Tumour-infiltrating immune cell or stromal cell PD-L1 expression has been 
shown to be predictive of PD-L1 response, although the mechanism is 
unclear (Herbst et al., 2014). (3) PD-L1 expression is highly dynamic and 
heterogeneous so failure to obtain representative multi-region biopsies, or 
biopsy of the tumour at an unrepresentative point in time may lead to 
spurious assumptions. (4) Here, tumour cell PD-L1 positivity is predominantly 
due to cell-intrinsic signalling and not reflective of the immunogenicity of the 
tumour. Other possible confounding factors including technical issues 
concerning IHC methods and interpretation and are not shown. 
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1.7 PD-L1 regulation and function in cancer 
 
1.7.1 Cell-extrinsic regulation of PD-L1 expression 
 
Presently, the best-defined activator of PD-L1 expression is IFN-γ. Following 
exposure to IFN-γ, the transcription factor interferon regulatory factor-1 (IRF-
1) binds to the PD-L1 promoter and initiates transcription, although IRF-1 is 
also important for constitutive PD-L1 expression (Lee et al., 2006). In 
addition, the induction of PD-L1 expression downstream of IFN-γ appears to 
be dependent on JAK/STAT signalling in A549 lung cancer cells (Lee et al., 
2006). Indeed, STAT3 binds to the PD-L1 promoter in APCs, with STAT1 
seemingly playing a relatively minor role (Wolfle et al., 2011). In addition, the 
PD-L1 promoter also contains a binding site for NF-κB, which is transiently 
activated following IFN-γ stimulation by the associated ERK and PI3K activity 
(Lee et al., 2005). However, whether NF-κB activity is necessary for IFN-γ-
driven PD-L1 expression remains unclear and may be tissue-specific (Lee et 
al., 2006; Lee et al., 2005). Similarly, TLR stimulation of multiple myeloma 
plasma cells led to increased PD-L1 expression through a mechanism 
involving the activation of MEK (Liu et al., 2007). Finally, hypoxia in the 
tumour microenvironment may have a direct impact on tumour cell and 
stromal cell PD-L1 expression, as a functional hypoxia-response element in 
the proximal PD-L1 promoter has recently been described (Noman et al., 
2014). ChIP experiments verified HIF1-α binding to the PD-L1 promoter 
under hypoxic conditions, implying that tumour-associated hypoxia may 
contribute to upregulation of PD-L1 in cancer. 
  
Chapter 1. Introduction 
 53 
 
1.7.2 Cell-intrinsic regulation of PD-L1 expression by oncogenes 
 
PD-L1 expression is elevated in many cancers (Dong et al., 2002), although 
there appears to be very few unifying principles of aberrant genetic or 
epigenetic regulation. Genetic mechanisms for directly increasing PD-L1 
expression include structural rearrangements of the promoter region, gene 
amplification, and loss of the 3’UTR. Using RNA-sequencing of B-cell 
lymphomas, recurrent translocation events in the major histocompatibility 
class II transactivator (CIITA) resulted in highly transcriptionally active gene 
fusions with PD-L1 and PD-L2, correlating with elevated expression of these 
PD-1 ligands (Steidl et al., 2011). Moreover, amplification of 9p24.1, a 
genetic region containing the proximal genes PD-L1, PD-L2 and JAK2, is 
found in some cases of Hodgkin lymphoma, and is invariably associated with 
increased PD-1 ligand transcription (Green et al., 2010). The combined 
increase in gene dosage and transcription mediated by elevated JAK2 
activity may concertedly drive high levels of PD-L1 and PD-L2 expression.  
 
Loss or shortening of 3’UTRs has been associated with overexpression of 
many genes involved in tumour progression (Mayr and Bartel, 2009). 
Recently, structural variations in the 3’UTR of PD-L1 were found in multiple 
cancers at a low frequency, with the highest prevalence in stomach 
adenocarcinoma (2%), B-cell lymphoma (8%) and adult T-cell 
leukaemia/lymphoma (27%) (Kataoka et al., 2016). Structural disruption of 
the PD-L1 3’UTR was found to be cell-intrinsic, or directly induced by viral 
integrations following infection (e.g. Esptein-Barr virus in stomach 
adenocarcinoma). Loss of the PD-L1 3’UTR was associated with increased 
PD-L1 mRNA expression in human cancers and increased PD-L1 expression 
in mouse cancer cell lines with genetically engineered deletion of the 3’UTR. 
Although the mechanism for this genetic regulation remains unclear, the 
authors speculate that miRNAs and a putative AU-rich element in the long 
PD-L1 3’UTR might have a role.  
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PD-L1 levels are also directly governed by cell-intrinsic signalling. In cancer, 
this is becoming increasingly evident, as several oncogenes have been 
implicated in controlling tumour cell PD-L1 expression and thus anti-tumour 
immunity (Pardoll, 2012). A simplified overview of the molecular control of 
PD-L1 expression is shown in Figure 1.5.  
 
The first report linking an oncogenic pathway to PD-L1 regulation and 
immune evasion reported that loss of the tumour suppressor PTEN in glioma 
could cause upregulation of PD-L1 mRNA translation, dependent on mTOR 
activity (Parsa et al., 2007). How this mechanism operates for the PD-L1 
transcript specifically remains unclear, as the 5’UTR does not contain 
canonical elements such as 5’ terminal oligopyrimidine tract (TOP) 
sequences that are known to be responsive to S6K1 activity. Since, mTOR 
has also been described as a driver of PD-L1 expression through 
upregulating PD-L1 translation in lung cancer (Lastwika et al., 2016). Using 
mouse models of Ras-driven lung cancer the authors were able to 
demonstrate that chronic rapamycin treatment reduces tumour PD-L1 protein 
expression in vivo. Moreover, rapamycin treatment appeared to combine well 
with anti-PD-1 therapy to reduce lung tumour burden. Considering the well-
known immunosuppressive effects of rapamycin, it is difficult to conclude 
whether the observed decrease in tumour PD-L1 expression in vivo is at 
least partly due to rapamycin-induced changes in tumour-associated 
leukocytes. 
 
Interestingly, a recently developed mouse model of lung squamous cell 
carcinoma driven by the loss of Pten and Lkb1 was found to harbour a 
subpopulation of tumour-propagating cells that expressed high levels of PD-
L1, suggesting that this cell population may be exceptionally immunoresistant 
(Xu et al., 2014a). Following on from this work, the authors found that LKB1 
loss in human and mouse Ras-driven lung cancer was associated with lower 
levels of PD-L1 (Koyama et al., 2016). These results imply that the loss of 
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Pten may be the dominant genetic determinant driving immune resistance in 
their mouse model of lung squamous cell carcinoma.  
 
MEK inhibition was found to be effective in reducing PD-L1 expression in 
acute myeloid leukaemia (Berthon et al., 2010). In support of this finding, 
melanoma cells that develop resistance to the BRAF inhibitor vemurafenib 
were found to elevate MEK activity and, in parallel, elevate expression of PD-
L1 (Jiang et al., 2013). Crucially, MEK inhibition significantly reduced tumour 
cell PD-L1 levels in BRAF inhibitor-resistant melanoma cells, as did siRNA-
mediated knock-down of the transcription factor c-jun. Based on these data, 
the authors predict the functional involvement of an upstream AP-1-
dependent enhancer at the PD-L1 locus. BRAF inhibition has been shown to 
decrease PD-L1 expression in some BRAF V600E positive cell lines, 
however, work from the Ribas laboratory has revealed that inhibitors of 
BRAF, MEK and PI3K result in variable effects on PD-L1 expression across 
an extensive panel of melanoma cell lines; in some cases decreasing PD-L1 
expression and occasionally even modestly increasing levels of PD-L1 (Atefi 
et al., 2014). These results imply that PD-L1 expression responses to such 
pathway inhibitors are nuanced, even in the same tissue type, and highlight 
the lack of molecular detail linking these pathways to PD-L1 gene 
expression. 
 
Using a GEMM of EGFR-mutant NSCLC, PD-L1 levels were shown to be 
strikingly elevated on lung tumour cells, suggesting the development of an 
intrinsic immunosuppressive phenotype (Akbay et al., 2013). Moreover, 
EGFR inhibitors successfully reduced PD-L1 expression in several NSCLC 
cell lines, implying that EGFR TKIs may be of use in combination with 
immunotherapy treatments. Notably, lung tumours from the mouse model of 
NSCLC driven by a mutant, human EGFR transgene were responsive to PD-
1 blockade. Conversely, a mouse model of NSCLC driven by oncogenic Kras 
and the loss of Trp53 was refractory to anti-PD-1 therapy. These data imply 
disparate immunosuppressive programmes at play in these mouse models. 
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Alternatively, their data might reflect the increased immunogenicity of EGFR+ 
cancer cells, as the EGFR transgene is a highly expressed cell surface 
protein of human origin. 
 
Oncogenic ALK-fusion proteins have been implicated in promoting PD-L1 
expression through different mechanisms. In T cell lymphoma, the 
nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) fusion protein 
induces activation of PD-L1 expression through STAT3 (Marzec et al., 2008), 
whereas in lung cancer, PD-L1 level upregulation by echinoderm 
microtubule-associated protein-like 4 (EML4)-ALK seems dependent on MEK 
and PI3K signalling rather than STAT3 (Ota et al., 2015). Nonetheless, 
inhibitors of ALK were effective in reducing PD-L1 expression in both 
scenarios.  
 
The proto-oncogene transcription factor MYC has recently been implicated in 
promoting PD-L1 expression in mouse T cell lymphoblastic leukaemia 
(Casey et al., 2016a). Oncogenic levels of MYC facilitated occupancy of the 
PD-L1 promoter, suggesting direct transcriptional regulation. In addition, 
another transcription factor, FoxA1, has been implicated in promoting PD-L1 
expression in an atypical Treg subset (FOXP3- FoxA1+ Tregs) involved in 
reducing autoimmune inflammation in the central nervous system (Liu et al., 
2014). When overexpressed, FoxA1 bound to the PD-L1 promoter in ChIP 
experiments, and modestly increased expression of a luciferase reporter 
bearing the PD-L1 promoter region. Furthermore, FoxA1+ Tregs express 
high levels of PD-L1 and their immunosuppressive function seems to be 
dependent on PD-L1 expression. Finally, PD-L1 may be a p53 target gene, 
as enforced expression of p53 upregulated PD-L1 expression, and moreover, 
DNA damage-induced expression of PD-L1 is dependent on p53 (Yoon et al., 
2015). However, there is conflicting evidence on this, as p53 has since been 
shown to upregulate the mircoRNA (miRNA) miR34, which can target PD-L1 
mRNA, indicating that p53 may in fact indirectly reduce PD-L1 expression in 
cancer (Cortez et al., 2016). 
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Numerous other studies have implicated miRNAs in the negative regulation 
of PD-L1 expression, including miR34, miR200, miR513, miR424 and 
miR570. Chen et al showed that epithelial to mesenchymal transition in lung 
cancer cells is accompanied by a ZEB1-mediated decrease in miR200, 
resulting in de-repression of PD-L1 (Chen et al., 2014). In addition, elevated 
PD-L1 expression was shown to enhance the metastatic capability of lung 
cancer cells in vivo. In humans, somatic mutations within the PD-L1 3’UTR 
binding site for miR-570 can partially disrupt miRNA binding and are 
associated with higher PD-L1 expression in gastric adenocarcinoma cells in 
vitro and in vivo (Wang et al., 2013; Wang et al., 2012). In cholangiocytes, 
miR-513 is downregulated following IFN-γ-stimulation, contributing to PD-L1 
induction by de-repression of PD-L1 mRNA translation (Gong et al., 2009). 
Interestingly, Kataoka and colleagues found that cells with PD-L1 3’UTR 
deletions could still respond to IFN-γ, suggesting that transcriptional and 
post-transcriptional control govern PD-L1 induction by IFN-γ (Kataoka et al., 
2016). 
 
 
 
Figure 1.5 The control of PD-L1 expression in cancer cells 
Schematic overview of the points of regulation governing PD-L1 expression 
in cancer. The regulatory pathways highlighted here mostly correspond to 
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experiments performed in cancer cells, but may also apply in non-malignant 
contexts. Question marks indicate that a functional link has been made with 
the regulation of PD-L1 expression but the mechanistic detail remains 
unclear. 
 
1.8 AU-rich element mediated mRNA decay and 
tristetraprolin 
 
1.8.1 AU-rich element-mediated decay 
 
Post-transcriptional control of gene expression in mammals can generally be 
subdivided into the regulation of mRNA translation, and mRNA degradation. 
Common genetic elements controlling mRNA stability include miRNAs and 
adenosine and uridine (AU)-rich elements (AREs). AREs are AUUUA 
sequences in the 3’UTR of mRNAs that confer instability. AREs were first 
described in 1986, when strikingly conserved AU-rich sequences were found 
in the 3’UTR of TNF mRNA and other mRNAs encoding proteins relating to 
the regulation of immunity (Caput et al., 1986). Since, AREs have been 
implicated in many cellular functions and disease. Remarkably, when 
classified by sequence alone, up to 5-8 % of human genes contain AU-rich 
elements (Bakheet et al., 2006). Commonly, these are known to be functional 
mainly in transcripts coding for cytokines, chemokines, immediate early 
genes and proto-oncogenes that require rapid and dynamic control of gene 
expression. In functionally validated AREs, the core AUUUA-pentamer motif 
is usually found within AU-rich context. AREs are classified into class I, II and 
III based on the core motif and surrounding RNA sequence (Chen and Shyu, 
1995). Class I AREs are found in AU-rich context but are non-overlapping, 
whereas class II AREs contain several overlapping nonamer sequences in 
AU-rich context (Barreau et al., 2005). Class III AREs are less common and 
non-canonical as they lack the AUUUA core pentamer sequence and instead 
contain only uridine-rich sequences (for example c-jun mRNA). Although the 
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functional differences between the ARE classes remains unclear, cytokine 
mRNAs tend to harbour class II AREs.  
 
Ultimately, AREs recruit AU-rich element binding proteins (ARE-BPs), most 
of which are destabilising, but some act to stabilise the labile transcript 
(Table 1). There is evidence to suggest that stabilising AUBPs function by 
competing with destabilising ARE-BPs for ARE binding (Linker et al., 2005).  
 
 
 
Table 1. AU-rich element binding proteins 
Known ARE-BPs and their effect on ARE-containing mRNAs. 
 
ARE-BPs, such as TTP, are not sufficient to degrade ARE-mRNA in isolation 
(Lai et al., 2003). Rather, ARE-BPs subsequently recruit the catalytic 
machinery to the target mRNA for deadenylation (shortening of the poly(A) 
tail), decapping and degradation. Specifically, ARE-mediated mRNA decay is 
initiated by mRNA deadenylation by the Ccr4-Caf1-Not complex, Pan2-Pan3 
complex or poly A-specific ribonuclease (PARN) complex, which allows for 
the activity of the exosome 3’-to-5’ RNA exonuclease complex. Alternatively, 
ARE-BPs such as TTP are involved in directing mRNAs to processing bodies 
(P-bodies), where partially deadenylated mRNAs associate with decapping 
machinery including Dcp1a, Dcp2 and Hedls, enabling the 5’-to-3’ RNA 
exonuclease activity of Xrn1 (Franks and Lykke-Andersen, 2007). 
  
ARE-BP Function
TTP Destabilising
BRF-1 Destabilising
BRF-2 Destabilising
KSRP Destabilising
HuR Stabilising
HuD Stabilising
AUF1 Destabilising/Stabilising
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1.8.2 Tristetraprolin biology 
 
Tristetraprolin (TTP) or zinc-finger protein 36 (ZFP36), is a CCCH-type zinc-
finger AU-rich element binding protein involved in destabilising target 
mRNAs. Perry Blackshear’s laboratory first discovered TTP, and 
subsequently named the protein tristetraprolin due to its three distinctive 
PPPPG repeats (Lai et al., 1990). However, TTP has several additional 
names including Nup475, G0S24 and TIS11, due to the fact that several labs 
cloned the Zfp36 sequence within a short space of time (Brooks and 
Blackshear, 2013). Currently, it is arguably the best studied of all ARE-
binding proteins.  
 
Using a TTP knock-out mouse, Blackshear and colleagues identified TNF-α 
as the first mRNA target of TTP (Taylor et al., 1996). TTP KO mice suffered 
from an autoimmune syndrome involving severe arthritis and weight loss. 
Strikingly, many aspects of the disease phenotype were almost completely 
reversed when KO mice were treated with a monoclonal antibody against 
TNF-α. Shortly after, it was shown that TTP downregulates TNF-α levels 
following co-induction of both TNF-α and TTP by LPS in macrophages, 
constituting a mechanism for rapid feedback inhibition (Carballo et al., 1998).  
 
TTP is subject to complex regulation by phosphorylation at many sites. In 
fact, 49 phosphosites have been documented to date, out of a total of 319 
amino acids in the mouse TTP protein (www.phoshphosite.org). Of these, 
only two phosphosites have been identified that are patently important for 
regulating the activity of TTP; S52 and S178 of mouse TTP (Figure 1.6). In 
vitro kinase assays initially verified phosphorylation of mouse TTP by MK2 
(MAPKAPK2) at S25 and S178 (Chrestensen et al., 2004; Mahtani et al., 
2001). Phosphorylation of these residues has been proposed to regulate TTP 
activity in several ways including: (1) increasing binding to 14-3-3 proteins, 
(2) changing the sub-cellular localisation of TTP, (3) decreasing target mRNA 
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binding by TTP, (4) preventing deadenylase recruitment, and (5) stabilising 
TTP protein.  
 
S52 and S178 weakly conform to the MK2 phosphorylation consensus motif 
(Hyd-X-R-X-L/N-phS/T-I/V/F/L, where Hyd is a hydrophobic residue), and 14-
3-3 binding consensus motif (R-S-X-phS-X-P) (Cargnello and Roux, 2012) 
(Figure 1.6). Phosphorylation of S52 and S178 has been shown to mediate 
exclusion from stress granules through a mechanism involving MK2-
mediated phosphorylation inducing 14-3-3 binding to TTP (Stoecklin et al., 
2004). It has been suggested that TTP binding to ARE-containing mRNAs 
may be partially inhibited by MK2 activity (Hitti et al., 2006), although the 
evidence for this remains contentious and there are reports suggesting that 
TTP’s mRNA binding efficiency is not influenced by MK2 (Clement et al., 
2011; Marchese et al., 2010).  
 
There are multiple reports suggesting that the hyerphosphorylated form of 
TTP protein is more stable. Increased TTP protein stability is dependent on 
MK2-mediated phosphorylation and reduced proteasomal targeting of TTP 
(Brook et al., 2006; Deleault et al., 2008). Indeed, MK2 knock-out cells have 
very low basal levels of TTP protein compared to wild-type cells (Hitti et al., 
2006). This mechanism may seem counterintuitive at first, but it has been 
proposed that the accumulation of a pool of inactive, stable, 
hyperphosphorylated TTP protein primes the cell for rapid TTP function and 
mRNA downregulation when termination of mRNA expression is required. 
Consistent with this concept, p38 signalling is co-activated by several stimuli 
that stimulate the expression of TTP target genes. For example, LPS can 
acutely induce TNF-α expression, TTP expression, and p38 signalling 
(Carballo et al., 1998). Hyperphosphorylated TTP is eventually activated by 
phosphatases resulting in feedback inhibition of TNF-α mRNA gene 
expression (Brooks and Blackshear, 2013). Recently, PP2A has been 
identified as the primary phosphatase responsible for activating TTP 
(Rahman et al., 2015; Sun et al., 2007). PP2A has been shown to physically 
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interact with TTP, and PP2A inhibition increases 14-3-3 binding to 
hyperphosphorylated TTP. 
 
The first crystal structure of human TTP bound to CNOT1 provided novel 
insights into how TTP interacts with the effector complex CCR4-NOT in 
human cells (Fabian et al., 2013). TTP interacts with CNOT1, an essential 
component of CCR4-NOT RNA deadenylase complex, through a highly 
conserved C-terminal region, which the authors named the CNOT1 
interaction motif (CIM) (Figure 1.6). Notably, the authors found that 
phosphorylation of serine residue 323 (within the human TTP CIM) 
dramatically reduced binding to CNOT1 in vitro. Interestingly, Lykke-
Andersen’s group showed that phosphorylation of TTP at MK2 target sites 
led to decreased deadenylation recruitment and activity using 
immunoprecipitation and in vitro deadenylation assays (Clement et al., 2011). 
Although the binding of the deadenylase complex seemed inversely 
proportional to 14-3-3 binding, the known binding sites for 14-3-3 and CNOT1 
are not predicted to significantly overlap (Fabian et al., 2013). Notably, the 
authors show that TTP also interacts with the Pan2-Pan3 complex (Clement 
et al., 2011). To our knowledge, the interaction site for Pan2-Pan3 with TTP 
remains to be identified. In addition, it is possible that TTP binds to the 
deadenylase PARN, although there is conflicting data on this (Clement et al., 
2011; Lai et al., 2003). 
 
In mammals, TTP is a member of a family of four related proteins; the other 
members are ZFP36L1, ZFP36L2 (also known as butyrate-response factor 1 
and 2; BRF-1 and BRF-2) and Zfp36l3, however the latter appears to be 
mouse or rodent-specific and is only expressed in placenta and yolk sac 
(Blackshear et al., 2005). TTP, ZFP36L1 and ZFP36L2 are more widely 
expressed and share target specificity for the AU-rich nonamer consensus 
motif (Brooks and Blackshear, 2013). One study showed that ZFP36L1 and 
ZFP36L2 proteins are negatively regulated by RSK downstream of ERK 
through phosphorylation of two conserved residues in the CIM. RSK was 
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shown to be capable of increasing phosphorylation of serine 334 of human 
ZFP36L1 in an in vitro kinase assay, decreasing binding to CNOT7. 
Tantalisingly, these residues are analogous to those proposed by Fabian et 
al. to be functionally important in regulating TTP itself (Adachi et al., 2014) 
(see also Figure 1.6). Furthermore, early in vitro kinase assays and mass 
spectrometry analysis by the Blackshear lab revealed TTP phosphorylation 
at several sites by ERK, although the functional relevance of these ERK 
target sites are yet to be verified (Cao et al., 2003). However, ERK and p38 
have been shown to act synergistically to stabilise TNF-α mRNA and 
regulate TTP protein stability and localisation (Brook et al., 2006; Deleault et 
al., 2008).  
 
 
 
Figure 1.6 Shematic of mouse TTP protein 
Functional annotation of mouse TTP protein. PPPPG repeats, zinc-finger 
domains and CNOT1 interaction motif (CIM) are highlighted. Asterisks 
correspond to serine residues (highlighted in red) that are known MK2 
phosphorylation sites. The CIM also contains known phosphosites, 
highlighted in red. Numbering corresponds to the amino acid sequence of 
mouse TTP.  
 
1.8.3 Decay-independent roles of tristetraprolin 
 
TTP has been shown to have mRNA-decay-independent functions, including 
repression of mRNA translation (Schott et al., 2014). Conserved PPPPG 
motifs 1 and 2 within TTP mediate the interaction with GYF2 of the EHP2-
GYF2 translational repression complex, thus preventing proper eIF4F 
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complex formation and cap-dependent translation initiation (Fu et al., 2016). 
This is the first report describing a function for the eponymous PPPPG 
repeats within TTP (Figure 1.6). Moreover, in some cases TTP appears to 
associate with polysomes and compete for AREs with the translation-
promoting AUBP, HuR (Tiedje et al., 2012). 
 
Furthermore, using an RNA interference screening approach in Drosophila 
cells, TTP was implicated in miRNA-mediated mRNA repression of ARE-
containing mRNAs, through association with Ago/eiF2C family members 
(Jing et al., 2005). miR16 (which is complementary to the ARE) affected the 
stability of a TNF-α 3’UTR reporter, and this effect was apparently dependent 
on TTP. 
 
1.8.4 Tristetraprolin in cancer 
 
Although it is rarely mutated in cancer (COSMIC database), TTP expression 
is dramatically reduced in many cancers (Brennan et al., 2009), and there is 
mounting evidence that TTP can have multifaceted anti-tumour effects; 
therefore, ZFP36 is a putative tumour suppressor gene (Stoecklin et al., 
2003). Mechanistically, how TTP expression is reduced in cancer versus 
normal tissue remains unclear, however there are indications that in tumours 
with Myc dysregulation, TTP transcription may be directly repressed by Myc 
through binding to TTP initiator elements (Rounbehler et al., 2012). The 
Cleveland and Blackshear laboratories have shown that re-expression of 
TTP in a Myc-driven B-cell lymphoma model can significantly halt disease 
progression in mice, which the authors partly attribute to reductions in cyclin 
D1 expression (a TTP target ARE-mRNA). However, it is likely that TTP 
regulates a plethora of ARE-mRNAs, therefore the reprogramming of the 
expression profile of cancers with low TTP expression or activity will be more 
complex. Indeed, rescue of cyclin D1 expression alone was not sufficient to 
re-establish the malignant phenotype once TTP was expressed (Rounbehler 
et al., 2012). In addition, TTP targets VEGF and COX-2 in colon carcinoma 
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cell lines and forced TTP transgene expression has therapeutic effects in 
xenograft mouse models of colon cancer (Cha et al., 2011; Essafi-Benkhadir 
et al., 2007; Lee et al., 2010). VEGF is well known to promote tumour 
angiogenesis, whereas tumour cell COX-2 expression has recently been 
shown to mediate evasion of anti-tumour immunity in melanoma (Zelenay et 
al., 2015). Intriguingly, VEGF mRNA stability is destabilised by MEK 
inhibition, and VEGF 3’UTR luciferase reporter assays respond to RAS 
activity (Essafi-Benkhadir et al., 2007). It seems enforced expression of TTP 
is able to partially counter-act RAS-ERK driven VEGF expression, but TTP 
activity is hindered by ERK signalling (Essafi-Benkhadir et al., 2007). The 
mechanistic detail of this link warrants further investigation. 
 
1.9 Conclusions 
 
Early genetic experiments in mice and syngeneic tumour transplant models 
have paved the way to the clinic for blockbuster drugs such as ipilimumab 
and nivolumab. The development of successful ICB therapies has led to 
substantial remodelling of classical drug discovery, with the sales of ICB 
expected to be in excess of $1.2 billion by the year 2020 in the US alone 
(Webster and Mentzer, 2014). Unlike targeted therapies, which have the 
advantage of traceable target mutations in tumours, the clinical emphasis 
now resides on identifying biomarkers of response to ICB. Investigating anti-
cancer immunity and immune-escape in relevant preclinical models can 
potentially accelerate our understanding of the clinical determinants of cancer 
immunotherapy response. In the search for reliable biomarkers, tumour cell 
or tumour-associated immune cell PD-L1 expression is currently the front-
runner. However, many unanswered questions still remain over the molecular 
regulation of PD-L1 expression in cancer, especially with regard to potential 
regulation by common oncogenic drivers.  
 
AU-rich element mediated mRNA decay is an important process regulating 
gene expression in immune cell biology and thus anti-cancer immunity. 
Chapter 1. Introduction 
 66 
These cis-acting elements act by recruiting highly regulated ARE-BPs, which 
often act in a combinatorial and competitive fashion. The most intensively 
studied ARE-BP is TTP. Given its complex regulation, it has been postulated 
that TTP acts as a molecular sensor for the ARE RNA degradation 
machinery. The relative paucity of ARE mutations in human disease may 
reflect the relative ease of altering ARE-BP function through dyregulation of 
these pathways. However, how these regulatory pathways are altered in 
cancer is poorly characterised. 
 
The majority of this thesis focuses on investigations into: (1) the 
immunogenicity of a RAS-driven mouse model of lung cancer, and the use of 
this model for the preclinical study of cancer immunology, (2) the regulation 
of PD-L1 expression in lung cancer by RAS and the ARE-BP TTP, and (3) 
the functional relevance of the regulation of PD-L1 expression by RAS and 
TTP in vivo. 
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2 Chapter 2. Materials and Methods 
 
2.1 Cloning, plasmids and stable cell lines 
 
peGFPC1-6XHis-FL-KSRP was a gift from Douglas Black (Addgene plasmid 
# 23001)(Hall et al., 2004) and the S193A mutant was generated by site-
directed mutagenesis (QuikChange II; Agilent).  
 
Full length human TTP was cloned from H358 genomic DNA into pCDNA3-
MycX2 generating two N-terminal Myc tags. The S218/228A TTP double 
mutant was generated by site-directed mutagenesis (QuikChange II; Agilent).  
 
For the luciferase reporter constructs, the full length human PD-L1 3’UTR 
was cloned from H358 genomic DNA into the TOPO-TA vector (Life 
Technologies). The six most 3’ ATTTA pentamers (including the three most 
highly conserved) were mutated to ATGTA (QuikChange Multi-site; Agilent). 
Wild type and mutant fragments were subcloned into the Xba1, BamH1 site 
of pGL3-control (Promega) to generate the reporter constructs. 
 
CT26 cells were transfected with linearised pUNO empty and pUNO-mouse 
PD-L1∆3’UTR plasmids (InvivoGen) before selection with blasticidin, and for 
PD-L1∆3’UTR cells, subsequent FACS sorting of PD-L1 high, blasticidin-
resistant cells. For the lentiviral pTRIPZ constructs, full-length mouse TTP 
was cloned from KPB6 genomic DNA into pCDNA3-MycX2 generating two N-
terminal Myc tags. MycX2-TTP was subsequently subcloned into the Age1-
Mlu1 site of pTRIPZ-empty (GE Healthcare), resulting in the final TTP (tet-
ON) construct, without the TurboRFP or shRNAmir-related elements of the 
parental pTRIPZ plasmid. Lentiviral particles were generated from HEK 
293FT cells (see Preparation of lentiviral particles, below) and infected target 
cells were subsequently selected with puromycin to establish stable cell lines. 
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For the construction of plenti-Cre shMsh2, the Puro-Cre.empty vector from 
the Tyler Jacks laboratory (Addgene plasmid #17408) was linearised with 
Xba1 and Not1, thus removing the puromycin resistance cassette. The U6 
promoter and downstream shRNA sequence was PCR amplified from shScr 
or shMsh2.2 p.LKO-1 vectors and the relevant PCR products were inserted 
into the lentiviral Cre plasmid backbone. 
 
2.2 Transfections 
 
2.2.1 siRNA 
 
For RNA interference, cells were reverse-transfected with a final 
concentration of 50 nM siGENOME siRNA pools of four siRNAs or the ON-
TARGETplus Non-targeting pool (“SiScrambled” control) and DharmaFECT 1 
transfection reagent (Dharmacon; GE Healthcare) in 96 well plates. Briefly, 
1.25 µl of siRNA was mixed with 3.75 µl HBSS (Gibco) and in a separate 
tube, 0.15 µl of DharmaFECT 1 was mixed with 14.85 µl HBSS per reaction. 
After a 5 min incubation, these solutions were mixed together and incubated 
for a further 15 min. 80 µl of cell suspension in antibiotic-free medium was 
plated onto 20 µl of siRNA-lipid complex per well of a 96 well plate. 
 
2.2.2 Transfections with expression vectors 
 
For transfection with TTP or KSRP constructs, cells were seeded in a 12 well 
plate in antibiotic-free medium, and the following day, transfected using 
Lipofectamine 2000 according to manufacturer’s instructions (Life 
Technologies). Media was changed 7 h post-transfection. 
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2.3 Luciferase assays 
 
H358 cells or ER-HRASG12V MCF10A cells were plated in 96 well plates and 
the following day co-transfected with pRL-TK control and pGL3-3’UTR PD-L1 
luciferase constructs using Lipofectamine 2000 (Life Technologies). 0.25 µl of 
Lipofectamine 2000, 15 ng of pRL-TK luciferase control and 85 ng of pGL3 
luciferase reporter (wild-type or mutant PD-L1 3’UTR) were used per well. 
For H358 cells, 24 h after transfection, PMA (200 nM; Sigma) was added, 
and 6 h later the Dual-Luciferase Reporter Assay (Promega) was performed. 
For ER-HRASG12V MCF10A cells, 24 h after transfection cells were serum-
starved overnight, and then treated with 4-OHT (100 nM) for 24 h before the 
Dual-Luciferase Reporter Assay (Promega) was performed according to 
manufacturer’s instructions. 
 
2.4 Preparation of lentiviral particles 
 
Lentiviral particles for use in vitro were produced by co-transfection of HEK 
293FT cells with the lentiviral construct, psPAX2 and pMD2.G plasmids. 48 h 
and 72 h after transfection, viral supernatant was harvested and filtered 
through a 0.45 µm filter. Filtered viral supernatants were diluted in fresh 
medium, supplemented with 8 µg/ml polybrene (Millipore) and used to infect 
target cells.  
 
For generation of high titre lentiviral preparations for in vivo application, 
transfections of 293FT cells were scaled-up for 15 cm dishes and the 
resulting viral supernatant was concentrated by spinning for 2 h in an 
ultracentrifuge at 70,000 g. Supernatant was gently removed and the 
remaining liquid volume further reduced by evaporation at room temperature, 
before the viral pellets were resuspended in PBS or HBSS and incubated 
overnight at 4 °C. 
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pLKO.1 shRNAs were sourced from Dharmacon. Sequences and reference 
number of shRNAs used in this thesis are listed in Table 2. 
 
Table 2. shRNA sequences 
  
 
 
2.5 Flow cytometry 
 
2.5.1 In vivo  
 
Lung tissue was harvested in ice-cold PBS before mincing and then 
enzymatic digestion in Liberase TM and Liberase TH (both 75 µg/ml final; 
Roche) with DNaseI (25 µg/ml final; Sigma) in HBSS (Gibco) for 45 min at 37 
ºC. After washing in DMEM + 10 % FCS, cells were filtered through 70 µm 
filters (BD Bioscience) and then washed in FACS buffer (PBS supplemented 
with 2 mM EDTA and 0.5 % BSA v/v final). Samples were then treated with 
Red Blood Cell Lysis Buffer (Qiagen), washed in FACS buffer, filtered again 
and resuspended with FcR blocking reagent (BD Bioscience) before antibody 
staining in FACS buffer. Samples were washed twice in FACS buffer and 
RNAi Reagent Target Gene Clone Number Reference Number Sequence
shRNA TTP mouse 1 TRCN0000102300 AAGTCGTCATAAATAAAGGGC
2 TRCN0000102302 AAGCTGATGCTTTGTCGCAGC
3 TRCN0000102304 TGGCGTAGTCATCAGGATCGG
4 TRCN0000102303 TTAGGGTCTCTTCGAGTCACA
5 TRCN0000102301 TTTATGTTCCAAAGTCCTCCG
shRNA PD-L1 mouse 1 TRCN0000068002 TTTGGAGCCGTGATAGTAAAC
2 TRCN0000067998 TTGAGCTTGTATCTTCAACGC
3 TRCN0000068000 TAGTTCATGCTCAGAAGTGGC
4 TRCN0000068001 TCGAATTGTGTATCATTTCGG
5 TRCN0000067999 TTATGCAGCAGTAAACGCCTG
shRNA Msh2 mouse 1 TRCN0000042493 AAACTGAGAAAGATTGCCGGG
2 TRCN0000042494 TTTATCCGTGAAATGATCTCG
3 TRCN0000042495 AAAGGCACCAATCTTCGTTGC
4 TRCN0000042496 AACAATGGCGTCTAAGTGAGC
5 TRCN0000042497 TTAATACCCTGATACAGTCGG
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resuspended in DAPI (1 µg/ml final; eBioscience) immediately before 
analysis.  
 
For immune profiling of mouse lung tissues, the relevant fluorescent minus 
one (FMO) and single-staining controls were included. The following 
antibodies were used in these experiments: CD45 (30-F1; eBioscience), 
CD11b (M1/70; eBioscience), Ly6G (1A8; BD Biosciences), F4/80 (CD: A3-I; 
BioLegend), CD3 (145-2C11; BD Biosciences), CD19 (1D3; eBioscience), 
CD11c (HL3; BD Biosciences), CD49b (DX5; eBioscience), CD4 (GK1.5; 
eBioscience), CD8a (53-6.7; eBioscience).  
 
2.5.2 In vitro 
 
For FACS analysis of cells lines, cells were harvested with trypsin or 
versene, washed in media and filtered before antibody staining in FACS 
buffer. Annexin V staining was performed using Annexin V binding buffer 
(Invitrogen) and following the manufacture’s instructions (Invitrogen). After 
staining, samples were washed twice in FACS buffer and resuspended in 
DAPI (1 µg/ml final; eBioscience) immediately before analysis on LSRII or 
LSRFortessa (BD Biosciences) cell analysers.  
 
For detection of intracellular ROS, adherent cells were washed once in PBS 
before staining in 5 µM H2DCFDA (Invitrogen) for 20 min at 37 °C. Cells were 
then harvested and stained for PD-L1 as described before FACS analysis. 
 
Cell cycle analysis was performed as follows: cells were pulsed with BrdU 
(10 µM, 45 min), harvested with trypsin or versene, washed in PBS, fixed in 
ice-cold 70 % ethanol. After washing in PBS, cells were resuspended in 2 M 
HCl at room temperature, incubated for 30 min with mixing, washed in PBS-T 
before staining with anti-BrdU antibody. Cells were then treated with RNase 
before staining with PI and FACS analysis. 
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2.6 Cell sorting and ex vivo IFN-γ ELISA 
 
Spleen, lung and lung tumour tissue was harvested and digested as above. 
For lung and tumour tissue, negative cell sorting by FACS was based on 
CD31, CD45 and DAPI negativity. For CD8 T cell negative sorting, selection 
was based on Cd11b, Ly6G, CD11c, F4/80, CD4, CD18, CD49b and DAPI 
negativity. 5 000 target cells were plated with 10 000 or 100 000 purified, 
CD8 T cells and incubated in a total of 200 µl of medium. After a 12 h 
incubation period, an IFN-γ ELISA was performed using 100 µl of conditioned 
media, according to the manufacturer’s instructions (eBioscience). Duplicate 
technical repeats were performed for each experimental condition. 
 
As a control, EL4 lymphoma cells or EG.7-OVA cells were used as targets 
and CD8 T effector cells were harvested from naïve mice or mice vaccinated 
against OVA. Briefly, mice received PBS control or 100 µg OVA protein and 
50 µg poly(I:C) (InvivoGen) in PBS by i.v administration, 6-7 days before 
sacrifice. 
 
2.7 EL4 TCR stimulation 
 
EL4 cells were plated in 24 well plates and the following day, stimulated with 
the addition of CD3/CD28 Dynabeads (Invitrogen) at a 1:1 cell to bead ratio. 
Cells were concomitantly treated with DMSO vehicle control or MEK inhibitor 
(25 nM trametinib GSK1120212). After 24 h, beads were removed with a 
magnet and by washing and cells were stained with antibodies against PD-L1 
and CD69 and prepared for flow cytometry as described. 
 
2.8 Quantitative real-time PCR (qPCR) 
 
RNA was extracted using RNeasy Mini Kit (QIAGEN). Generally, 1 µg of 
RNA was used to generate cDNA using SuperScript VILO or SuperScript II 
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Reverse Transcriptase (Life Technologies). qPCR reactions were carried out 
using QuantiTect Primer Assays (QIAGEN) and SYBR Green reagents (Life 
Technologies). Gene expression changes relative to the stated housekeeping 
gene were calculated using the ∆∆CT method. 
 
2.9 RNA-immunoprecipitation 
 
RNA-immunoprecipitation (RNA-IP) reactions were carried out using Magna-
RIP RNA-IP Kit (Millipore) with IgG control, anti-TTP or anti-KSRP antibodies 
according to the manufacturer’s instructions, except for the exclusion of 
EDTA from lysis and wash buffers, as TTP is a zinc-finger protein. Total RNA 
was isolated and qPCR was carried out using methods specified in the above 
section, except using the % input method to calculate RNA enrichment. 
 
2.10  Immunoprecipitation 
 
For each immunoprecipitation reaction, 25 µl slurry of Dynabeads (Life 
Technologies) was coupled to 3 µg of anti-Myc antibody (9E10; in-house). In 
some experiments, beads were cross-linked using DSS following 
manufacturer’s instructions (ThermoFisher). Beads were washed in Lysis 
Buffer (20 mM Tris-HCl, pH 7.4, 137.5 mM NaCl, 10 % glycerol, 1 % Triton X-
100) and incubated overnight with rotation at 4 ºC with cleared cell lysates 
prepared in Lysis Buffer supplemented with protease and phosphatase 
inhibitor cocktails (Calbiochem). Beads were washed three times with IP 
Wash Buffer (modified Lysis Buffer: 0.1 % Triton X-100, final), before elution 
with LDS Sample Buffer (Life Technologies). 
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2.11 In vivo studies 
 
All studies were performed under a UK Home Office approved project license 
and in accordance with institutional welfare guidelines. 
 
2.11.1 KP mice 
 
KrasLSL-G12D/+; Trp53F/F mice were sourced from the Mouse Models of Human 
Cancer Consortium and were backcrossed to C57Bl/6 for 6 generations. 
Lung tumours were initiated as described (DuPage et al., 2009a) using 
intratracheal intubation of 1x106 pfu adenovirus expressing Cre-recombinase 
(Gene Transfer Vector Core). Lung tumour or normal lung tissue was 
analysed 12 weeks after infection. KrasLSL-G12D/+; Trp53F/F; Rag2+/- mice were 
generated by crossing KrasLSL-G12D/+; Trp53F/F mice of mixed strain 
background with C57B/6 Rag2+/- JAX mice (The Jackson Laboratory).  
 
For the anti-PD-L1 therapy study, tumours were initiated as described 
(DuPage et al., 2009a) using 1x106 pfu adenovirus expressing Cre-
recombinase (Gene Transfer Vector Core). 12 weeks after infection, animals 
were randomly assigned treatment groups and were then micro-CT scanned 
to analyse tumour burden using SkyScan 1176 as described (Castellano et 
al., 2013). Animals were treated with 10 mg/kg, endotoxin-free, anti-PD-L1 
10F.9G2 or isotype control LTF-2 antibody (BioXCell) twice weekly, for two 
weeks by intraperitoneal injection, resulting in a total of four doses per 
animal.  
 
For anti-PD-L1 and anti-CTLA-4 combination therapy, we treated KP mice 
with anti-PD-L1 antibody (10F.9G2, 10 mg/kg) and anti-CTLA-4 antibody 
(9H10, 5 mg/kg) in combination, by concomitant i.p administration. 
Alternatively, mice received the combination of isotype control antibodies 
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(LTF-2 and Syrian hamster IgG, respectively). Mice received a total of three 
doses of combination therapy over a two-week treatment course, with 
injections on day 0, 4 and 8.  
 
For trametinib MEK inhibitor treatments, mice received 3 mg/kg GSK1120212 
by oral gavage daily, for two-weeks periods as indicated (Castellano et al., 
2013). 
 
2.11.2 Tumour transplant models 
 
For CT26 tumour studies, 8-10 week old BALB/c or nu/nu mice received 
1x105 CT26-derivative cells in PBS by subcutaneous injection into the left 
flank and were then immediately randomly assigned into treatment cohorts. 
Mice were treated with water or doxycycline by oral gavage (50 mg/kg) on 
day three after cell injection and then daily, with a two-day break every five 
days of treatment. Tumours were measured using callipers and volume was 
estimated using the formula: width2 x length x 0.5, where length is the longest 
dimension and width is the corresponding perpendicular dimension. 
 
2.11.3 CD4 and CD8 T cell depletion 
 
CD4 GK1 and CD8 2.43 IgG2b rat monoclonal antibodies were diluted in 
sterile PBS and were injected i.p at a dose of 300 µg to deplete CD4 and 
CD8 T cells. A rat IgG2b antibody against an irrelevant antigen (large-T 
antigen) was used as a control. Three days later, CD4 and CD8 T cell 
populations were quantified by FACS. CD4 antibody clone RM4-5 and CD8 
antibody clone 53.6-7 were used as detection antibodies (eBioscience). 
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2.11.4 In vivo imaging: micro computerised tomography (µCT) 
 
Mice were anesthetised by inhalation of isoflurane (Abbott Labs) and CT 
scanned using SkyScan 1176 (Bruker). Breathing rate and body temperature 
were measured throughout the scan using in-built physiological monitoring 
devices. Scanning parameters were as follows: aluminium filter 0.5 mm, 0.7 
degrees rotation step over 180 degrees, 60 ms exposure, source current 500 
mA, source voltage 50 kV, image isotropic pixel size 35 µm. Lung images 
were grouped into bins based on the respiratory cycle with RespGate 
software and images reconstructed using N-Recon. Estimations of lung 
tumour volumes were generated by highlighting 3D regions of interest in 
CTAnalyser. 
 
2.12  CRISPR/Cas 
 
The CRISPR/Cas genome editing was performed on CT26 cells using a 
U6gRNA-Cas9-2A-GFP construct targeting mouse Zfp36 with gRNA 
sequence GTCATGGCTCATCGACTGGAGG (Sigma, MM0000323992). 
Following plasmid transfection, single GFP-positive cells were selected by 
FACS for expansion in culture. Transfection with Cas9-2A-GFP only, served 
as a negative control. KO of functional TTP was confirmed by Western 
blotting and complete Zfp36 allele disruption was confirmed by TOPO-TA 
cloning followed by sequencing. 
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2.13  Histopathology 
 
2.13.1 Immunohistochemistry 
 
Tissue was prepared for histology by incubation in 10 % NBF for 24 h 
followed by 70 % ethanol for a further 24 h before embedding in paraffin. For 
CD3 staining, sections were boiled in sodium citrate buffer (pH6) for 15 min 
and incubated for 1 h in anti-CD3 antibody (ab134096; Abcam), followed by 
biotinylated secondary antibody and HRP/DAB detection. Tumours from 
nu/nu mice served as a negative control for CD3 staining. Haematoxylin and 
eosin staining was performed using standard methods. 
 
2.13.2  RNAscope 
 
In situ hybridisation was performed using RNAscope probes and buffers 
according to manufacturer’s instructions (Advanced Cell Diagnostics). 
Tissues were fixed, embedded in paraffin and sectioned as above. Sections 
older than 2-3 weeks were not used for mRNA detection due to the potential 
loss of signal. A positive control probe for PPIB and negative control probe 
that is bacteria-specific were included in all experiments. Probes used for the 
detection of human and mouse PD-L1 mRNA are as follows: Probe-Hs-
CD274 600861, Probe-Mm-Cd274 420501. 
 
2.14  Bioinformatics 
 
Using two published RAS activation gene expression signatures (Loboda et 
al., 2010; Sweet-Cordero et al., 2005), we identified high and low RAS 
activity LUAD TCGA RNASeq samples. We determined high and low RAS 
activity using GSEA (GeneSetTest, Bioconductor) against genes ranked by 
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their log2 normalized counts scaled across all tumour samples. Only the 
upregulated genes from the signatures were used in the GSEA. Samples with 
a significant GSEA association (FDR < 0.05) of a RAS signature to the upper 
portion of the rank were assigned as having high RAS activity. Those with a 
significant association to the lower portion of the rank were assigned as 
having low RAS activity. Once assigned, we identified RAS-dependent gene 
expression changes between the high and low RAS activity groups by 
standard RNASeq analysis methods (DESeq2, FDR < 0.05). A short-list of “T 
cell Function” related genes was generated from gene ontology annotation 
based on the nanoString Technologies nCounter Human PanCancer Immune 
Profiling Panel. 
 
2.15  Mass Spectrometry 
 
Gel bands were excised and subjected to digestion as described (Plaza-
Menacho et al., 2014). Tryptic peptides were analysed by LC-MS using 
Ultimate 3000 uHPLC system connected to a Q-Exactive mass spectrometer 
(Thermo Fisher Scientific) and acquired in data-dependent mode (DDA) for 
identification and in targeted SIM/PRM mode for quantification. A SIM 
isolation list was setup for the following peptides: STSLVEGR (m/z 424.7272, 
2+, non phos), STSLVEGR (m/z 464.7104, 2+, phos S52), QSISFSGLPSGR 
(m/z 618.3276, 2+, non phos) and QSISFSGLPSGR (m/z 658.3057, 2+, phos 
S178). For SIM/PRM scans, MS1 peaks were acquired at resolution of 
70,000 (at m/z 200) and scan time (1x256 ms); MS2 fragment ion resolution 
was 17,500 (at m/z 200) scan time (64x4 ms); and SIM/PRM cycle time was 
(1280 ms). For identification and generation of spectral libraries, the resulting 
DDA data was searched against a mouse Uniprot database containing 
common contaminants 
(UniProt_KB2012_08_taxonomy_mouse_10090_canonical_with_contaminan
ts.fasta) as well as a custom database containing the Myc-tagged mouse 
Zfp36 sequence using the Andromeda search engine and MaxQuant (version 
1.3.0.5). For MaxQuant, a false discovery rate of 0.1 % was used to generate 
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protein, peptide and site identification tables. The DDA data were uploaded 
into Perseus (MaxQuant) for statistical analyses of phosphosite 
identifications. The targeted mass spectrometry raw data was uploaded into 
Skyline (version 3.5.0.9319) for identification, quantification and further 
statistical analyses. 
 
2.16  Cell culture  
 
Cells were grown in a humidified, 37 °C incubator with a controlled 
atmosphere of 5 % CO2 and 95 % air. Specific culture conditions and origin 
of all the cell lines used in this study are listed in Table 3.  
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Table 3. Cell lines and growth conditions 
 
Cell line Source Normal medium Starvation medium 
H358 ATCC RPMI + 10 % FCS N/A 
A427 CRUK Cell Services RPMI + 10 % FCS N/A 
H1792 ATCC RPMI + 10 % FCS N/A 
KPB6 Sergio Quezada 
Laboratory 
DMEM + 10 % FCS N/A 
Type II pneumocytes Olivier Pardo, 
Michael Seckl 
(Imperial College, 
London) and 
(Molina-Arcas et al., 
2013b) 
DCCM-1 + 10 % 
FCS 
+ 0.5 % FCS for 
qPCR and FACS 
+ 0 % FCS for 
mRNA half-life 
analysis 
NL-20 Silvia Carvalho, 
Yosef Yarden 
(Weizmann Institute, 
Rehovot) and 
(Molina-Arcas et al., 
2013b) 
F12 + 4%FCS and 5 
μg/mL 
insulin, 10 ng/mL 
EGF, 500 ng/mL 
hydrocortisone, 1 
μg/mL transferrin, 
0.1x 
non-essential amino 
acids, 2.7g/L 
glucose 
+ 0.4 % FCS 
368T1 Tyler Jacks 
Laboratory 
DMEM + 10 % FCS N/A 
H23 CRUK Cell Services RPMI + 10 % FCS N/A 
293FT CRUK Cell Services DMEM + 10 % FCS N/A 
TTP KO and TTP 
WT MEFs 
Perry Blackshear 
Laboratory 
DMEM + 10 % FCS + 0.5 % FCS 
MCF10A (Molina-Arcas et al., 
2013b) 
F12:DMEM mix (1:1) 
and 5 % horse 
serum, 20 ng/ml 
EGF, 10 µg/ml 
insulin, 100 ng/ml 
cholera toxin, 0.5 
µg/ml hydrocortisone 
+ 5 % horse serum  
CT26 CRUK Cell Services RPMI + 10 % FCS N/A 
 
N/A, not applicable. 
  
Chapter 2. Materials and Methods 
 81 
2.17  Western blotting 
 
Protein lysates for Western blotting were prepared by cell harvest in lysis 
Buffer (20 mM Tris-HCl, pH 7.4, 137.5 mM NaCl, 10 % glycerol, 1 % Triton X-
100) supplemented with phosphatase and protease inhibitor cocktails 
(Calbiochem). Lysates were left on ice for 20 min before clearing at 12 000 
rpm on a bench-top centrifuge at 4 °C. Protein concentrations in 
supernatants were estimated using a Bradford assay (Bio-Rad). Samples 
were boiled in SDS loading buffer for 5 min before loading onto SDS-
polyacrylamide gels. Generally, 25-30 µg of protein was loaded per lane. 
Primary antibodies used are listed in Table 4. Secondary antibodies were 
conjugated to horseradish peroxidase (GE Healthcare). 
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Table 4. Antibodies 
 
 
CST, Cell Signalling Technologies. 
Antibody 
epitope 
Application Concentration Company Catalogue number 
p-ERK WB 1:1000 CST 9101 
p-AKT 
(S473) 
WB 1:1000 CST 9271 
PD-L1 (anti-
human) 
Flow 
cytometry 
Manufacturer’s 
instructions 
eBioscience 12 5983 42 
 
Isotype 
control 
Flow 
cytometry 
Manufacturer’s 
instructions 
eBioscience 9012-4714-025 
 
PD-L1 (anti-
mouse) 
Flow 
cytometry 
Manufacturer’s 
instructions 
eBioscience 14-5982-82 
 
Isotype 
control 
Flow 
cytometry 
Manufacturer’s 
instructions 
eBioscience 
12-4321-41 
  
CD45  Flow 
cytometry 
1:300 eBioscience 11-0451-82 
 
CD31  Flow 
cytometry 
1:100 eBioscience 11-0311-81 
 
TTP RNA-IP See 
Experimental 
Procedures 
Santa Cruz sc-8458 
 
TTP 
endogenous 
WB 1:1000 Miilipore ABE285 
KSRP RNA-IP See 
Experimental 
Procedures 
Cambridge 
Bioscience 
A302-021A 
 
KSRP WB 1:1000 CST 5398S 
 
Myc (9E10) IP/WB/IHC 3 µg/IP, 1:2000 
WB 
CRUK Cell 
Services 
N/A 
ERK WB 1:1000 CST 9107 
 
p-CREB 
(S133) 
WB 1:1000 CST 9196 
AKT WB 1:1000 CST 2920 
p-PXSP WB 1:1000 CST 2325 
p-RXXS/T WB 1:1000 CST 9611 
 
p-p38 
(T180/Y182) 
WB 1:1000 CST 9211 
CD3 IHC 1:500 Abcam ab134096 
Calreticulin Flow 
cytometry 
1:100 Abcam ab2907 
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2.18  Statistics 
 
Unless stated otherwise, data were compared using unpaired, two-tailed 
Student’s t-tests. 
 
  
Chapter 3. Results 1. Tumour immunogenicity in genetically engineered 
mouse models of cancer 
 85 
3 Chapter 3. Results 1. Tumour immunogenicity in 
genetically engineered mouse models of cancer 
  
3.1 Introduction 
 
Since only a subset of cancer patients currently responds to 
immunotherapies in the clinic, preclinical testing of immunotherapies is 
required to accelerate the discovery of biomarkers for response, and 
systematically test rational combination treatment strategies. To date, much 
of the preclinical work on cancer immunotherapy has relied on syngeneic, 
subcutaneous transplants of highly mutated and immunogenic cancer cells. 
More complex GEMMs of cancer have since been developed to model 
cancer at the orthotopic site with a physiological tumour microenvironment. 
GEMMs also have the capacity to reflect a more heterogeneous, clonal 
disease. However, it remains unclear whether these increasingly used 
GEMMs are suitable for the study of immune checkpoint blockade.  
 
Here, we investigate the immunogenicity of Kras G12D LSL/+; Trp53 F/F 
(KP) mouse lung tumours. We provide evidence that (1) immunogenic cell 
death inducing agents fail to elicit a sustained immune response against 
these tumours, (2) KP tumours are resistant to anti-PD-L1 and anti-CTLA-4 
immunotherapy, and (3) KP tumour progression is not significantly impeded 
by the adaptive immune system. 
 
In this chapter, I present images generated from histopathological analyses 
performed by Bradley Spencer-Dene and Emma Nye on my behalf. 
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3.2 Results 
 
3.2.1 Steady-state and therapy-induced immune contexture of Kras 
G12D LSL/+; Trp53 F/F mouse tumours 
 
We set out to analyse the potential anti-tumour effects mediated by eliciting 
immunogenic cell death (ICD) in a GEMM of lung cancer. Specifically, we 
employed a widely-used mouse model of NSCLC where oncogenic Kras 
expression and concomitant loss of Trp53 in the lung epithelium can be 
achieved by intratracheal delivery of adenovirus expressing Cre recombinase 
(DuPage et al., 2009a). Please note that Kras G12D LSL/+; Trp53 F/F mice 
will be referred to as KP mice throughout. 
 
Firstly, we selected a small panel of inhibitors based on their ability to (1) 
promote lung cancer cell death, and/or (2) elicit characteristics of 
immunogenic cell death. Firstly, we tested their efficacy in vitro.  
 
We selected carboplatin, which has not been shown to induce ICD but is 
used as standard of care for lung cancer in the clinic. We also chose the 
microtubule poison paclitaxel, as this chemotherapy or similar agents can be 
used as first-line treatment for lung cancer patients and has also been shown 
to induce aneuploidy, ER-stress and traits of ICD (Senovilla et al., 2012). 
Similarly, we used the anthracycline chemotherapeutic doxorubicin, as this is 
known to induce ICD (Galluzzi et al., 2015), but is not commonly used for the 
treatment of NSCLC in the clinic. In addition, we used tunicamycin, which 
specifically causes ER-stress by inducing the unfolded protein response as a 
consequence of the inhibition of protein glycosylation. We chose selumetinib 
(AZD6244), a potent and specific MEK inhibitor that is in clinical testing (now 
phase III) in NSCLC (Janne et al., 2013) with little known about its impact on 
traits of ICD. Finally, we selected bortezomib; a clinically approved 
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proteasome inhibitor used in patients with multiple myeloma, but there are 
indications that it also has activity in lung cancer (Kumar et al., 2012; Xue et 
al., 2011), and may stimulate signs of ICD through ER-stress caused by 
unfolded protein accumulation.  
 
Using this panel of inhibitors, we first calculated inhibitor doses that killed 
368T1 Kras-mutant mouse lung cancer cells (derived from KP mice) to a 
similar degree. We could therefore control for differences in cell death as 
much as possible when making comparisons between inhibitor effects on the 
mode of cell death. To this end, we used crystal violet and Cell Titre Blue 
assays to analyse cell proliferation and cell survival over a range of drug 
concentrations. Once a single dose of the inhibitor was selected that killed 
approximately 70 % of cells after 72 h, we verified this using an independent 
technique; annexin V and DAPI staining measured by flow cytometry (Figure 
3.1A). This analysis is quantified in Figure 3.1B. All drugs started to induce 
cell death by 24 h to a modest degree, which was substantially higher and 
comparable at 72 h, with the possible exception of taxol, which caused lower 
levels of cell death consistent with a predominantly cytostatic effect on this 
cell line.  
 
Next, we examined the ability of these agents to induce characteristics of 
immunogenic cell death in vitro. One key trait of immunogenic cell death is 
the exposure of calreticulin (CRT) at the cell membrane (Obeid et al., 2007). 
We tested the ability of our drug panel to induce CRT exposure by flow 
cytometry (Figure 3.1C). At 24 h after drug addition we observed significant 
increases in ecto-CRT following treatment with paclitaxel (taxol), bortezomib 
and selumetinib (AZD6244), however paclitaxel showed the most striking 
increase. Surprisingly, doxorubicin did not significantly increase ecto-CRT 
exposure in our hands, perhaps reflecting differences in sensitivity between 
cell lines used here and in studies by Kroemer and colleagues. 
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We tested the specificity and sensitivity of our flow cytometry assay by 
genetic silencing of CRT expression in 368T1 cells by stably introducing an 
shRNA against CRT as a control (Figure 3.1D). Indeed, we could detect 
lower levels of ecto-CRT exposure in shCRT cells relative to parental 368T1 
cells, verifying the specificity of the primary and secondary antibody 
detection. 
 
 
 
Figure 3.1 Drug selection for the efficient induction of immunogenic 
cancer cell death 
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(A and B) Flow cytometry analysis of cell death as measured by annexin V 
and DAPI staining in 368T1 lung cancer cells, induced by the indicated 
cytotoxic agents at 24 h and 72 h, and quantified in (B). Data are mean ± 
SEM of biological duplicates. 
(C) Ecto-calreticulin (CRT) as measured by flow cytometry 24 h after the 
addition of the indicated cytotoxic agents. Data are mean ± SD of biological 
triplicates. *P < 0.05; Unpaired, two-tailed Student’s t-test; n.s, not significant. 
(D) Representative histograms from flow cytometry analysis of 368T1 cells 
treated with taxol or vehicle for 24 h. shRNA-mediated knock-down of CRT 
was used as a control to verify the specificity of the CRT antibody. 
Tun, tunicamycin. Doxo, doxorubicin. Btz, bortezomib. Taxol, paclitaxel. 
Carbo, carboplatin. AZD, AZD6244, selumetinib. Drug doses used are 
indicated in (B). 
 
We asked whether taxol might be inducing CRT exposure by inducing 
aneuploidy, as this has been reported previously (Senovilla et al., 2012). Cell 
cycle analysis by flow cytometry revealed approximately 17 % of 368T1 cells 
were tetraploid after 24 h of treatment with taxol (Figure 3.2). The JNK 
inhibitor SP600125, known to promote aneuploidy by disrupting microtubule 
dynamics (MacCorkle and Tan, 2004), served as a positive control. 
Collectively, these results suggest that taxol strongly induces aneuploidy and 
ecto-CRT in 368T1 lung cancer cells. Whether CRT exposure is completely 
dependent on aneuploidy in this case still remains unclear. Although 
hyperploidy has been associated with ER-stress and CRT exposure 
(Senovilla et al., 2012), we did not observe a clear double population of CRT 
high and low cells in our flow cytometry analysis of ecto-CRT in taxol-treated 
cells, as may have been expected given the majority of cells remain diploid at 
24 h.  
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Figure 3.2 Paclitaxel induces tetraploidy in lung cancer cells 
Quantification of tetraploid populations in 368T1 lung cancer cells 24 h after 
treatment with vehicle, paclitaxel (taxol; 4 nM), or the JNK inhibitor SP600125 
(45 µM). Cells were pulse labelled with BrdU and then propidium iodide 
before standard cell cycle analysis by flow cytometry. Data represent the 
mean ± SD of biological triplicates. 
 
Based on our results, we proceeded to test the efficacy of taxol and 
carboplatin, or bortezomib and carboplatin in vivo in tumour-bearing KP mice. 
We selected taxol and bortezomib due to their ability to induce CRT 
exposure, and combined them with carboplatin to increase the likelihood of 
apoptosis induction in vivo. Furthermore, the taxol and carboplatin 
combination reflects a standard of care regimen often used in the clinic for 
patients with NSCLC, increasing the clinical relevance of our approach. 
Firstly, to test efficacy in vivo, we measured tumour cell apoptosis by TUNEL-
staining at the short time-point of 24 h after treatment (Figure 3.3A). A 
representative image is shown in Figure 3.3B. All drug treatments resulted in 
a significant induction in tumour cell apoptosis when compared with vehicle 
control treated animals. However, the absolute numbers of TUNEL-positive 
cells in each case remained low (Figure 3.3B). We speculate that this may be 
partly explained by the rapid clearance of apoptotic cells in vivo.  
 
 
 
Figure 3.3 Induction of tumour cell apoptosis by chemotherapies and 
targeted therapies in vivo 
(A) Quantification of TUNEL positive cells in KP mouse lung tumours 24 h 
after treatment with PBS vehicle control, or carboplatin (50 mg/kg i.p) and 
paclitaxel (10 mg/kg i.p) (Carb/Tax), bortezomib (Btz; 0.5 mg/kg i.p) or 
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bortezomib and carboplatin (Btz/Carb). n = 3-6 mice per group with 1-8 
tumours per mouse quantified. The total number of tumours quantified for 
each condition is indicated in parenthesis. *P < 0.05; Mann-Whitney test. 
(B) Representative histological images of TUNEL staining in KP mouse lung 
tumours treated with PBS vehicle control or Carb/Tax as described in (A). 
 
Given the evident apoptosis and associated CRT exposure in vitro, we tested 
whether our treatment strategies may stimulate anti-tumour immune 
responses. We analysed the immune contexture of tumour-bearing lungs 
from KP mice 24 h after treatment with vehicle, carboplatin and taxol, 
bortezomib alone, or bortezomib and carboplatin. In theory, tumour cell 
apoptosis will be followed by apoptotic debris being cleared and presented by 
APCs, thereby augmenting anti-tumour immunity by acting as an in situ 
tumour vaccine. 
 
We analysed the composition of whole lungs rather than individual tumours 
as single tumours were often small, limiting the number of cell populations 
that can be investigated by FACS. We predominantly focussed on the 
carboplatin and paclitaxel treatment (Carb/Tax), as the number of KP mice 
was limited, and this combination seemed the most promising from previous 
results concerning ecto-CRT and in vivo tumour cell apoptosis. Populations 
of, F480+ CD11b+ cells (representing interstitial macrophages), Ly6G+ 
CD11b high cells (representing neutrophils and monocytes) CD49b+ cells 
(predominantly NK and NKT cells) and CD3+ cells (representing T 
lymphocytes and NKT cells) did not change significantly after any of the 
therapies relative to PBS-treated mice (Figure 3.4).  
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Figure 3.4 Stable immune cell populations following therapy in the 
lungs of KP mice 
(A) 24 h after therapy with the indicated cytotoxic drugs, F480+ CD11b high 
cells were quantified by flow cytometry analysis in tumour-bearing lungs from 
KP mice. Carboplatin (50 mg/kg i.p) and paclitaxel (10 mg/kg i.p) (Carb/Tax), 
bortezomib (Btz; 0.5 mg/kg i.p) or bortezomib and carboplatin (Btz/Carb). 
Shown are F480+ CD11b high cells representing interstitial macrophages. 
(B) Quantification of Ly6g+ CD11b high cells as in (A), representing 
neutrophils and monocytes. 
(C) Quantification of CD49b+ cells as in (A), representing NK cell 
populations.  
(D) Quantification of CD3+ cells as in (A), representing T lymphocytes and 
NKT cells. 
Each data point represents an individual mouse and group numbers are 
indicated in parenthesis. Unpaired, two-tailed Student’s t-test; n.s, not 
significant. 
 
However, we observed a significant increase in the total number of CD11c+ 
cells in tumour-bearing lungs 24 h after Carb/Tax (Figure 3.5A). In addition, 
we also observed a significant increase in the frequency of F4/80+CD11b low 
cells (Figure 3.5B). The CD45+ CD11c+ population predominantly describes 
APCs including macrophages, monocytes and DCs, whereas CD45+ F4/80+ 
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CD11b low cells represent the alveolar macrophage population in the lung. 
Therefore, the therapy-induced increases in these cell populations could 
reflect the recruitment of professional APCs to clear apoptotic debris. It 
remains unclear at this point whether this increase in frequency is due to 
local proliferation of these populations, or recruitment from a distant site.  
 
Next, we addressed whether this local increase in APC populations was 
specific to tumour-bearing mice, or if it was a tumour-independent 
phenomenon. Interestingly, base-line levels of lung CD11c+ cells were higher 
in normal mice than in tumour-bearing animals, possibly implying a level of 
immunosuppression or barrier exclusion; however, we did not observe an 
increase in this population after therapy in tumour-free control mice (Figure 
3.5C). Similarly, F4/80+ CD11b low cells were slightly increased in normal 
lungs, and there was no increase in frequency following therapy in healthy 
mice (Figure 3.5D). Rather, we observed a slight decrease in both immune 
cell populations when expressed as a percentage of the total cells analysed, 
possibly reflecting the modest decrease in total CD45+ leukocytes in the lung 
after chemotherapy in healthy mice. Taken together, our data suggest that 
there is a tumour-specific increase in the population of CD11c+ phagocytes 
and F4/80+ CD11b low alveolar macrophages after Carb/Tax chemotherapy 
in KP mice. 
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Figure 3.5 Therapy-induced changes in the immune contexture in the 
lungs of KP mice 
(A) 24 h after therapy with the indicated cytotoxic drugs, CD11c+ cells were 
quantified by flow cytometry analysis in tumour-bearing lungs from KP mice. 
Carboplatin (50 mg/kg i.p) and paclitaxel (10 mg/kg i.p) (Carb/Tax), 
bortezomib (Btz; 0.5 mg/kg i.p) or bortezomib and carboplatin (Btz/Carb). 
Shown are CD11c+ cells representing dendritic-like cells. 
(B) Quantification of F480+ CD11b low cells as in (A), representing alveolar 
macrophages. 
(C) Tumour-free mice were treated with the indicated cytotoxic drugs and 
CD11c+ cells in lung tissues were quantified. 
(D) Tumour-free mice were treated with the indicated cytotoxic drugs and 
F480+ and CD11b low cells in lung tissues were quantified. 
Each data point represents an individual mouse and group numbers are 
indicated in parenthesis. Unpaired, two-tailed Student’s t-test; n.s, not 
significant. Percentage total represents the percentage of viable cells. 
 
Since CD11c+ DCs are crucial for mediating anti-tumour immunity (Salmon et 
al., 2016a), we further investigated the dynamics and phenotype of this cell 
infiltrate. We further classified the CD11c+ population by including the MHCII 
marker, which is more specific to the conventional DC subset, and represents 
DCs that are capable of presenting antigen. We analysed these populations 
at four days after treatment to see if there was retention of increased APC 
populations long-term after therapy. However, although the fraction of CD45+ 
leukocytes was not changed after therapy at four days (Figure 3.6A), we 
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noted a significant reduction in CD11c+ cells (Figure 3.6B) and CD11c+ 
MHCII high cells (Figure 3.6C) in mice treated with Carb/Tax. Although this 
was unexpected, this effect is consistent with myelosuppression as a 
reported adverse effect in lung cancer patients treated with carboplatin and 
paclitaxel together (Langer et al., 1995). Also, this myelosuppression was 
unlikely to have been significant at 24 h post-treatment.  
 
 
 
Figure 3.6 Long-term suppression of CD11c+ cells in tumour-bearing 
lungs by chemotherapy 
(A) Four days after therapy with the indicated cytotoxic drugs, CD45+ cells 
were quantified by flow cytometry analysis in tumour-bearing lungs from KP 
mice. Carboplatin (50 mg/kg i.p) and paclitaxel (10 mg/kg i.p).  
(B) Quantification of CD45+ CD11c+ cells as a percentage of total CD45+ 
cells. 
(C) Quantification of CD45+ CD11c+ MHCII high cells as a percentage of 
total CD45+ cells and as a percentage of total viable cells. 
Each data point represents an individual mouse and group numbers are 
indicated in parenthesis. Unpaired, two-tailed Student’s t-test; *P < 0.05. 
Percentage total represents the percentage of viable cells. 
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Even short-term activity of APCs in the tumour microenvironment following 
activation of apoptosis could be sufficient to elicit an adaptive immune 
response against the tumour. Therefore, we checked whether chemotherapy 
could lead to infiltration of CD4 and CD8 T cells at four days post-Carb/Tax 
treatment, which is typically enough time to mount an adaptive T cell 
response following antigen exposure. For example, Rafi Ahmed and 
Colleagues have shown that antigen-specific CD8 T cell responses to viral 
infection begin as early as three days, and peak at eight days post-infection 
(Murali-Krishna et al., 1998). However, we did not observe an increase in the 
frequency of CD4+ or CD8a+ T lymphocytes in the diseased lung tissue of 
KP mice treated with Carb/Tax chemotherapy (Figure 3.7). We concede that 
it is difficult to foresee how the dynamics of a T cell viral response compare 
to an anti-tumour response, where some prior exposure to antigens and a 
degree of T cell anergy is expected in the latter. However, our results 
suggest that Carb/Tax chemotherapy is capable of inducing an acute and 
tumour-specific increase in APCs in the lung, but it is not sufficient to 
generate a significant subsequent adaptive T cell response. We have shown 
that the paclitaxel component of this therapy can induce indications of ICD 
(CRT exposure at the cell membrane), but the chronic signs of 
myelosupression demonstrated here are a concern, and will most likely have 
negative implications for mounting an anti-tumour immune response. In 
further work, it would also be interesting to analyse infiltration at the longer 
time-point of 7-10 days after therapy. 
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Figure 3.7 Lack of adaptive immune infiltrate following chemotherapy 
in tumour-bearing lungs 
(A) Four days after therapy with the indicated cytotoxic drugs, CD45+ CD3e+ 
CD4+ cells were quantified by flow cytometry analysis in tumour-bearing 
lungs from KP mice. Carboplatin (50 mg/kg i.p) and paclitaxel (10 mg/kg i.p).  
(B) Quantification of CD45+ CD3e+ CD8a+ cells as in (A). 
Each data point represents an individual mouse and group numbers are 
indicated in parenthesis. Percentage total represents the percentage of 
viable cells. 
 
3.2.2 KrasLSL/+; Trp53 F/F mouse tumours are resistant to immune 
checkpoint blockade 
 
Our results from previous sections do not exclude the possibility that KP 
tumours are indeed immunogenic, and capable of responding to 
immunotherapies. The striking clinical successes in the treatment of NSCLC 
in the clinic (Borghaei et al., 2015) prompted us to test the efficacy of 
commonly used ICB antibodies in KP mice. As a first approach, we tried 
treatment with anti-PD-L1 antibody monotherapy. We selected the highest 
dose of antibody that successfully caused NSCLC regressions in humans; 10 
mg/kg (Brahmer et al., 2012). Firstly, we confirmed that the antibody was 
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successfully reaching and binding to the target lung tissue in healthy mice, by 
secondary detection of the therapeutic rat antibody with an anti-rat APC 
antibody by flow cytometry (Figure 3.8). 24 h after antibody injection, we 
observed significant and reproducible binding to lung cells at this dose. 
 
 
 
Figure 3.8 Anti-PD-L1 antibody effectively binds to the target lung 
tissue in vivo 
(A) Representative histograms from flow cytometry analysis of anti-rat 
secondary antibody binding to lung tissue from wild-type C57Bl/6 mice 24 h 
after i.p injection with 10 mg/kg rat anti-PD-L1 antibody (clone 10F.9G2) or 
rat isotype control (LTF-2). Data are representative of three independent 
mice per group. Single, viable cells were analysed from freshly isolated lung 
tissue. 
(B) Quantification of anti-PD-L1 antibody binding efficiency in vivo as 
described in (A) by means of secondary detection with anti-rat antibody. MFI, 
mean fluorescence intensity. ***P<0.001, unpaired, two-tailed Student’s t-
test. 
 
We also combined PD-L1 blockade with the MEK inhibitor trametinib, since 
trametinib has shown promising results in NSCLC patients and in our own 
laboratory in KP mice (unpublished data) and does not negatively impact on 
anti-tumour immunity (Ebert et al., 2016). We monitored tumour progression 
over time by µCT scanning of the lungs. Interestingly, anti-PD-L1 antibody 
therapy did not result in detectable anti-tumour activity, even in combination 
with MEK inhibitor (Figure 3.9A and Figure 3.9B). MEK inhibitor alone led to 
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significant reductions in tumour volume, suggesting that some cell death is 
induced by this therapy.  
 
Immunotherapies can have non-standard regression dynamics, with 
paradoxical increases in tumour size, likely corresponding to immune cell 
infiltration, which is then followed by clinical regressions (Topalian et al., 
2014). These characteristics necessitate longer-term tumour monitoring. 
However, following these animals over time through survival analysis also 
revealed no benefit of anti-PD-L1 therapy, and surprisingly, no survival 
benefit of MEK inhibitor treatment either (Figure 3.9C and Figure 3.9D). As 
MEK inhibitor was only administered for two weeks, we anticipate that any 
benefit from tumour regression was masked by long-term recovery of tumour 
growth off therapy. 
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Figure 3.9 Anti-PD-L1 immune checkpoint blockade is not effective in 
KP mice 
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(A) Waterfall plot showing tumour volume change over a two-week treatment 
period as measured by µCT scanning. Each bar represents volume change 
of an individual tumour. Tumours were initiated by intratracheal 
administration of Adeno-Cre to the lung. 16 weeks post-infection mice were 
treated daily with the MEK inhibitor trametinib (3 mg/kg, o.g) and with anti-
PD-L1 antibody 10F.9G2 (10 mg/kg, i.p) twice per week for two weeks in 
total. 
(B) Representative images showing tumour progression from µCT scanning 
from the experiment described in (A). 
(C) Representative histological images of lungs from mice at sacrifice from 
the experiment described in (A). 
(D) Kaplan-Meier survival plot of the experiment described in (A).  
 
Our results suggest that PD-L1 blockade as a monotherapy or in conjunction 
with the targeted agent trametinib does not show signs of anti-tumour 
immune activity in the KP mouse model of NSCLC. However, we cannot 
exclude that we have only partially inhibited the immunosuppressive 
mechanisms at play in these tumours. Recent reports have indicated that 
anti-PD-1 antibody combined with anti-CTLA-4 antibody has superior efficacy 
compared to either monotherapy in melanoma (Larkin et al., 2015a). 
Moreover, Tregs, which are suppressed following CTLA-4 blockade, have 
been implicated in immunosuppression in a modified KP mouse model (Joshi 
et al., 2015a). Therefore, we examined the anti-tumour effect of anti-PD-L1 
and anti-CTLA-4 combination therapy on KP lung tumours (Figure 3.10).  
 
Similar to the results from anti-PD-L1 antibody monotherapy, the combination 
treatment of anti-PD-L1 and anti-CTLA-4 antibody did not result in detectable 
anti-tumour responses. Short-term µCT analysis over two weeks only 
revealed significant progression of lesions with a comparable rate to that of 
isotype-treated mice (Figure 3.10A and Figure 3.10B). Furthermore, following 
disease progression long-term showed that survival of mice treated with the 
combination therapy was not significantly different to the isotype control-
treated cohort. This lack of anti-tumour activity was also clearly evident by 
inspection of surface lung tumours at sacrifice (Figure 3.10C and Figure 
3.10D). 
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Figure 3.10 KrasLSL-G12D/+; Trp53 F/F mouse tumours are refractory 
to anti-PD-L1 + anti-CTLA4 combination immunotherapy 
(A) Representative µCT scans of tumours (indicated by arrows) at time = 0 
weeks and two weeks of treatment with anti-PD-L1 antibody (10F.9G2, 10 
mg/kg) and anti-CTLA-4 antibody (9H10, 5 mg/kg) or isotype controls by i.p 
administration. Mice received three doses of combination therapy in total 
over a two-week course, with injections on day 0, 4 and 8.  
(B) Waterfall plot of tumour volume change over a two-week treatment 
period, as described in (A). Unpaired, two-tailed Student’s t-test; n.s, not 
significant. Each bar represents volume change of an individual tumour. 
(C) Gross histological analysis of surface tumour burden (nodules are 
indicated by arrows) from mice treated as described in (A). 
Chapter 3. Results 1. Tumour immunogenicity in genetically engineered 
mouse models of cancer 
 103 
(D) Kaplan-Meier analysis of survival of mice treated as described in (A). 
Wilcoxen-rank test; n.s, not significant.  
 
3.2.3 KrasLSL-G12D/+; Trp53 F/F mouse tumours are poorly 
immunogenic 
 
In light of these negative data, we reasoned that the lack of response to 
immunotherapies might reflect the poor immunogenicity of KP tumours. 
Therefore, we set out to directly assess the immunogenicity of KP tumours, 
and the direct functional influence of the adaptive immune system on tumour 
progression.  
 
As a first approach, we trialled antibody-mediated depletion of CD4+ and 
CD8+ T cells. We injected wild-type mice with monoclonal antibodies against 
CD8 and CD4 and then analysed the abundance of these cell populations by 
flow cytometry. We used a detection antibody raised against a distinct 
epitope to the depletion antibody to minimise the issue of lack of detection 
simply due to occlusion of the antigen. Three days after depletion antibody 
injection we noted significant reductions in CD45+ CD3+ cells (Figure 3.11A), 
and specifically, CD45+ CD3+ CD4+ T cells and CD45+ CD3+ CD8a+ T cells 
(Figure 3.11B). Secondly, we confirmed that our data represent bona fide 
depletion of T lymphocytes, rather than occlusion of the detection antigen by 
titrating depletion antibody against detection antibody in a splenocyte cell 
mixture in vitro (Figure 3.11C). As expected, higher concentrations of 
depletion antibody did not affect detection of CD4+ or CD8+ T cells. 
 
Chapter 3. Results 1. Tumour immunogenicity in genetically engineered 
mouse models of cancer 
 104 
 
 
Figure 3.11 Strategy for the depletion of CD4 and CD8 T cells in vivo 
(A and B) Flow cytometry analysis of mouse spleen (A) and lung tissue (B) 
freshly isolated from mice treated with anti-CD8 (2.43. IgG2b rat, 300 µg) and 
anti-CD4 (GK1. IgG2b rat, 300 µg) antibodies or isotype control antibodies by 
i.p administration 72 h before sacrifice. Data are representative of three mice 
per group. Detection antibodies used to detect CD4 and CD8 T cells were 
distinct from those used to deplete. *P <0.05, unpaired, two-tailed Student’s t-
test. 
(C) Quantification of flow cytometry data from a competition assay between 
detection and depletion antibodies. Higher concentrations of depletion 
antibody cocktail were titrated into the cell mixture and the level of detection 
of CD4 and CD8 T cells by detection antibodies was quantified. Percentage 
total represents the percentage of viable cells. 
 
We have shown that antibody depletion of CD4 and CD8 T cells can be 
technically effective in principle. However, the depletion is short-term, 
requiring repeat administration of expensive antibodies and may not 
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guarantee absolute depletion. Secondly, this approach will not give 
information regarding the functional effects of adaptive immunity before the 
depletion phase of the experiment. For these reasons, we adopted a genetic 
approach to completely abrogate T and B cell function from birth. We crossed 
the KP mouse onto Rag2-/- mice, which completely lack functional, mature T 
and B cells (Shinkai et al., 1992). Figure 3.12 shows the absence of T and B 
cells in the tumour microenvironment in KP; Rag2-/- mice. KP; Rag2-/+ mice 
are normal with respect to adaptive immunity and can be generated as 
littermates with KP; Rag2-/- immunodeficient mice from crosses, and have 
been used as immunocompetent controls in subsequent experiments. 
Intriguingly, we noted CD3+ T cells, but very few B220+ B cells in the 
tumours of KP; Rag2-/+ mice (Figure 3.12). 
 
 
 
Figure 3.12 Characterisation of KrasLSL-G12D/+; Trp53 F/F; Rag2 KO 
mice 
Histological analysis of lung tumours from KP; Rag2 +/- and KP; Rag2 -/- 
mice. CD3 staining and B220 immunostaining show T cell and B cell 
populations, respectively. 
 
Using this GEMM, we monitored the latency, frequency and growth-rate of 
lung tumours in immunocompetent and immunocompromised settings. 
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Notably, we observed similar levels of total lung tumour burden as quantified 
by H & E staining and quantification of percentage tumour area (Figure 3.13A 
and Figure 3.13B). Similarly, using volumetric tracking of individual lesions by 
µCT scanning, we found comparable growth rates for tumours in KP; Rag+/- 
and KP; Rag-/- mice (Figure 3.13C). Next, we compared the onset of 
tumorigenesis in KP; Rag2-/- and KP; Rag2-/+ mice by measuring the 
number of tumours visible by H & E staining at the early time-point of nine 
weeks post-infection (Figure 3.13D). From this analysis we concluded that 
there is no significant difference in tumour onset between immunocompetent 
and immunocompromised mice. In sum, these data suggest that T cells and 
B cells do not significantly restrain tumour progression in the KP mouse 
model. 
 
 
 
Figure 3.13 Adaptive immunity does not restain tumour progression or 
tumour initiation in KrasLSL-G12D/+; Trp53 F/F mice 
(A) Tumour burden was quantified using a semi-automated software package 
(Ariol – Leica Biosystems) from H&E sections from KP Rag-/- and KP Rag+/- 
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mice 15 weeks after tumour initiation with Ad-Cre. Unpaired, two-tailed 
Student’s t-test.  
(B) Representative H&E staining of tumour-bearing lungs from KP Rag-/- and 
KP Rag+/- mice 15 weeks after tumour initiation with Ad-Cre.  
(C) Waterfall plot showing tumour volume change over a two week period for 
KP Rag-/- and KP Rag+/- mice, as measured by µCT scanning. Unpaired, 
two-tailed Student’s t-test. Each bar represents volume change of an 
individual tumour. 
(D) Tumour number was measured by microscopic inspection of 5 H&E 
slides per mouse taken at the early time-point of 9 weeks post-infection with 
Ad-Cre. Mann-Whitney U test. 
Numbers of individual mice per group are indicated in parentheses. n.s, not 
significant. 
 
Our results from previous sections have highlighted that PD-L1 blockade 
does not have therapeutic value in this mouse model, even when combined 
with anti-CTLA-4 treatment or cytotoxic agents. However, we wanted to 
directly examine whether therapeutic effects of anti-cancer compounds could 
have non-cell autonomous effects mediated by the adaptive immune system 
in this model. To this end, we treated KP; Rag2-/- and KP; Rag2-/+ mice with 
trametinib (GSK1220212, or GSK) as before, but also combined with 
paclitaxel (taxol). Docetaxel and another MEK inhibitor, selumetinib, have 
shown significant promise in the KP model of lung cancer when combined 
(Chen et al., 2012). The docetaxel and selumetinib combination induces 
significant tumour cell apoptosis, with superior activity to either agent alone 
(Chen et al., 2012). Indeed, we observed significant reductions in tumour 
volume with GSK/Taxol therapy compared with vehicle-treated mice (Figure 
3.14A). Although we did observe more complete regressions in the 
immunocompetent mice, the anti-tumour response was not significantly 
different between KP; Rag2-/- and KP; Rag2-/+ mice. In addition, long-term 
tracking of the tumours off-treatment revealed similar growth dynamics in 
both cohorts of mice, with tumours growing back after the initial regressions 
(Figure 3.14B). Thus, there is no obvious adaptive immunity generated 
following these anti-tumour responses in KP; Rag+/- mice. Unfortunately, 
only a small number of tumours could be tracked at this late stage after 
therapy due to the fusing of individual nodules as the tumours grew, making 
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volumetric quantification of the single lesions impossible. Collectively, these 
data imply that there are no significant non-cell autonomous anti-tumour 
effects mediated by the adaptive immune system following GSK/Taxol 
therapy in KP mice.  
 
 
 
Figure 3.14 No significant contribution of adaptive immunity to therapy 
response in KP mouse lung cancer 
(A) Waterfall plot of tumour volume change over a two-week treatment period 
as measured by µCT scanning. Each bar represents volume change of an 
individual tumour. Mice were treated with vehicle control or MEK inhibitor 
trametinib GSK1120212 (GSK) by daily oral gavage (3 mg/kg) and paclitaxel 
(taxol) by i.p administration once weekly (10 mg/kg) for two weeks. 
(B) Tumours quantified in (A) were monitored by µCT scanning for an 
additional 3 weeks off-treatment. Tumours that fused into neighbouring 
structures and other tumours at later time points could no longer be 
quantified as single nodules and so have been omitted from this analysis.  
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KP tumours are ostensibly refractory to T and B cell attack and so are 
unlikely to be immunogenic under steady-state conditions. However, this may 
reflect profound immunosuppression or early immunoediting of potent 
antigens that renders the tumours capable of growing unabated. This would 
lead to a negligible negative impact on the overall tumour burden when 
measured long-term. To further investigate the possibility of immunoediting 
processes during tumour development in KP mice, we generated KP; Rag1-/- 
mice on a clean C57Bl/6 background (11 generations of backcrossing), which 
can be used for syngeneic transplantation experiments. Using KP; Rag1-/- or 
KP; Rag1+/- mice, we could directly assess if tumour immunoediting had 
occurred by comparing tumour progression in wild-type syngeneic hosts of 
lung tumour cell lines derived from the immunocompetent or immunodeficient 
strain. We established four independent lung tumour cell lines from a single 
KP;Rag+/- mouse and four lines from a KP;Rag-/- mouse. We injected the 
cell lines subcutaneously into C57Bl/6 syngeneic recipients or Rag1-/- 
C57Bl/6 recipients and followed tumour progression over time (Figure 3.15). 
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Figure 3.15 Examination of tumour immunoediting in KrasLSL-G12D/+; 
Trp53 F/F mice 
(A) Four independent tumour cell lines were derived from different tumours 
from both KP; Rag1-/- and KP; Rag1+/- C57Bl/6J mice at 12 weeks post-
infection with Adeno-Cre. Established cell lines were transplanted 
subcutaneously into syngeneic wild-type or Rag1-/- recipient mice as 
indicated (1.5 x105 cells in PBS into the left flank). Tumour growth was 
monitored with calipers. 
(B) For the “KPRag1-/- c” cell line, tumours were monitored over an extended 
60 day period. 
 
Most cell lines from the KP;Rag+/- and KP;Rag-/- hosts grew comparably in 
immunodeficient and immunocompetent recipients, with progressive growth 
in both contexts, consistent with a similar degree of immunogenicity for all 
cell lines. However, there was one notable exception; the KP; Rag1-/- c cell 
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line, which reproducibly failed to grow progressively in the WT mice (3/3 
cases), and moreover, this was the only cell line for which we observed a 
complete tumour regression (1/3 cases) (Figure 3.15A). Crucially, the c-/- cell 
line grew progressively in the Rag1-/- recipients, indicating an immune-
mediated control mechanism. Long-term monitoring of the WT mice 
harbouring the c-/- line over a two-month period revealed sustained control 
and stable disease in 2/3 mice. The single mouse that had previously 
rejected the tumour remained disease-free over this extended period (Figure 
3.15B). 1/3 of the WT mice with stable disease eventually experienced 
progressive tumour growth of the KP;Rag1-/- c line at 58-60 days post-
injection, implying immune-escape (Figure 3.15B). We proceeded to repeat 
the experiment with the c-/- line to check the reproducibility of these effects 
(Figure 3.16). As expected, we observed the same trend, with the tumours 
growing progressively only in the Rag1-/- recipients.  
 
 
 
Figure 3.16 KPRag1-/- c lung cancer cell line is immunogenic 
The KP;Rag1-/- c cell line was injected subcutaneously into either wild-type 
(WT) C57Bl/6 recipients, or immunocompromised Rag1-/- C57Bl/6 recipients 
(1.5 x105 cells in PBS into the left flank). Tumour growth was monitored using 
calipers. * denotes where a mouse was sacrificed prematurely due to 
ulceration or a skin condition. n = 4 mice per group. 
 
The behaviour of the KP;Rag1-/- c cell line is suggestive of tumour cell 
immunogenicity. To confirm this, we rechallenged a WT mouse that had 
previously experienced a complete rejection of a tumour derived from the 
KP;Rag1-/- c cell line (Figure 3.17). Consistent with the existence of 
immunological memory and an anti-tumour immune response against this 
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cell line, the rechallenged mouse remained disease-free and did not develop 
a tumour at the site of injection, whereas naïve or Rag1-/- recipient control 
mice developed tumours as expected. 
 
 
 
Figure 3.17 Immunological memory and rejection of the KPRag1-/- c 
lung cancer cell line 
The KP;Rag1-/- c cell line was injected subcutaneously into either wild-type 
(WT) C57Bl/6 recipients, or immunocompromised Rag1-/- C57Bl/6 recipients 
(1.5 x105 cells in PBS). A mouse that had previously rejected a KP;Rag1-/- c 
tumour was rechallenged (as indicated) with a second cell injection into the 
contralateral flank. 2/3 WT mice and 3/3 of the Rag-/- mice were naïve 
recipients included as a control. Tumour growth was monitored using 
calipers. * denotes where a mouse was sacrificed prematurely due to 
ulceration or a skin condition. n = 2-3 mice per group. 
 
In summary, these data provide evidence that some KP lung cancer cell 
clones can be immunogenic. The immunogenic cell line KP;Rag1-/- c was 
derived from an immunocompromised mouse, suggesting that immunoediting 
in WT mice may take place in the KP model. Whether the immunogenic 
determinant in this cell line is a rare neoantigen, or a tumour-associated 
antigen remains to be determined. We plan to investigate this further using 
RNA sequencing to determine mutations and gene expression differences 
between this cell line and others that are not rejected. If significant 
immunoediting does take place in this mouse model, it must only have 
minimal effect on the tumour burden and tumour onset, as described in our 
characterisation of the KP;Rag2-/- model. We speculate that immunogenic 
clones are destroyed rapidly, and very early in tumour development, 
therefore having minimal impact on tumour progression long-term.  
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We have shown that KP tumours are refractory to common immunotherapy 
treatments, but could potentially harbour uncommon immunogenic tumour 
cell clones that may be removed through immunoediting in an 
immunocompetent host. A determinant of immunotherapy response to PD-1 
blocking agents is the engagement of the checkpoint pathway in the tumour 
microenvironment. Therefore, we questioned whether KP tumours were 
similar to human NSCLC tumours in expression and upregulation of 
immunosuppressive proteins such as PD-L1 (Topalian et al., 2012; Zitvogel 
and Kroemer, 2012b). Unexpectedly, we found high levels of tumour cell PD-
L1 expression at the mRNA and protein level, with higher levels in the tumour 
relative to the adjacent healthy lung tissue (Figure 3.18A). Interestingly, 
Lastwika and colleagues recently showed that PD-L1 expression is 
upregulated in lung tumour tissue relative to normal lung in three independent 
mouse models of lung cancer: KRASLA2, EGFRL85R and NNK-driven mouse 
models (a carcinogen that introduces KRAS mutations) (Lastwika et al., 
2016). In support of these data, an independent study showed that EGFRL85R 
mouse lung cancers overexpress PD-L1 relative to wild-type lung tissue by 
using a microarray based approach (Akbay et al., 2013). Genentech have 
also stated that most mouse tumour models constitutively express PD-L1, 
which does not reflect the more heterogeneous situation in human cancer 
(Herbst et al., 2014). Finally, cell lines derived from KP lung tumours that we 
have tested in our laboratory (e.g. KPB6 cell lines) express high levels of PD-
L1 (data not shown). Collectively, these results may indicate that there may 
be profound immunosuppression in these lung tumours, thus protecting the 
tumour cells from the host adaptive immune system. Alternatively, these data 
might suggest that PD-L1 is expressed by Kras-driven tumours purely 
through a cell-intrinsic process, and this is not functionally important for 
tumour progression. 
 
To help delineate between these possibilities, we checked PD-L1 mRNA and 
PD-L1 protein expression in tumours from KP; Rag2-/- and KP; Rag2-/+ mice 
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(Figure 3.18B). This analysis revealed similar levels of tumour cell PD-L1 
mRNA expression in tumours from both immunocompetent and 
immunocompromised mice, supporting the notion that upregulation of tumour 
cell PD-L1 expression in this mouse model is through cell intrinsic signalling 
mechanisms rather than through selection by the adaptive immune system. 
We verified that epithelial tumour cells were expressing high levels of PD-L1 
in KP mouse tumours (rather than other cell types in the tumour) by 
analysing PD-L1 expression on CD45- CD31- DAPI- cells (thus excluding 
leukocytes, endothelial cell and dead cells) using FACS (Figure 3.18C). 
Consistently, we observed higher PD-L1 expression on these cells than 
matched normal lung. 
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Figure 3.18 Kras-driven murine lung tumours express high levels of 
PD-L1 independently of adaptive immunity 
(A) RNA-scope-based in-situ hybridisation for PD-L1 mRNA and 
corresponding H & E staining of KP mouse lung tumours. PD-L1 mRNA is in 
red. 
(B) RNA-scope-based in-situ hybridisation for PD-L1 mRNA, PD-L1 
immunostaining and corresponding H & E staining of KP; Rag1+/- and KP; 
Rag1-/- mouse lung tumours. 
(C) Flow cytometry analysis of surface PD-L1 protein expression in CD45-
CD31-DAPI- cells freshly isolated from KP mouse tumours or matched, 
normal adjacent lung tissue. Data are normalised to normal tissue controls. 
Each paired data point represents an individual mouse. Data are pooled from 
two independent experiments.  
 
Tuveson, Fearon and colleagues have shown that anti-tumour T cells are 
effectively excluded by cancer-associated fibroblasts in a mouse model of 
pancreatic cancer, and only when this barrier is overcome can T cells 
mediate an anti-tumour response (Feig et al., 2013). Hence, we directly 
tested the in vitro reactivity of T cells isolated from tumour-bearing KP mice 
against tumour cells freshly isolated from the same mouse. This approach 
eliminates any barriers between T cells and tumour cells, as they are co-
cultured in vitro. T cell effector response is assessed by measurement of 
IFN- γ by ELISA.  
 
Firstly, we isolated a purified population (approximately 96 % pure) of CD3+ 
CD8+ T cells from the spleens of tumour-bearing mice by a negative 
selection FAC-sorting strategy (Figure 3.19A). We also isolated CD45- 
CD31- tumour cells or normal lung epithelial cell populations by positive FAC-
sorting. Co-culture with normal lung cells served as a negative control. PMA 
and ionomycin stimulation of unsorted splenocytes served as a technical 
positive control for IFN- γ detection. As a relevant biological positive control, 
we also included CD8 T cells isolated from wild-type mice vaccinated against 
the model antigen OVA. As targets, we included the EL4 lymphoma cell line 
engineered to express OVA constitutively (E.G7-Ova cells).  
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As expected, PMA and ionomycin treatment caused a massive release of 
IFN- γ (Figure 3.19B). CD8 T cells from OVA-vaccinated mice also released 
IFN- γ at detectable levels when presented with E.G7-Ova targets, but at 
much lower levels. As expected, CD8 T cells from naïve mice were not 
capable of reacting to E.G7-Ova targets, demonstrating the specificity of the 
assay.  
 
Crucially, we were not able to detect CD8 T cell effector responses to purified 
lung tumour cells relative to normal lung cells. These results indicate that if 
any anti-tumour CD8 T cells exist in this GEMM, they are present at a low 
frequency, which is below the limit of detection of this assay (Figure 3.19B). 
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Figure 3.19 CD8 T cells from tumour-bearing KP mice do not express 
IFN-γ when presented with autologous lung tumour cells in vitro 
(A) Flow cytometry analysis of unsorted mouse spleen (left) and the 
experimental, sorted CD8 T cell population isolated by a negative sorting 
strategy.  
(B) ELISA detection of IFN-γ after 16 h of co-culture of effectors (CD8+ T 
cells) with target cells (CD45-CD31- cells). PMA and ionomycin treated 
splenocytes serve as a positive technical control. EG7-OVA target T 
lymphoma cells and CD8 T cells from mice vaccinated with ovalbumin serve 
as a positive biological control. 1x105 CD8+ T effector cells were incubated 
with 5x103 target tumour cells. Mean ± SEM of biological duplicates.  
 
3.2.4 Suppression of mismatch repair to increase tumour 
immunogenicity 
 
Next-generation sequencing of lung tumours from autochthonous GEMMs by 
our lab (data not shown) and others (McFadden et al., 2014b; Westcott et al., 
2015a) have revealed very few non-synonymous somatic mutations. Since 
neo-antigen load contributes to immunogenicity of tumours and response to 
immune checkpoint blockade (Gubin et al., 2014), we reasoned that the low 
number of somatic mutations in KP lung tumours (especially in relation to 
human smoker’s lung cancer) might contribute to the observed lack of tumour 
immunogenicity in the KP model. 
 
A recent report has indicated that mismatch-repair (MMR)-deficient colorectal 
tumours are more likely to respond to PD-1 blockade with pembrolizumab 
than MMR-proficient colorectal tumours (Le et al., 2015). As expected, they 
found a greatly increased somatic mutational burden in the MMR-deficient 
tumours. Furthermore, tumour somatic mutational burden has recently been 
correlated with clinical response to PD-1 blockade in NSCLC (Rizvi et al., 
2015b). Here, the authors identified mutations in MSH2 (a key mismatch 
repair gene) in a lung tumour from a patient with a very high non-
synonomous mutational burden and durable response to pembrolizumab. 
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Therefore, we attempted to increase the immunogenicity of KP tumours by 
genetically introducing MMR deficiency into the model. We reasoned that 
chronic, early-stage shRNA-mediated silencing of an essential component of 
the MMR machinery in tumour cells might contribute to an increased somatic 
mutation rate. We chose to silence Msh2 expression because (1) it is 
necessary for the formation of the Msh2: Msh6 complex that detects DNA 
mismatches at the first stage of the repair process (Acharya et al., 1996) and 
(2) it is commonly mutated in cancer with microsatellite instability and high 
somatic mutation frequency (de la Chapelle, 2004). For example, Lynch 
syndrome or hereditary non-polyposis colorectal cancer, is a condition with 
early-onset and a very high frequency of colorectal cancer as a result of loss 
of function mutations in one copy of MSH2 (de la Chapelle, 2004).  
 
Firstly we tested different pLKO.1 shRNA clones in KPB6 lung cancer cells to 
select the hairpin sequence that gave the greatest knock-down of Msh2 gene 
expression. All shRNAs (5/5) knocked-down Msh2 at the protein level, but 
shMsh2.2 gave the most profound gene silencing, so we proceeded with this 
hairpin (henceforth referred to as shMsh2) (Figure 3.20A). We then 
subcloned the shRNA sequence and associated promoter from pLKO.1 into a 
lentiviral vector expressing Cre recombinase from the Tyler Jacks laboratory 
(Figure 3.20B). The resulting plenti-Cre shRNA vector can be used to 
simultaneously initiate tumours in KP mice and achieve RNA interference in 
the nascent tumour as the construct is integrated into the genome following 
infection. As a control, we also generated the plenti-Cre shScrambled (shScr) 
construct, which is not predicted to target any known genes in the human or 
mouse genome. The only other modification we made to the original Jacks 
vector was the removal of the puromycin resistance gene, in order to prevent 
the expression of puromycin by tumour cells in vivo, which could potentially 
be immunogenic. 
 
We verified the knock-down efficiency of the plenti-Cre shMsh2 construct in 
unselected KPB6 cells (as puromycin selection could no longer be 
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performed) (Figure 3.20C). We still observed substantial knock-down of 
Msh2 protein with this construct, considering that we did not expect to reach 
100 % infection efficiency with the viral titre used. Next, we verified the Cre 
activity of the lentiviral constructs by infecting 3TZ reporter cells, which 
harbour a LSL-LacZ cassette under the control of a constitutively active 
promoter. X-gal staining can therefore be used as a readout for Cre activity. 
Importantly, both the plenti-Cre shSc and the plenti-Cre shMsh2 lentiviruses 
were able to initiate recombination of the LSL cassette and drive LacZ 
expression (Figure 3.20D). Based on these results, we proceeded to test 
these lentiviruses in KP mice by intratracheal delivery of lentivirus to the lung. 
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Figure 3.20 Generation of a plentiCre-shRNA contruct for in vivo 
silencing of mismatch repair machinery 
(A) Western blotting analysis of Msh2 expression in KPB6 cells lines stably 
expressing the indicated pLKO.1 shRNA lentiviral constructs. 
(B) Vector map of plentiCre-shRNA construct. 
(C) Western blotting analysis of Msh2 expression in KPB6 cells 48 h after 
infection with the indicated lentivirus. 
(D) β-galactosidase staining of 3TZ; LSL-β-galactosidase cells, 48 h after 
infection with the indicated lentivirus. 
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Both plenti-Cre shSc and plenti-Cre shMsh2 lentiviruses were able to initiate 
lung tumourigenesis in vivo in KP mice. We observed µCT-detectable 
tumours by 15 weeks post-infection (Figure 3.21A). Firstly, we checked 
knock-down of Msh2 in plenti-Cre shMsh2 tumours by two independent 
methods; (1) Western blotting (Figure 3.21B), and (2) immunohistochemistry 
(Figure 3.21C). Unfortunately, Msh2 levels were found to be comparable to 
the shScr control tumours by both methods. Notably, Msh2 protein levels 
were elevated in tumour tissue relative to normal adjacent lung.  
 
 
 
Figure 3.21 plenti Cre-shMsh2 initiates KP mouse lung tumourigenesis 
but fails to silence tumour Msh2 expression in vivo 
(A) Representative μCT scans of KP mice 15 weeks after infection with plenti 
Cre-shScr and plenti Cre-shMsh2. Arrows indicate detectable lung tumours. 
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(B) Western blotting analysis of lung tumours and normal adjacent lung 
tissue from KP mice infected with the indicated lentivirus. Samples were 
derived from individual tumour nodules from two mice. 
(C) Immunohistochemical analysis of Msh2 expression in tumour-bearing 
lungs from KP mice as in (A).  
 
Taken together, these data suggest that there is selection against Msh2 
silencing in lung tumours in vivo. We speculate that Msh2 silencing is 
detrimental for tumour cell survival, possibly through the deleterious accrual 
of somatic mutations. We speculate that the increase in Msh2 expression in 
lung tumour reflects the increased proliferation rate of the tumour cells and 
thus the increased rate of DNA replication and spontaneous mismatches 
arising. Indeed, we note that MSH2 expression is increased in human lung 
tumours compared to matched normal lung tissue from a publically available 
dataset (Selamat et al., 2012) (Figure 3.22), suggesting that the tumour cell 
Msh2 expression from our mouse model may reflect the situation in the 
human disease.  
 
 
 
Figure 3.22 MSH2 expression is increased in human lung tumours 
Turkey box-and-whisker plot of MSH2 mRNA expression in human, matched 
lung and lung adenocarcinoma samples from the Selamat et al dataset. Data 
are presented as log2-median-centered intensity. n = 58 per group. *P < 
0.05, Wilcoxen signed-rank test. 
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3.3 Conclusions 
 
Our results from this chapter imply that the commonly used KP mouse model 
of lung cancer is poorly immunogenic. Most notably, our data from the KP; 
Rag2-/- model shows that adaptive immunity does not significantly restrain 
tumour growth in this model. Taken together with reports that the somatic 
mutation rate in similar GEMMs is very low, we conclude that neo-antigen 
burden is unlikely to be sufficient to confer sensitivity to immune checkpoint 
blockade. We cannot rule out that there are tumour-associated antigens in 
KP tumours that may facilitate an anti-tumour immune response. Similarly, 
our negative data cannot formerly exclude the possibility that there is 
profound immune-suppression in the KP model that cannot be eliminated 
with PD-L1 and CTLA-4 blockade alone, and is so efficient that KP; Rag2+/- 
and KP; Rag2-/- mice are ostensibly identical with respect to tumour 
progression. Hence, we aim to directly compare the KP model with a 
modified immunogenic GEMM (iGEMM). This is on going work in our 
laboratory. The attempted knock-down of mismatch repair enzyme Msh2 in 
vivo was unsuccessful, most likely due to strong counter-selection against 
Msh2 knock-down over the 15 week period usually required for tumours to 
become fully established. It will be interesting to test whether the same is true 
in vitro, or if the proposed counter-selection is at least partly non-cell 
autonomous. In future experiments, we would favour using irreversible knock-
out of the target gene using CRISPR/Cas to prevent loss of gene silencing.  
 
We were particularly interested in the observation that KP tumours express 
high levels of PD-L1 mRNA and protein, despite the apparent low 
immunogenicity of these tumours and the scarcity of tumour infiltrating T 
cells. We hypothesise that in this model, PD-L1 upregulation may be partly a 
tumour cell intrinsic phenomenon. The next chapter addresses the regulation 
of PD-L1 expression by RAS. 
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4 Chapter 4. Results 2. Regulation of PD-L1 by RAS 
and TTP in vitro 
 
4.1 Introduction 
 
The immunosuppressive molecule PD-L1 is upregulated in many cancers 
and contributes to evasion of the host immune system. The relative 
importance of the tumour microenvironment and cell-intrinsic signalling in the 
regulation of PD-L1 expression remains unclear. The inflammatory cytokine 
IFN-γ is the best-characterised stimulus for PD-L1 expression (Lee et al., 
2005), however, several studies suggest cell-intrinsic oncogenic signalling 
can also promote PD-L1 expression in cancer cells, such as EGFR and AKT 
pathway activation (Akbay et al., 2013; Parsa et al., 2007). This raises the 
interesting concept of intrinsic tumour immunoresistance (Pardoll, 2012), in 
addition to adaptive evasion of the anti-tumour immune response (Schreiber 
et al., 2011). To date, RAS has not been directly linked to the regulation of 
PD-L1 expression. Studies performed on melanoma (Jiang et al., 2013) and 
acute myeloid leukaemia (Berthon et al., 2010) suggest that MEK signalling 
is implicated in the upregulation of PD-L1 in some tumour cell lines, but there 
are examples in melanoma where this relationship is less clear (Atefi et al., 
2014), and the molecular basis of this regulation remains poorly defined. 
 
In this chapter, I present images generated from histopathological analyses 
performed by Bradley Spencer-Dene and on my behalf. 
  
Chapter 4. Results 2. Regulation of PD-L1 by RAS and TTP in vitro 
 126 
 
4.2 Results 
 
4.2.1 Cell-intrinsic Upregulation of PD-L1 through Oncogenic RAS 
Signalling 
 
We tested the potential role of oncogenic RAS signalling itself to regulate 
tumour PD-L1 expression. To test whether oncogenic RAS signalling was 
sufficient to increase PD-L1 expression, we utilized ER-RASG12V fusion 
constructs, which allow for the rapid activation of oncogenic RAS signalling 
and downstream effectors such as MEK and PI3K with 4-hydroxytamoxifen 
(4-OHT). Firstly, we utilised the immortalised breast epithelial cell line 
MCF10A harbouring ER-HRASG12V, as this system allows for robust 
activation of RAS signalling (Figure 4.1A) (Molina-Arcas et al., 2013a). 
Initiation of oncogenic HRAS signalling led to a significant induction of PD-L1 
mRNA expression at six hours and at 24 hours (Figure 4.1B). Moreover, 
oncogenic RAS strongly induced PD-L1 surface protein expression in 
MCF10A cells, which normally only express very low levels of PD-L1 protein 
(Figure 4.1C). 
 
 
 
Figure 4.1 Oncogenic RAS signalling is sufficient to drive PD-L1 
expression in breast epithelail cells 
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(A) Western blotting analysis of ER-HRASG12V MCF10A cells treated with 4-
OHT or vehicle in starvation medium for 24 h. 
(B) qPCR analysis of ER-HRASG12V MCF10A cells treated with 4-OHT or 
vehicle in starvation medium for 6 h or 24 h. Mean ± SEM of two independent 
experiments. 
(C) Representative histogram from flow cytometry analysis of MCF10A-ER-
HRASG12V cells treated with 4-OHT or vehicle in starvation medium for 24 h. 
Data are representative of two independent experiments. 
4-OHT, 100 nM. ****P<0.0001, unpaired, two-tailed Student’s t-test. 
 
To extend our observations to a tissue type where RAS mutation is much 
more frequent, we investigated the significance of this finding in lung cells 
lines. Firstly, we tested PD-L1 mRNA levels following short-term induction of 
KRASG12V activity in immortalised human type II pneumocytes. 
Downstream RAS effector signalling through ERK and PI3K was evident as 
early as 30 min after addition of 4-OHT (Figure 4.2A). Activation of oncogenic 
RAS signalling coincided with the rapid induction of CCND1 and c-MYC 
mRNAs, as well as a strong induction of PD-L1 mRNA expression (Figure 
4.2B). At three hours post-induction, RAS signalling led to an increase of 
almost six fold in PD-L1 mRNA, which was of the same order of magnitude 
following stimulation with IFN-γ under the same experimental conditions (~12 
fold induction), indicating that the observed increase in PD-L1 gene 
expression is likely to be physiologically relevant (Figure 4.2C). Finally, long-
term activation of oncogenic RAS over four-days led to a profound increase 
in PD-L1 protein expression at the cell surface as measured by flow 
cytometry (Figure 4.2D). We observed a much higher basal level of PD-L1 
protein expression in the immortalised lung cell lines used compared to 
MCF10A cells, but a significant further induction of PD-L1 expression was 
still achieved with the activation of KRAS G12V. Taken together with the data 
from MCF10A cells, these results suggest that the observed PD-L1 induction 
by RAS is not a RAS isoform-specific, or a tissue-specific phenomenon. 
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Figure 4.2 Oncogenic RAS signalling is sufficient to drive PD-L1 
expression in lung cells 
(A) Western blotting analysis of serum-starved type II pneumocyte cells 
harbouring an ER-KRASG12V construct, stimulated with 4-OHT for the 
indicated times. 
(B) qPCR analysis of mRNA expression from the experiment described in 
(A). Data represent the mean ±SEM of duplicates. 
(C) qPCR analysis of PD-L1 mRNA expression in serum-starved type II 
pneumocyte cells harbouring an ER-KRASG12V construct, stimulated with 
IFN-γ for the indicated times. Data represent the mean ±SEM of duplicates. 
(D) Flow cytometry analysis of PD-L1 protein surface expression in serum-
starved type II pneumocyte cells harbouring an ER-KRASG12V construct, 
stimulated with 4-OHT or vehicle control for 4 d. 
4-OHT, 100 nM. IFN-γ, 20 ng/ml. 
 
Similarly, induction of oncogenic KRAS signalling (Figure 4.3A) increased 
PD-L1 surface protein expression in immortalised human type II pneumocyte 
and NL-20 lung cell lines at the shorter time-point of 24 h post-RAS induction 
(Figure 4.3A and Figure 4.3B). To dissect which downstream effectors of 
RAS are responsible for regulating PD-L1 expression, we used the specific 
inhibitors of MEK and pan type I PI3Ks, GSK1120212 (trametinib) and GDC-
0941 (pictilisib), respectively. These inhibitors strongly reversed the 
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activation of ERK and AKT signalling, respectively, downstream of RAS 
(Figure 4.3A). Notably, the increased PD-L1 surface protein expression 
following activation of oncogenic KRAS signalling could be blocked by both 
the MEK and PI3K inhibitors, either alone, or in combination (Figure 4.3C). 
MEK inhibition also significantly reversed KRAS-mediated PD-L1 
upregulation at the mRNA level, however PI3K inhibition only reduced PD-L1 
protein expression (Figure 4.3D). This effect is concordant with evidence for 
AKT signalling specifically increasing PD-L1 expression predominantly 
through activating translation of the transcript (Parsa et al., 2007). 
 
 
 
Figure 4.3 Oncogenic RAS signalling drives PD-L1 expression through 
MEK and PI3K pathways 
(A) Western blotting analysis of ER-KRASG12V NL-20 cells and ER-KRASG12V 
type II pneumocytes treated with 4-OHT, MEK inhibitor or PI3K inhibitor in 
starvation medium for 24 h. 
(B) Flow cytometry analysis of PD-L1 expression in ER-KRASG12V NL-20 
cells and ER-KRASG12V type II pneumocytes treated with 4-OHT or vehicle in 
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starvation medium for 24 h. Data represent the mean ± SEM of three 
independent experiments and are relative to 10 % FCS medium controls. 
(C) Flow cytometry analysis of ER-KRASG12V type II pneumocytes treated 
with 4-OHT, MEK inhibitor and PI3K inhibitor in starvation medium for 24 h. 
Mean ± SD of two independent experiments. 
(D) qPCR analysis from the experiment described in (D). Mean ± SEM of 
biological triplicates. 
MFI, Mean Fluorescence Intensity. 4-OHT, 100 nM. MEK inhibitor 
GSK1120212, 25 nM. PI3K inhibitor GDC-0941, 500 nM. ****P<0.0001, 
***P<0.001, **P<0.01, *P<0.05, n.s; not significant. Unpaired, two-tailed 
Student’s t-tests.  
 
We verified that the induction of PD-L1 expression by 4-OHT treatment was 
attributable to the induction of RAS activity in the RAS-ER cell, rather than 
other effects including the activity of endogenous oestrogen receptor protein 
by treating parental MCF10A and type II pneumocyte cells with 4-OHT 
(Figure 4.4). As expected, there was no change in PD-L1 expression in the 
absence of expression of the RAS-ER constructs. 
 
 
 
Figure 4.4 Parental MCF10A and type II pneumocyte cells do not 
respond to 4-OHT 
Parental MCF10A and type II penumocytes were treated with 4-OHT (100 
nM) or ethanol control for 24 h before FACS analysis of surface PD-L1 
expression. 
 
To test if PD-L1 induction was stimulated by general oncogenic stress, or if 
this was an effect specific to oncogenic RAS and RAS-effector signalling, we 
introduced a doxycycline-inducible c-MYC construct into immortalised NL-20 
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lung epithelial cells. However, overexpression of c-MYC expression was not 
able to increase PD-L1 expression (Figure 4.5), despite massive upregulation 
of c-MYC in these cells. This suggests that the regulation of PD-L1 
expression is not a general phenomenon associated with oncogene 
activation. However, our results are contrary to a recent report that oncogenic 
MYC upregulates PD-L1 expression in T cell acute lymphoblastic leukaemia, 
possibly reflecting tissue-specific differences (Casey et al., 2016b).  
 
 
 
Figure 4.5 Oncogenic stress through forced MYC overexpression does 
not drive PD-L1 expression 
qPCR analysis of c-MYC and PD-L1 expression in NL-20 cells harboring a 
doxycyline-inducible MYC construct (pSLIK MYC), 24 h after the addition of 1 
µg/ml doxycycline. Data represent the mean ± SD. *P<0.05; unpaired, two-
tailed Student’s t-test. 
 
Next, we wanted to assess if the regulation of PD-L1 expression by RAS was 
operating by a strictly cell-intrinsic mechanism, because we reasoned that 
activation of oncogenic RAS signalling has been linked to increased 
production of IL-6 (Ancrile et al., 2007), which may activate STAT signalling 
and thus PD-L1 expression. Hence, RAS might control PD-L1 expression via 
an autocrine loop. To test this hypothesis, we analysed the effect of adding 
conditioned medium from RAS-active type II pneumocyte cells to 
unstimulated cells. Firstly, we observed that activation of oncogenic RAS 
signalling in type II pneumocytes did not increase IL-6 mRNA levels (Figure 
4.6A). Furthermore, conditioned medium from RAS-stimulated cells did not 
have significant effects on PD-L1 protein expression on parental type II 
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pneumocytes (Figure 4.6B), collectively implying that RAS controls PD-L1 
expression independently of IL-6 and independently of other autocrine 
factors. 
 
 
 
Figure 4.6 PD-L1 induction by RAS in vitro is not mediated by an 
autocrine-loop 
(A) qPCR analysis of IL-6 expression in ER-KRASG12V type ii pneumocytes 
24 h after the addition of 4-OHT. Mean ± SEM of biological triplicates.  
(B) Flow cytometry analysis of surface PD-L1 protein expression in parental 
type ii pneumocytes after 24 h incubation with conditioned medium derived 
from ER-KRASG12V type ii pneumocytes activated with 4-OHT for 24 h. 
Mean ± SEM of biological triplicates. 
4-OHT, 100 nM. 
 
To assess whether more potent, acute activation of MEK signalling was also 
capable of inducing PD-L1 expression in a manner comparable to oncogenic 
RAS, we used the phorbol ester PMA, a potent chemical activator of MEK-
ERK signalling (Rusanescu et al., 2001). We observed a dramatic and rapid 
increase in PD-L1 expression in H358 cells, an effect that was largely 
reversed with the inhibition of MEK (Figure 4.7A), functionally excluding other 
pathways that may be activated by phorbol ester treatment, such as protein 
kinase C. This result suggests that other pathways that may activate MEK 
signalling are potentially relevant in the regulation of PD-L1 in cancer. 
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Furthermore, MEK inhibition, but not PI3K inhibition, significantly reduced 
PD-L1 mRNA expression in KRAS-mutant lung cancer cell line H358 (Figure 
4.7B), suggesting that basal levels of oncogenic RAS signalling are important 
for driving PD-L1 upregulation. This result is also consistent with Figure 4.3C 
and Figure 4.3D, which indicates that PI3K signalling regulates PD-L1 at the 
protein but not the mRNA level. 
 
More extensive analysis of PD-L1 surface expression on multiple human and 
mouse KRAS-mutant lung cancer cell lines revealed generally consistent PD-
L1 downregulation following MEK and PI3K inhibition, suggesting this 
regulatory pathway is of broad significance (Figure 4.7C). PD-L1 expression 
on H1792 cells responded least to inhibition of RAS effector pathways, 
possibly reflecting that this cell line had low basal PD-L1 expression 
compared to H358 cells, for example, which expressed the highest levels of 
PD-L1 (data not shown). Taken together, these results suggest that 
oncogenic RAS signalling through MEK and PI3K is sufficient to drive PD-L1 
expression. 
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Figure 4.7 MEK and PI3K inhibition reduces RAS-driven PD-L1 
expression 
(A) qPCR analysis of H358 cells treated with PMA for 3 h following a 30 min 
pre-treatment with DMSO or MEK inhibitor. Mean ± SD of two independent 
experiments. 
(B) qPCR analysis of H358 cells treated with MEK inhibitor and PI3K inhibitor 
for 24 h. Mean ± SEM of two independent experiments. 
(C) Surface expression of PD-L1 was measured by flow cytometry. MFI 
values are adjusted for the isotype control in each condition. Data represent 
the mean ± SEM. 
MFI, Mean Fluorescence Intensity. MEK inhibitor GSK1120212, 25 nM. PI3K 
inhibitor GDC-0941, 500 nM. PMA, 200 nM. ****P<0.0001, n.s; not 
significant. Unpaired, two-tailed Student’s t-tests. 
 
To extend our observations to a non-malignant setting, we considered the 
potential regulation of PD-L1 by wild-type RAS in T lymphocytes. PD-L1 is 
strongly upregulated in stimulated T cells following engagement of the T cell 
receptor. As signalling downstream of the T cell receptor relies on RAS 
signalling (Downward et al., 1990a), we tested to what extent PD-L1 
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induction was dependent on MEK activity in this system. To this end, we 
stimulated CD4 T cell lymphoma EL4 cells with anti-CD3 and anti-CD28 
beads and measured stimulation and PD-L1 induction by flow cytometry. We 
used EL4 cells as a model system to obviate primary T cell isolation from 
animals in these preliminary experiments.  
 
As expected, T cell receptor signalling in stimulated EL4 cells resulted in 
upregulation of the activation marker CD69 and coordinate upregulation of 
PD-L1 expression, although only modestly and only in a subset of cells, 
perhaps due to aberrant oncogenic signalling in these cancer cells and the 
high basal levels of PD-L1 (Figure 4.8). However, inhibition of MEK signalling 
completely reversed activation of both CD69 and PD-L1 expression, and 
even slightly decreased PD-L1 levels to below basal (unstimulated) levels 
(Figure 4.8), implying that this regulatory pathway may also have functional 
significance in T cell PD-L1 expression. This hypothesis will require further 
testing in untransformed T cells. 
 
 
 
Figure 4.8 T cell receptor-dependent induction of PD-L1 is dependent 
on MEK activity 
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Flow cytometry analysis of surface protein PD-L1 and CD69 expression on 
unstimulated or CD3 + CD28 bead stimulated (24 h) with EL4 T cell 
lymphoma cells. Cells were co-treated with DMSO vehicle or MEK inhibitor 
GSK1120212, 25 nM. 
 
4.2.2 RAS Signalling Increases PD-L1 mRNA Stability through AU-rich 
Elements in the 3’UTR 
 
To investigate how RAS-MEK signalling regulates PD-L1 expression 
mechanistically, we first asked whether RAS regulates PD-L1 via a 
transcriptional mechanism by inducing oncogenic KRAS signalling with 4-
OHT in ER-KRASG12V type II pneumocytes and concomitantly blocking 
transcription with actinomycin D (Figure 4.9A). Surprisingly, we found human 
PD-L1 mRNA to have a short half-life, which was significantly stabilised by 
the induction of oncogenic KRAS signalling (Figure 4.9A). Moreover, murine 
PD-L1 mRNA also had a comparably short half-life, and the stability of the 
transcript could be reduced further still when MEK was inhibited (Figure 
4.9B), implicating KRAS-MEK signalling in the stabilization of the labile PD-
L1 transcript. Inhibition of PI3K, however, did not result in altered PD-L1 
mRNA stability in KPB6 cancer cells (Figure 4.9C). This corroborates our 
data showing that PI3K pathway activity does not influence PD-L1 mRNA 
expression in cancer cells, but rather PD-L1 protein levels. 
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Figure 4.9 RAS-MEK signalling controls PD-L1 mRNA stability 
(A) Stability of human PD-L1 mRNA measured by qPCR in ER-KRASG12V 
type II pneumocytes in starvation medium after the concomitant addition of 
actinomycin D (5 µg/ml or 10 µg/ml) and 4-OHT or vehicle. Values are 
normalized to the 0 h time point when actinomycin D was added. Mean ± 
SEM of two independent experiments. *P<0.05; comparing 4 h and 8 h time-
points of EtOH + 5 µg/ml ActD, and 4-OHT + 5 µg/ml ActD. 
(B) Stability of murine PD-L1 mRNA measured by qPCR after the addition of 
actinomycin D (5 µg/ml) and DMSO or MEK inhibitor. KPB6 cells were pre-
treated with DMSO or MEK inhibitor for 30 min before actinomycin D 
addition. Values are normalized to the 0 h time point when actinomycin D 
was added. Mean ± SEM of two independent experiments. *P<0.05; 
comparing 2 h and 4 h time-points of DMSO + 5 µg/ml ActD, and MEKi + 5 
µg/ml ActD. 
(C) Stability of murine PD-L1 mRNA measured by qPCR after the addition of 
actinomycin D (5 μg/ml) and DMSO or PI3K inhibitor GDC-0941 (500 nM). 
KPB6 cells were pre-treated with DMSO or PI3K inhibitor for 30 min before 
actinomycin D addition. Data represent the mean ± SEM and are normalized 
to the 0 h time point when actinomycin D was added, and are representative 
of two independent experiments. 
4-OHT, 100 nM. MEK inhibitor GSK1120212, 25 nM. ***P<0.0005, *P<0.05, 
n.s; not significant. Unpaired, two-tailed Student’s t-tests. 
 
Common genetic elements conferring mRNA instability include miRNA 
binding sites and AU-rich elements (AREs) in the 3’UTR of the transcript 
(Garneau et al., 2007). The core motif for AREs is an ATTTA pentamer 
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sequence, however functional AREs are often found in an AU-rich context, 
conforming to the WWATTTAWW nonamer consensus (where W denotes an 
A or T) (Zubiaga et al., 1995) constituting the binding site for several AU-rich 
element binding proteins (AUBPs) (Brooks and Blackshear, 2013), which can 
subsequently recruit mRNA decay machinery (Lykke-Andersen and Wagner, 
2005). Upon inspection of the 3’UTR of PD-L1, we noted a high number of 
ARE pentamers. Specifically, out of 14 ATTTA pentamer sequences in the 
human transcript and 11 in the murine transcript, there were three conserved 
AREs conforming to the nonamer consensus (Figure 4.10A and Figure 
4.10B). Using standard nomenclature, this arrangement conforms to class I 
AREs. 
 
 
 
Figure 4.10 PD-L1 3’UTR contains multiple conserved AU-rich elements 
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(A) DNA sequence of human and mouse PD-L1 3’UTR showing ATTTA 
pentamer sequences in red. 
(B) Sequence alignment of murine and human PD-L1 3’UTR showing 
fragments containing the three most highly conserved ATTTA pentamer 
sequences in AU-rich context highlighted in red. 
(C) Schematic representation of the murine and human PD-L1 mRNA. AU-
rich element ATTTA pentamer sequences are in orange, and highly 
conserved pentamers are in red. 
 
To analyse the functional importance of these AREs, we constructed a 
luciferase reporter containing a fragment of the 3’UTR of human PD-L1 
containing the last six ATTTA pentamers, including the three conserved 
nonamer sequences (Figure 4.11C). It has been shown that mutation of 
functional ATTTA pentamers to ATGTA can increase the expression of the 
ARE-containing mRNA (Rajagopalan et al., 1995; Yang et al., 2004). Indeed, 
mutating the six ATTTA pentamer sequences to ATGTA increased 
expression of the PD-L1 3’UTR luciferase reporter in ER-HRASG12V MCF10A 
and H358 cells, suggesting these AREs are functionally relevant for 
controlling the expression of PD-L1 (Figure 4.11A and Figure 4.11B).  
 
Crucially, stimulation with 4-OHT in ER-HRASG12V MCF10A cells, or PMA in 
H358 cells, increased expression of the wild-type reporter, whereas the 
ATGTA mutant reporter was insensitive to these treatments (Figure 4.11A 
and Figure 4.11B). In sum, these data suggest that AREs in the 3’UTR of 
PD-L1 mRNA can mediate control of PD-L1 expression by RAS-MEK 
signalling. 
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Figure 4.11 AU-rich elements control the expression of PD-L1 mRNA 
downstream of RAS 
(A) Luciferase reporter expression from a reporter containing a wild-type 
(ATTTA x 6) or mutant (ATGTA x 6) fragment of the human PD-L1-3’UTR 
after 4-OHT or vehicle treatment for 24 h in starvation medium. Data are 
normalized to a Renilla luciferase internal control and represent the mean ± 
SEM of three independent experiments. 
(B) Luciferase expression from a reporter containing a wild-type (ATTTA x 6) 
or mutant (ATGTA x 6) fragment of the human PD-L1 3’UTR after DMSO or 
PMA (200 nM) treatment for 6 h. Data are normalized to a Renilla luciferase 
internal control and represent the mean ± SEM of three independent 
experiments. 
4-OHT, 100 nM. ***P<0.0005, **P<0.005; *P<0.05; N.s; not significant; 
unpaired, two-tailed Student’s t-test. 
 
4.2.3 AU-rich element Binding Proteins TTP and KSRP are Negative 
Regulators of PD-L1 Expression 
 
To assess which AU-rich element binding proteins (AUBPs) could mediate 
regulation of PD-L1 expression downstream of RAS signalling, we first 
performed a selected siRNA screen of likely candidate genes: AUF1, KSRP, 
HuR and TTP (also known as tristetraprolin or ZFP36), in three RAS mutant 
lung cancer cell lines (Figure 4.12A-C). Knockdown efficiency was verified in 
each case by qPCR (Figure 4.12D-F). siRNA-mediated knockdown of KSRP 
and TTP had the strongest and most consistent effects on PD-L1 mRNA 
expression across the cell line panel.  Knockdown of either KSRP or TTP 
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increased PD-L1 expression, suggesting they are negative regulators of PD-
L1 expression.  
 
 
 
Figure 4.12 A selective siRNA-mediated screen of AU-rich element 
binding proteins reveals TTP and KSRP as novel negative regulators of 
PD-L1 expression 
(A-C) qPCR analysis of PD-L1 expression and verification of knock-down (D-
E), 48 h after transfection with siRNAs targeting AU-rich binding proteins 
(AU-BPs) in H358, A427 and H23 cells relative to siScrambled (siSc) control. 
Mean ± SD of biological triplicates. 
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TTP is a member of a small family of related protein, including ZFP36L1 (or 
BRF-1) and ZFP36-L2 (or BRF-2), which are less well-studied RNA-binding 
proteins with ostensibly similar roles in destabilising mRNA targets, but with 
limited overlap in mRNA targets (Adachi et al., 2014). Therefore we tested 
the potential functional contribution of BRF-1 and BRF-2 on PD-L1 regulation. 
However, siRNA-mediated knockdown of the expression of TTP family 
members BRF-1 and BRF-2 was incapable of increasing PD-L1 expression 
to the extent achieved by silencing TTP expression (Figure 4.13A and Figure 
4.13B), indicating a degree of mechanistic specificity for TTP itself in this 
pathway. 
 
 
 
Figure 4.13 Knock-down of TTP family members BRF-1 and BRF-2 does 
not increase PD-L1 expression 
(A) qPCR analysis of PD-L1 expression in H23 cells 48 h after transfection 
with siRNAs targeting AU-rich binding proteins (AU-BPs), relative to 
siScrambled (siSc) control. Data represent the mean ± SEM of two 
independent experiments. 
(B) qPCR analysis of knock-down efficiency in H23 cells 48 h after siRNA 
transfections, relative to siScrambled control. Data represent the mean ± 
SEM of two independent experiments. 
 
Overexpression of KSRP or TTP was sufficient to significantly decrease PD-
L1 expression (Figure 4.14A and Figure 4.14B) and PD-L1 3’UTR luciferase 
reporter expression in H358 cells (Figure 4.15A and Figure 4.15B), 
corroborating our results from the siRNA screen and confirming that KSRP 
and TTP impart their control on PD-L1 expression through the 3’UTR of the 
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transcript. However, overexpression of KSRP and TTP together did not have 
a marked additive effect on the expression of PD-L1 (Figure 4.14), or the PD-
L1 3’UTR luciferase reporter (Figure 4.15). This may reflect a degree of 
redundancy in their role, or that they do not functionally cooperate to 
destabilise PD-L1 mRNA. 
 
 
 
Figure 4.14 Overexpression of TTP and KSRP decreases PD-L1 
expression 
(A) qPCR and Western blotting analysis of H358 cells 24 h after transfection 
with empty or Myc-TTP constructs. qPCR data represent the mean ± SD of 
biological triplicates and are representative of two independent experiments. 
*, non-specific band. 
(B) qPCR and Western blotting analysis of H358 cells 24 h after transfection 
with empty or KSRP constructs. qPCR data represent the mean ± SD of 
biological triplicates and are representative of two independent experiments. 
***P<0.001, **P<0.01. Unpaired, two-tailed Student’s t-test. 
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Figure 4.15 TTP and KSRP impart their negative control of PD-L1 mRNA 
through the 3’UTR, but do not cooperate 
(A) qPCR analysis of PD-L1 expression 24 h after transfection with the 
indicated constructs. Data represent the mean ± SEM of two independent 
experiments. 
(B) Luciferase expression from a reporter containing a fragment of the 
human, wild type PD-L1-3’UTR 24 h after co-transfection with the indicated 
constructs. Data are normalized to a Renilla luciferase internal control and 
represent the mean ± SEM of two independent experiments. 
****P<0.0001, ***P<0.001, **P<0.01; unpaired, two-tailed Student’s t-test. 
 
We further examined the regulation of PD-L1 mRNA by TTP by using TTP 
WT and TTP KO MEFs. In the TTP KO MEFs, TTP mRNA is expressed but 
no functional TTP protein can be made due to the introduction of a premature 
stop codon at the endogenous locus (Lai et al., 2006; Taylor et al., 1996). As 
expected, the total absence of functional TTP protein in the TTP KO MEFs 
increased the half-life of PD-L1 mRNA relative to TTP WT MEFs (Figure 
4.16A). Moreover, acute activation of TTP expression with serum temporally 
coincided with a dramatic and transient decrease in PD-L1 mRNA in TTP WT 
MEFs, but not in the TTP KO MEFs (Figure 4.16B), with PD-L1 levels 
recovering to near baseline at 6 h after serum addition. In sum, these data 
provide evidence for the negative regulation of PD-L1 mRNA expression by 
the AUBPs KSRP and TTP. 
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Figure 4.16 PD-L1 mRNA is stabilised in TTP KO MEFs  
(A) Stability of murine PD-L1 mRNA measured by qPCR after the addition of 
actinomycin D (5 μg/ml) in TTP WT or TTP KO MEFs. Values are normalized 
to the 0 h time point when actinomycin D was added and are representative 
of two independent experiments. 
(B) qPCR analysis of TTP expression and PD-L1 expression following serum 
stimulation in serum-starved TTP WT or TTP KO MEFs. Data are 
representative of two independent experiments. 
 
4.2.4 RAS Regulates PD-L1 Expression through TTP 
 
To address how RAS signalling controls PD-L1 mRNA stability and 
expression, we tested whether the RAS pathway regulates the activity of 
KSRP and/or TTP. Firstly, to test whether AUBP binding to the mRNA was 
subject to regulation by RAS-MEK signalling, we performed RNA 
immunoprecipitation with antibodies against KSRP or TTP in KPB6 mouse 
lung cancer cells treated with DMSO or MEK inhibitor. Notably, our trial 
experiments of RNA immunopreciptation using anti-TTP antibodies failed to 
show binding to PD-L1 mRNA, however, it transpired that this was due to the 
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inclusion of EDTA in the immunoprecipitation buffers (not shown). TTP is a 
zinc-finger protein so chelation of zinc ions by EDTA renders the protein 
unable to bind RNA.  
 
Using a revised protocol excluding EDTA from all buffers, we found that TTP 
and KSRP both significantly co-precipitated with PD-L1 mRNA, implying they 
directly regulate PD-L1 expression through binding the transcript (Figure 
4.17A and Figure 4.17B), however MEK inhibition did not significantly alter 
the occupancy of TTP or KSRP on PD-L1 mRNA. Importantly, the high 
degree of enrichment for PD-L1 mRNA in TTP and KSRP 
immunoprecipitates was not observed for a control mRNA (Gapdh) lacking 
AREs in the 3’UTR (Figure 4.17C and Figure 4.17D), verifying the relative 
specificity of the immunoprecipitation reactions. We observed a small degree 
of enrichment of Gapdh mRNA in the anti-KSRP RNA-IP control experiments, 
but this was approximately five-fold lower in terms of percentage input that 
PD-L1 mRNA. 
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Figure 4.17 TTP and KSRP bind to PD-L1 mRNA, but their occupancy is 
not affected by MEK activity 
(A and B) qPCR analysis of PD-L1 mRNA from RNA immunoprecipitates 
using IgG control or anti-TTP antibody, or in (B), anti-KSRP antibody, from 
KPB6 cells treated with DMSO or MEK inhibitor for 5.5 h. Mean ± SD of 
biological triplicate IPs. 
(C and D) qPCR analysis of Gapdh control mRNA from RNA 
immunoprecipitates using IgG control or anti-TTP antibody, or in (B), anti-
KSRP antibody, with lysate from KPB6 cells pre-treated with DMSO or MEK 
inhibitor GSK1120212 for 5.5 h (25 nM). Data represent the mean ± SD of 
biological triplicate IPs. 
MEK inhibitor, GSK1120212, 25 nM. ****P<0.0001, ***P<0.001, **P<0.01, 
n.s; not significant; unpaired, two-tailed Student’s t-test. 
 
We also verified the binding of TTP to PD-L1 mRNA in the human NSCLC 
cell line H358 (Figure 4.18). Although the relative levels of TTP binding to 
PD-L1 mRNA was lower in this setting, we still observed significant binding o 
TTP to the transcript relative to the GAPDH control.  
 
 
 
Figure 4.18 TTP binds to PD-L1 mRNA 
(A) qPCR analysis of PD-L1 mRNA from RNA immunoprecipitates from H358 
cells using IgG control or anti-TTP antibody. 
(B) qPCR analysis of GAPDH mRNA from RNA immunoprecipitates from 
H358 cells using IgG control or anti-TTP antibody. This serves as a control 
mRNA to verify the specificity of the protein-mRNA interaction, as GAPDH 
mRNA does not contain AU-rich elements in the 3’UTR. 
Data represent the mean ± SEM of triplicate RNA immunoprecipitation 
reactions.  
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Next, we asked whether MEK and AUBPs regulate PD-L1 expression 
through the same pathway by using siRNA-mediated knockdown of TTP or 
KSRP in the context of MEK inhibition. Importantly, the knockdown of TTP 
was largely able to rescue the decrease in PD-L1 expression caused by MEK 
inhibition (Figure 4.19A and Figure 4.19B), suggesting MEK and TTP 
regulate PD-L1 levels through a shared pathway. The knockdown of KSRP, 
however, could not rescue this phenotype, despite profound silencing of 
KSRP expression (Figure 4.19C and Figure 4.19D). Moreover, MEK 
inhibition significantly increased TTP mRNA expression (Figure 4.19B) and, 
concordantly, chronic activation of oncogenic KRAS signalling in ER-
KRASG12V type II pneumocytes significantly decreased TTP mRNA 
expression (Figure 4.19E), implying that RAS-MEK activity controls TTP 
expression.  
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Figure 4.19 Regulation of PD-L1 by MEK is TTP-dependent 
(A and B) qPCR analysis of H358 cells following siRNA-mediated knock-
down of TTP (24 h) followed by MEK inhibition (24 h). Mean ± SEM of two 
independent experiments. 
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(C and D) qPCR analysis of H358 cells following siRNA mediated knock-
down of KSRP (24 h) followed by MEK inhibition (24 h). Mean ± SEM of two 
independent experiments.  
(E) qPCR analysis of ER-KRASG12V type II pneumocytes treated with 4-OHT 
for 24 h. Mean ± SEM of three independent experiments. 
MEK inhibitor, GSK1120212, 25 nM. ****P<0.0001; ***P<0.001; **P<0.005; 
*P<0.05; N.s; not significant; unpaired, two-tailed Student’s t-test. 
 
The serine/threonine phosphatase PP2A has been implicated in positively 
regulating TTP function (Rahman et al., 2015; Sun et al., 2007). Therefore, 
we tested whether inhibition of PP2A with the inhibitor okadaic acid (OA) 
would increase PD-L1 expression. Indeed, OA significantly and rapidly 
increased PD-L1 mRNA expression in TTP WT MEFs, but not TTP KO MEFs 
(Figure 4.20A), demonstrating that PP2A activity decreases PD-L1 
expression specifically through modulating TTP activity.  
 
Conversely, ERK has been shown to phosphorylate (Taylor et al., 1995) and 
negatively regulate TTP activity and expression (Bourcier et al., 2011; 
Deleault et al., 2008; Essafi-Benkhadir et al., 2007; Hardle et al., 2015). In 
addition, the downstream kinase RSK has been implicated in the negative 
regulation of TTP family members by the phosphorylation of a conserved 
motif, which is important in binding effector proteins for mRNA degradation 
(Adachi et al., 2014). Inhibition of MEK decreased phosphorylation of TTP at 
PXSP (ERK target-site consensus) and RXXS/T (RSK/AKT target-site 
consensus) motifs (Figure 4.20B and Figure 4.20C), confirming that TTP is 
regulated by phosphorylation downstream of MEK signalling in cancer cells. 
In line with these data, we observed a more potent decrease in PD-L1 mRNA 
expression in H358 cells when inhibitors of MEK and RSK were combined 
(Figure 4.20D). Mutation of two of the highest confidence predicted ERK-
target residues on human TTP, S218 and S228, abrogated detection of TTP 
with the phospho-PXSP motif-specific antibody (Figure 4.20B). The reduction 
of the phospho-TTP signal with MEK inhibitor suggested that these residues 
might be functionally relevant, but the S218A 228A double-mutant TTP did 
not show enhanced activity in reducing PD-L1 mRNA expression compared 
to wild-type TTP when overexpressed in H358 cells (data not shown), 
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implying the involvement of other target residues that are not readily detected 
with this antibody. Furthermore, although AKT signalling has been shown to 
regulate KSRP activity through phosphorylation of S193 (Diaz-Moreno et al., 
2009), a KSRP S193A phospho-mutant did not show enhanced activity in 
reducing PD-L1 mRNA expression compared to wild-type KSRP when 
overexpressed in H358 cells (Figure 4.20E). 
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Figure 4.20 TTP is controlled by phosphorylation downstream of MEK 
(A) qPCR analysis of TTP WT or TTP KO MEFs treated with okadaic acid or 
DMSO for 2 h. Mean ± SEM of two independent experiments. 
(B) Western blotting analysis of H358 cells expressing the indicated 
constructs. 6.5 h post-transfection, cells were treated with DMSO or MEK 
inhibitor for an additional 16 h. Arrow indicates Myc-TTP. 
(C) Western blotting analysis of immunoprecipitations from H358 cells 
transfected with wild type Myc-TTP. 6.5 h post-transfection, cells were 
treated with DMSO or MEK inhibitor for an additional 16 h. Arrow indicates 
Myc-TTP; * indicates co-precipitating protein. 
(D) qPCR analysis of PD-L1 expression in H358 cells treated for 5.5 h with 
the indicated inhibitors. MEK inhibitor, GSK1120212 (25 nM); RSK inhibitor, 
BI-D1870 (10 µM). Data represent the mean ± SD of two independent 
experiments. ****P<0.0001. 
(E) qPCR analysis of PD-L1 expression in H358 cells 24 after transfection 
with empty, wild-type KSRP or phospho-mutant KSRPS193A constructs. Data 
represent the mean ± SEM of two independent experiments. 
****P<0.0001, ***P<0.001, **P<0.01, n.s, not significant; unpaired, two-tailed 
Student’s t-test. 
 
4.2.5 RAS-ROS-p38 Signalling Controls TTP Activity 
 
To further explore the potential regulation of TTP activity by RAS-MEK 
signalling, we performed mass spectrometry on immunoprecipitated Myc-
TTP after PMA, MEK inhibitor, or PMA and MEK inhibitor treatment in CT26 
colon carcinoma cells (Table 5). We selected the CT26 cell line due to its 
immunogenicity and Kras mutant status. We proceed to use this cell line 
further in in vivo studies in Chapter 5.  
 
The mass spectrometry analysis revealed MEK-dependent phosphorylation 
of S52 and S178; PMA significantly enhanced phosphorylation of these 
residues and this effect was reversed with MEK inhibition. Moreover, MEK 
inhibition alone was sufficient to reduce phosphorylation of these residues 
(Figure 4.21).  
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Table 5. Mass spectrometry analysis reveals MEK-dependent TTP 
phosphorylation events  
Table of identified mouse TTP phosphopeptides from MS analyses pooled 
from two independent biological experiments. Identifications are 1 % FDR 
controlled. PEP indicates the probability that the identification is incorrect. 
Phosphosite assignment probabilities are indicated in parenthesis.  
 
 
 
Figure 4.21 S52 and S178 of mouse TTP are phosphorylated in 
response to MEK signalling 
(A) Semi-quantitative analysis of non-phosphorylated and phosphorylated 
peptides corresponding to S52 and S178 phosphosites of mouse TTP, 
generated in Skyline. Myc-TTP was immunoprecipitated from CT26 cells 
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stably expressing a doxycycline inducible Myc-TTP construct, 1 h after 
treatment with DMSO vehicle, PMA (200 nM), MEK inhibitor GSK1120212 
(25 nM) or PMA and MEK inhibitor together. Data represent the mean ± SD 
of technical triplicates and are representative of two independent biological 
experiments.  
(B) MS/MS mass spectra for phosphopeptides STphSLVEGR (S52) and 
QSIphSFSGLPSGR (S178). -98 indicates the loss of H3PO4.  
 
TTP is tightly regulated by p38 signalling through phosphorylation by the 
downstream kinase MK2 (also known as MAPKAPK2), resulting in 
decreased TTP activity and increased target mRNA stability (Mahtani et al., 
2001; Stoecklin et al., 2004). In parallel, phosphorylation of S52 and S178 
stabilizes TTP protein (Brook et al., 2006), which is consistent with the 
increased abundance of total TTP peptides detected in the PMA versus the 
MEK inhibitor-treated condition observed in our mass spectrometry analysis 
(Figure 4.21). 
 
Since oncogenic RAS can stimulate p38 activity through promoting the 
accumulation of reactive oxygen species (ROS) downstream of MEK-ERK 
activation (Nicke et al., 2005), we reasoned that p38 signalling might 
contribute to TTP inactivation downstream of RAS. Indeed, oncogenic RAS 
signalling dramatically increased intracellular ROS in MCF10A cells, and 
ROS levels were distinctly correlated with the extent of PD-L1 induction 
(Figure 4.22). Moreover, the addition of the potent anti-oxidant N-acetyl-L-
cysteine (NAC) largely reversed the induction of PD-L1 protein by RAS 
(Figure 4.22), collectively suggesting that ROS induction by oncogenic RAS 
is functionally important in driving PD-L1 expression. 
 
 
 
Chapter 4. Results 2. Regulation of PD-L1 by RAS and TTP in vitro 
 156 
Figure 4.22 ROS accumulation is critical for RAS-induced PD-L1 
upregulation 
Flow cytometry analysis of PD-L1 surface protein, and intracellular ROS 
measured by staining with H2DCFDA, in MCF10A ER-HRASG12V cells 
treated with 4-OHT or vehicle ± NAC for 24 h. Data are representative of two 
independent experiments. 
4-OHT, 100 nM. NAC, 10 mM. 
 
Chronic endogenous mutant RAS expression has been shown to select for a 
compensatory state of lower ROS levels, achieved by the activation of an 
Nrf2 transcriptional programme (DeNicola et al., 2011). Therefore, we tested 
whether chronic activation of oncogenic RAS signalling would result in 
comparable PD-L1 expression to acute activation of RAS. Surprisingly, we 
found that PD-L1 expression was further increased after four days of 
stimulation, suggesting that potential compensatory transcriptional 
mechanisms are unlikely to reverse PD-L1 induction at these time-points 
(Figure 4.23). 
 
 
 
Figure 4.23 Long-term RAS activation leads to augmented PD-L1 
expression  
Representative histograms from flow cytometry analysis of surface PD-L1 
protein expression on MCF10A ERHRASG12V cells 24 h or 4 days (d) after 
treatment with vehicle or 4-OHT (100 nM). Data are representative of two 
independent experiments. 
 
Strikingly, specific activation of the p38 pathway using an inducible version of 
the upstream kinase MEKK3 (∆MEKK3-ER; Figure 4.24B) (Garner et al., 
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2002) was sufficient to activate PD-L1 protein expression, albeit to a lesser 
extent than that achieved by RAS itself (Figure 4.24A). Importantly, co-
treatment with NAC was considerably less effective in reversing PD-L1 
induction in this context, implying ROS operates upstream of p38 signalling in 
this pathway. 
 
 
 
Figure 4.24 p38 signalling is sufficient to drive PD-L1 induction 
downstream of ROS 
(A) Flow cytometry analysis of PD-L1 surface protein in MCF10A ER-
∆MEKK3 cells treated with 4-OHT or vehicle ± NAC for 24 h. Data are 
representative of three independent experiments. 
(B) Western blotting analysis of MCF10A cells harboring an inducible version 
of the kinase domain of MEKK3 (ER-∆MEKK3), 24 h after the addition of 4-
OHT or vehicle. 
4-OHT, 100 nM. NAC, 10 mM. 
 
Downstream of p38 activation, MK2 phosphorylates TTP at two conserved 
serine residues involved in binding to 14-3-3 proteins; S52 and S178 of the 
mouse protein, of which S52 conforms to the RXXS/T phosphosite motif 
(Chrestensen et al., 2004). We therefore analysed the potential role MK2 
activity downstream of RAS in the induction of PD-L1 expression. Two 
independent, specific, ATP-competitive inhibitors of MK2 strongly reversed 
RAS-dependent PD-L1 induction in MCF10A cells (Figure 4.25). 
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Figure 4.25 MK2 activity is required for optimal PD-L1 induction by RAS 
Representative histograms from flow cytometry analysis of surface PD-L1 
protein expression on MCF10A ERHRASG12V cells 24 h after treatment with 
vehicle, 4-OHT (100 nM) or 4-OHT and MK2 inhibitor PF 3644022 (1 µM) or 
MK2 inhibitor III (1 µM). Data are representative of two independent 
experiments. 
 
Since p38 operates upstream of MK2, we also tested the efficacy of p38 
inhibitor SB203580 on PD-L1 expression in H358 cancer cells. Unexpectedly, 
p38 inhibition increased PD-L1 expression in this system, although only 
modestly (Figure 4.26A). We confirmed p38 was inhibited effectively by 
Western blotting for the phosphorylated form of the downstream substrate 
CREB (Figure 4.26B). However, we also noted that ERK activity was 
dramatically stimulated upon addition of the p38 inhibitor (Figure 4.26B). ERK 
pathway activation following treatment with SB203580 and other p38 
inhibitors has been reported by others (Hall and Davis, 2002). This effect 
may account for the lack of p38 inhibitor activity against PD-L1 expression. 
Indeed, this is consistent with MEK inhibition reversing the activation of PD-
L1 expression by p38 inhibition (Figure 4.26A). 
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Figure 4.26 p38 inhibitor SB203580 paradoxically increases PD-L1 
expression 
(A) qPCR analysis of PD-L1 expression in H358 cells treated for 5.5 h with 
the indicated inhibitors. MEK inhibitor, GSK1120212 (25 nM); p38 inhibitor, 
SB203580 (10 µM). Data represent the mean ± SEM of two independent 
experiments. ****P<0.0001; *P<0.05; NS, not significant; unpaired, two-tailed 
Student’s t-test. 
(B) Western blotting analysis of H358 cells treated with the indicated 
inhibitors for 5.5 h. Phospho-CREB (S133) signal serves as an indicator of 
p38 MAPK pathway activity.  
MEK inhibitor, GSK1120212 (25 nM); p38 inhibitor, SB203580 (10 µM). 
 
To analyse the functional significance of these MK2 target residues 
downstream of RAS-MEK pathway activation, we generated TTP KO CT26 
colon carcinoma cell lines using CRISPR/Cas in order to obviate functional 
contributions from endogenous TTP. Western blotting confirmed lack of TTP 
protein expression in KO clone #1 (Figure 4.27A), and this was further 
validated by TOPO-TA cloning of the endogenous Zfp36 locus followed by 
sequencing to confirm total allele disruption (Figure 4.27B). All colonies 
sequenced for clone KO clone #1 carried missense mutations (Figure 4.27C).  
 
Interestingly, the total number and frequency of unique mutations suggested 
that the CT26 cell line is tetraploid for this region of chromosome seven. 
We then reconstituted TTP KO CT26 cells with either a wild-type (WT) or 
phosphosite-mutant (S52A S178A), tetracycline-inducible TTP transgene.  
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Figure 4.27 CRISPR/Cas-mediated disruption of Zfp36 
(A) Western blotting analysis of CT26 cell clones following genome editing by 
CRISPR/Cas. TTP KO clone #1 was selected for use in subsequent 
experiments in the main text. Parental clones, Cas9-transfected clones and 
the overexpression of Myc-TTP transgene serve as controls. 
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(B) Complete Zfp36 allele disruption was confirmed by TOPO-TA cloning and 
sequencing. Shown are representative sequencing histograms showing a 
common nonsense mutation (“mutA”) proximal to the gRNA binding site.  
(C) Quantification of the number of different nonsense mutations found in 
clone #1, found by TOPO-TA cloning and sequencing. 
 
Immunoprecipitation of Myc-tagged TTP following acute MAPK activation 
with PMA revealed phosphorylation of WT TTP, but not of the S52A S178A 
mutant protein at RXXS/T sites (Figure 4.28B). Moreover, the S52A S178A 
mutant TTP had enhanced activity in reducing PD-L1 mRNA expression 
relative to WT TTP (Figure 4.28C and Figure 4.28D). We also noted 
increased protein stability of WT TTP following PMA stimulation in the input. 
In concordance with our results from mass spectrometry analysis, the TTP 
S178A 52A double mutant TTP input did not change in response to PMA 
treatment, reflecting abrogation of the phosphorylation-dependent change in 
protein stability. In sum, these results suggest that a RAS-ROS-p38 
signalling axis contributes to PD-L1 upregulation through phosphorylation 
and inactivation of TTP. 
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Figure 4.28 RAS-induced p38 activity decreases TTP activity 
(A) Sequence alignments of the conserved phosphosites targeted by MK2 in 
the mouse (Mm) and human (Hs) TTP protein. The phosphorylated serines 
are highlighted in red. 
(B) Western blotting of immunoprecipitation reactions from CT26 TTP KO 
cells harboring doxycycline-inducible WT or phospho-mutant Myc-TTP 
constructs, treated with doxycycline for 24 h before the addition of PMA or 
vehicle for an additional 1 h. Arrow indicates Myc-TTP. 
(C) Western blotting analysis of Myc-TTP expression 24 h after the addition 
of doxycycline or vehicle. Arrow indicates Myc-TTP. 
(D) qPCR analysis of CT26 TTP KO cells harboring doxycycline-inducible 
WT or phospho-mutant Myc-TTP constructs, treated with doxycycline or 
vehicle for 48 h. Mean ± SEM of two independent experiments.  
*P < 0.05; unpaired, two-tailed Student’s t-test. PMA, 200 nM. Dox., 
doxycycline, 1 µg/ml. 
 
4.3 Conclusions 
 
In this chapter, we demonstrate that oncogenic RAS signaling can increase 
tumor cell-intrinsic PD-L1 expression, implying that RAS can directly 
contribute to evading immune destruction in lung cancer. The use of tumor 
PD-L1 expression in stratifying patients for cancer immunotherapy may be 
confounded by antigen-independent processes including the cell-intrinsic 
signaling mechanisms controlling tumor PD-L1 expression outlined here. Our 
observations indicate a role for mutant RAS in contributing to the uncoupling 
of tumor PD-L1 expression from the immunogenicity of the tumor. 
 
We reveal that RAS-MEK signaling controls expression of PD-L1, at least in 
part, by modulating the stability of the transcript. We show that the mouse 
and human PD-L1 mRNAs are labile transcripts containing multiple AREs in 
the 3’UTR that are functionally important for controlling PD-L1 expression. 
Moreover, we demonstrate that AREs permit the regulation of PD-L1 
expression downstream of RAS. miRNAs such as miR-200 and miR-513 
have also been implicated in regulating the stability of the PD-L1 transcript 
(Chen et al., 2014; Gong et al., 2009). However, we show that mutation of 
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AREs in the 3’UTR of PD-L1 is sufficient to abrogate sensitivity of the 3’UTR 
reporter to RAS-MEK activity, implying that miRNAs that do not target these 
sites are unlikely to be pertinent in this pathway downstream of RAS. 
 
We identify TTP as a principle AUBP responsible for negatively regulating 
PD-L1 expression. Our data are consistent with a previous report identifying 
PD-L1 mRNA as a TTP target in an RNA-immunoprecipitation, microarray-
based screen in mouse macrophages (Stoecklin et al., 2008). Using an RNA 
interference approach, we also identify KSRP as an additional AUBP capable 
of negatively regulating PD-L1 expression in cancer cells. As our selective 
screening of candidate AUBPs was non-exhaustive, it is plausible that other 
AUBPs may be involved in coordinately regulating PD-L1 expression in lung 
cancer. Indeed, differential expression of TTP, KSRP and other AUBPs may 
account for the disparities in the extent of PD-L1 upregulation following 
knockdown of TTP or KSRP between the cancer cell lines analysed in this 
study. 
 
Mechanistically, MEK inhibition reduced PD-L1 mRNA stability, coinciding 
with an increase in TTP expression and reduction in phosphorylation of TTP 
at ERK and RSK/AKT consensus motifs. Conversely, activation of MAPK and 
the associated ROS accumulation led to enhanced TTP phosphorylation, 
notably by MK2 at key inhibitory sites. Intriguingly, p38 inhibition has been 
shown to significantly decrease PD-L1 expression in lymphoma (Yamamoto 
et al., 2009). Our results offer a possible mechanistic explanation for these 
findings and imply that p38 and MK2 inhibitors may be effective in reducing 
PD-L1 expression in other malignancies. Collectively, our data support the 
finding that chronic RAS activity leads to a concerted reduction in TTP 
function.  
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5 Chapter 5. Results 3. Regulation of PD-L1 by RAS 
and TTP in vivo 
 
5.1 Introduction 
 
Thus far, we have investigated the molecular detail of how RAS regulates 
PD-L1 mRNA stability through the ARE-element binding protein TTP. Here, 
we aim to investigate the relevance of this regulatory pathway in vivo. We 
investigate the regulation of PD-L1 expression in human lung cancer using 
publically available datasets and bioinformatics analysis. In addition, we 
establish an experimental mouse model to directly test the functional 
importance of TTP expression in tumour immunoresistance and progression. 
 
In this chapter, I present bioinformatics analyses that were conducted by Phil 
East and Sophie de Carne on my behalf. This includes the GSEA and the 
associated interpretation of TCGA datasets. I also present images generated 
from histopathological analyses performed by Bradley Spencer-Dene on my 
behalf. 
 
5.2 Results 
 
5.2.1 RAS Pathway Activation is Associated with PD-L1 Upregulation 
in Human Lung Cancer 
 
To further evaluate the role of oncogenic RAS signalling in regulating PD-L1 
expression in human lung cancer, we analysed TCGA gene expression data 
from patient-derived lung adenocarcinoma (LUAD) samples. To account for 
the effects of alternative oncogenes that can activate downstream RAS 
effector pathways such as EGFR, BRAF and ALK, we used two published 
RAS activation gene expression signatures (Loboda et al., 2010; Sweet-
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Cordero et al., 2005) to classify samples regarding their RAS pathway 
activity. The Loboda-Watters signature was derived from a meta-analysis of 
RAS mutant lung, colon and breast tumour samples and cell lines and 
consists of 105 upregulated genes associated with RAS activation. The 
Sweet-Cordero-Jacks signature constitutes gene expression data from lung 
tumours from the KRAS LA2 mouse model of NSCLC, compared to human 
RAS-mutant lung cancers, consisting of 89 upregulated genes. Both 
signatures have been biologically validated in their respective studies, and 
the use of both of them in parallel increases the robustness of our analytical 
approach. The overlap between the gene signature sets is only three genes 
out of a total of 194 genes, implying they provide truly distinct approaches for 
sample segregation. 
 
Using these independently generated gene expression signatures, we were 
able to segregate patient LUAD samples into “high” and “low” RAS pathway 
activity based on gene expression. Encouragingly, annotation of KRAS 
mutation status revealed a strong enrichment for KRAS mutant samples in 
the high RAS activity cohorts in both signatures, although this was weaker in 
the Loboda-Watters signature (Figure 5.1). As expected, the majority of the 
KRAS mutations annotated were in the G12 position, as denoted by a red 
block next to the patient sample row (Figure 5.1). 
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Figure 5.1 Clustering of TCGA LUAD samples into high and low RAS 
pathway activity using GSEA 
Heat maps showing human lung adenocarcinoma samples from the TCGA 
dataset clustered into RAS high or low pathway activity groups using RNA 
sequencing expression data and published RAS activity gene expression 
signatures (Loboda et al., 2010; Sweet-Cordero et al., 2005). KRAS mutation 
status, and specifically KRAS codon 12 mutation status, are shown for each 
sample. 
 
Next, we compared the expression of T cell function related genes between 
high and low RAS activity cohorts. We found CD274 (PD-L1) expression to 
be significantly increased in the high RAS pathway activity samples in both 
the Sweet-Cordero-Jacks and the Loboda-Watters signatures (2.65 and 2.71 
fold change, respectively) (Figure 5.2A and Figure 5.2B). However, the 
expression of the pan-leukocyte marker PTPRC (coding for CD45) and 
lymphocyte marker CD3E were only modestly increased in the high RAS 
pathway activity cohort (PTPRC 1.26 and 1.21, CD3E 1.36 and 1.04 fold 
change) indicating that the differential in PD-L1 expression is not likely to be 
solely attributable to a higher degree of leukocyte infiltration and inflammation 
in the tumour microenvironment. Notably, when comparing high and low RAS 
pathway activity samples we did not find concordant differences in TTP 
expression between the two signatures; it was only significantly changed in 
the Loboda-Watters signature (1.9 fold change).  
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Figure 5.2 High RAS pathway activity in human lung tumours is 
associated with high PD-L1 expression  
(A) Heat-maps showing fold change in expression of T cell function related 
genes between high and low RAS pathway activity TCGA lung 
adenocarcinoma (LUAD) cohorts using two independent RAS gene 
expression signatures. Genes are ranked in order of significance from left to 
right. Wald test with Benjamini-Hochberg correction. 
(B) Box-and-whisker plots showing PD-L1 expression represented as log2 
normalized count in RAS high versus low pathway activity TCGA LUAD 
cohorts using two independent RAS gene expression signatures. Wald test 
with Benjamini-Hochberg correction. 
 
To further explore the in vivo relevance of TTP regulation in lung cancer, we 
compared TTP expression in FACS-sorted epithelial cells isolated from 
normal lung or matched tumour tissue from KP mice (KrasLSL-G12D/+; Trp53F/F 
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mice where tumour formation was initiated by local introduction of a Cre-
expressing adenovirus to the lung) (Figure 5.3A), and found that TTP 
expression was downregulated in lung tumour tissue (Figure 5.3B). PD-L1 
mRNA expression was generally higher in tumour tissue than in normal lung 
but not significantly increased. However, PD-L1 protein expression was 
significantly elevated on tumour tissue relative to normal adjacent lung, 
hence we speculate that AKT pathway activation downstream of KRAS may 
contribute to increasing PD-L1 protein expression in vivo (Figure 5.4).  
 
 
 
Figure 5.3 TTP is reduced in murine, Kras-driven lung cancer 
(A) FACS sorting strategy to isolate CD45-CD31-DAPI-EpCAM+ cells from 
macroscopically dissected lung tumours or normal adjacent lung tissue from 
KrasLSL-G12D/+; Trp53F/F mice. 
(B) qPCR analysis of PD-L1 and TTP expression in FACS purified CD45-
CD31-DAPI-EpCAM+ cells derived from lung tumours or matched normal 
adjacent lung tissue from KrasLSL-G12D/+; Trp53F/F mice. Each point represents 
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data from an individual mouse and is normalized to the matched normal lung 
tissue. ***P<0.0005; unpaired, two-tailed Student’s t-tests. 
 
 
 
Figure 5.4 PD-L1 protein expression is upregulated on Kras-driven lung 
tumour cells in vivo 
Flow cytometry analysis of PD-L1 expression on CD45-CD31-DAPI- cells 
derived from macroscopically dissected lung tumours or normal adjacent lung 
tissue from KrasLSL-G12D/+; Trp53F/F mice. Each point represents data from an 
individual mouse and is normalized to the matched normal lung tissue. Data 
are pooled from two independent experiments. MFI; Mean Fluorescence 
Intensity. *P<0.05; unpaired, two-tailed Student’s t-test. 
 
Consistent with our results from the KP mouse model of NSCLC, we found 
that TTP was strikingly downregulated in human tumour samples (0.21 fold 
change) from a publically available dataset comparing mRNA expression in 
matched normal lung and lung adenocarcinoma tissue (Selamat et al., 2012), 
confirming that aberrant regulation of TTP expression is indeed relevant in 
the human disease, but may not be a trait specific to tumours with high RAS 
activity (Figure 5.5A). Rather, our data suggests that remaining tumour TTP 
activity is suppressed at the level of post-translational modification by RAS 
signalling. KRAS mutation status alone did not strongly segregate with higher 
PD-L1 expression in this smaller dataset of lung cancer samples, perhaps 
indicating that other common drivers of RAS effectors do indeed need to be 
considered to reliably reflect the regulation of PD-L1 by RAS pathway activity 
in vivo (Figure 5.5B). Unexpectedly, PD-L1 expression was not significantly 
increased in the lung tumours versus normal lung tissue in this dataset, 
despite significant TTP suppression. This may reflects the complex 
combination of antigen-dependent cell-extrinsic, and antigen independent cell 
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intrinsic combinatorial effects that influence PD-L1 expression in lung cancer. 
TTP suppression was not significantly correlated with the KRAS mutational 
status in this lung cancer dataset (Figure 5.5B), in line with our TCGA data 
analysis. Interestingly, in breast cancer, a malignancy where RAS 
deregulation and mutation is uncommon, we observed a strong inverse 
correlation between TTP expression and PD-L1 expression (Figure 5.5C). 
TTP was suppressed and PD-L1 was upregulated in breast cancer compared 
to normal breast tissue. Notably, somatic mutational load is dramatically 
lower in breast versus lung carcinoma on average (Cancer Genome Atlas, 
2012; Cancer Genome Atlas Research, 2014). Therefore this scenario more 
likely reflects cell-intrinsic and antigen independent control of PD-L1 
expression (for example, when considering infiltration by T cells due to 
recognition of tumour neo-antigens). This pattern of TTP regulation may be 
more reflective of Myc transcriptional repression of TTP expression in lung 
and breast, as has been previously reported for lymphoma (Rounbehler et 
al., 2012).  
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Figure 5.5 TTP is reduced in human lung cancer and breast cancer 
(A) TTP mRNA expression in matched patient lung and LUAD samples. 
Expression is represented as log2 median-centered intensity. Wilcoxon 
signed-rank test. 
(B) PD-L1 and TTP mRNA expression from the Selamat et al cohort as in 
(A), but with dot-plot representation where KRAS mutant samples are 
highlighted in red. Expression is represented as log2 median-centered 
intensity. 
(C) PD-L1 and TTP mRNA expression in matched patient breast and breast 
carcinoma samples. Expression is represented as log2 median-centered 
intensity. Wilcoxon signed-rank test. 
 
Using “KM-plotter” software, we found lower tumour TTP expression to be 
significantly correlated with shorter time to progression following surgery in 
lung adenocarcinoma patients (Figure 5.6). Similar results were obtained 
when patients were segregated based on either lower quartile or upper 
quartile TTP expression thresholds. These data imply that TTP function may 
delay lung tumour progression in vivo. 
 
 
 
Figure 5.6 Low TTP tumour expression is associated with shorter time 
to progression in human lung cancer 
Kaplan-Meier plots showing time until first progression, generated using “KM-
plotter” for lung adenocarcinoma patients (Gyorffy et al., 2013). Samples 
were segregated into low or high TTP expression groups using lower quartile 
(left panel) or upper quartile (right panel) TTP expression thresholds. 
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To further explore the functional relevance of the control of PD-L1 expression 
by RAS in lung cancer, we analysed PD-L1 mRNA and phosphorylated ERK 
(pERK) levels and localisation in human patient lung adenocarcinoma 
samples. We analysed PD-L1 mRNA (by a proprietary in situ hybridisation 
technique, RNAscope) rather than protein because PD-L1 antibodies 
commercially available at this time did not give satisfactory results on human 
tissue in our hands. In addition, it is particularly pertinent to measure PD-L1 
mRNA given the regulatory mechanism we describe in Chapter 4. 
 
Although these data are only preliminary given that we only had material from 
two patients, we observed localised regions of high pERK levels (especially 
near the periphery of the tumour) that were associated with areas of high PD-
L1 mRNA detection (Figure 5.7). These findings will need to be verified by 
analysing additional cases, but are generally consistent with our findings from 
TCGA data analysis (Figure 5.2). 
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Figure 5.7 Localised RAS activity is assocaited with regions of high PD-
L1 mRNA expression in human lung tumours 
Histological analysis of KRAS mutant lung adenocarcinoma samples from 
two different patients. PD-L1 mRNA was detected by RNAscope. Regions of 
high pERK activity are also shown at higher magnification (20X). 
 
5.2.2 Restoration of Tumour Cell TTP Expression Enhances Anti-
tumour Immunity 
 
Next, we set out to directly assess the functional importance of the regulation 
of PD-L1 expression by TTP and RAS in tumour progression. To this end, we 
tested several different syngeneic tumour transplant models for sensitivity to 
PD-L1 antibody treatment. Firstly, we tested KPB6 cells, as they are Kras-
mutant lung cancer cells from a C57Bl/6 background and therefore can be 
transplanted into C57Bl/6 immunocompetent hosts (unpublished). However, 
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based on our observations in Chapter 3, we reasoned that these cancer cells 
might lack potent neoantigens as they are derived from an autochthonous 
GEMM. Therefore, we engineered KPB6 cells that express a modified, non-
secreted form of the model antigen ovalbumin, fused to the fluorescent 
protein cherry (∆OVA-Cherry).  We then subcutaneously injected parental 
KPB6 cells, and in parallel, injected the OVA-derivative cells into the 
contralateral flank. We then treated tumour-bearing mice with MEK inhibitor, 
PD-L1 monoclonal antibody, the combination therapy, or vehicle and isotype 
control antibodies and measured tumour growth over time (Figure 5.8A). This 
treatment schedule was generally well tolerated, with little or no weight loss 
throughout the drug treatment course in female or male mice (Figure 5.8B).  
 
Although the KPB6 parental line responded to MEK inhibitor, there was no 
significant effect of anti-PD-L1 antibody therapy, perhaps reflecting the lack 
of antigens expressed by this cell line. The KPB6-OVA cells were 
spontaneously rejected after approximately nine days post-engraftment. 
Temporally, this indicates that this rejection was linked to a spontaneous 
adaptive immune response against the tumour. Unfortunately, these results 
preclude this system from testing ways to increase anti-tumour immunity, as 
any functional modulation of PD-L1 expression will likely be masked by this 
strong spontaneous response. 
 
Secondly, we tested the same treatment schedule on the Lewis lung 
carcinoma cell line LLC1 from C57Bl/6 strain background (Figure 5.8C). We 
chose to test this lung cancer cell line because there are reports that show 
LLC1 tumours are responsive to modulation of tumour-cell PD-L1 expression 
(Chen et al., 2014). Conversely, we did not find that anti-PD-L1 antibody 
treatment significantly controlled tumour progression; only MEK inhibitor 
reduced tumour growth and, moreover, PD-L1 did not combine strongly with 
MEK inhibitor (Figure 5.8C). 
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Next, we used the Kras-mutant, mouse colon carcinoma cell line CT26, 
based on its immunogenicity and sensitivity to anti-PD-L1 antibody therapy 
(Duraiswamy et al., 2013). For this cell line, we engineered CT26 cells to 
overexpress PD-L1 cDNA, and analysed the growth of several 
concentrations of parental or PD-L1-high derivative CT26 cells in syngeneic 
BALB/c mice (Figure 5.8D). In this preliminary experiment, we observed that 
PD-L1-high cells generally grew faster than parental cells engrafted at the 
same concentration, suggesting that this model may be amenable to test the 
functional role of the regulation of PD-L1 expression by TTP in vivo. 
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Figure 5.8 Surveying immunogenicity and PD-L1-dependence of 
syngeneic tumour models 
(A) Tumour growth curves following subcutaneous injection with 5 x105 
KPB6, and with 5 x105 KPB6∆OVA-Cherry lung cancer cells in the 
contralateral flank.  
(B) Weight of mice over treatment period. Mice with weights ranging from 17-
22 g are female, and from 25-33 are male. 
(C) Tumour growth curves following subcutaneous injection with 1 x105 LLC1 
lung cancer cells. 
(D) Tumour growth curves following subcutaneous injection with different 
concentrations of parental (Par.) and PD-L1∆3’UTR overexpressing CT26 
colon carcinoma cells.  
The start of therapy is indicated with arrows. MEK inhibitor GSK1120212 was 
given by oral gavage daily (3 mg/kg). Tumour dimensions were monitored 
with calipers. Anti-PD-L1 antibodies or isotype control antibodies were given 
i.p once weekly (10 mg/kg). 
 
We tested several approaches to experimentally manipulate TTP expression 
levels before tumour cell engraftment. Firstly, we used shRNAs against TTP. 
In conjunction, we also targeted PD-L1 with shRNAs in an attempt to reverse 
functional effects of PD-L1 upregulation following TTP knock-down. However, 
TTP knock-down levels were very poor for all of the shRNA sequences 
tested from the pLKO.1 clone collection (Figure 5.9A). Only shTTP#2 
significantly reduced TTP expression in 368T1 mouse lung cancer cells, and 
this was associated with a small but significant increase in PD-L1 expression. 
Similar results were obtained in CT26 cells for shTTP#2 and the best shRNA 
for PD-L1 in this system from the pLKO.1 set, but effects on target gene 
expression were still modest and there was an unanticipated upregulation of 
TTP expression with the shRNA against PD-L1 (Figure 5.9A). Attempts to 
knock-down TTP and PD-L1 with next-generation back-bone shRNA 
constructs from Transomics also failed (data not shown). Given these results, 
we attempted to overexpress TTP protein as an alternative approach. 
 
To this end, we constructed constitutive TTP expression vectors in pCDNA 
and pBABE backbones and introduced them stably into CT26 cells. However, 
we found that long-term selection of these cells failed to result in cells 
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expressing TTP at detectable levels, despite complete resistance to selection 
antibiotics (Figure 5.9B). We speculate that this effect may be due to the 
long-term negative effects of high levels of TTP overexpression, since TTP 
has been implicated in cell-autonomous tumour-suppressive roles 
(Rounbehler et al., 2012).  
 
 
 
Figure 5.9 Optimisation of the experimental modulation of TTP 
expression 
(A) qPCR analysis of PD-L1 and TTP expression in 368T1 and CT26 mouse 
cancer cells stably expressing the indicated shRNAs. Data are mean ± SEM 
from biological triplicates. 
(B) Western blotting analysis of Myc2-mTTP transgene expression in multiple 
CT26-derivative cell lines harbouring the indicated constructs. Transfection of 
pCDNA3 Myc-mTTP serves as a positive control. mTTP, mouse TTP. 
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To overcome the issues regarding long-term constitutive expression of TTP, 
we next generated a series of stable CT26 cell lines expressing Myc-tagged, 
mouse TTP under a tetracycline-inducible promoter (TTP tet-ON). TTP 
expression was induced upon addition of doxycycline in a dose-dependent 
manner (Figure 5.10A), resulting in decreased PD-L1 protein expression at 
the cell surface (Figure 5.10B). In addition, we engineered these CT26 cells 
to constitutively express either empty vector as a control (Empty), or mouse 
PD-L1 cDNA lacking the 3’UTR (PD-L1 ∆3’UTR). Overexpression of PD-L1 
∆3’UTR rendered total PD-L1 levels effectively insensitive to TTP induction 
(Figure 5.10B).  
 
 
 
Figure 5.10 3’UTR-dependent suppression of PD-L1 by TTP transgene 
induction 
(A) Western blotting analysis of stable CT26 cell lines expressing Myc-
tagged, mouse TTP under a tetracycline-inducible promoter (TTP tet-ON), 
and expressing either empty vector (Empty) or mouse PD-L1 cDNA lacking 
the 3’UTR (PD-L1 ∆3’UTR). Cells were treated with doxycycline (Dox., 0.1 
μg/ml or 1 μg/ml) or vehicle for 24 h before analysis. Arrow indicates Myc-
TTP. 
(B) Representative histograms from flow cytometry analysis of PD-L1 surface 
expression in CT26 stable cells lines in (A) after treatment with doxycycline 
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(Dox., 1 μg/ml) or vehicle for 48 h or 72 h. Data are representative of three 
independent experiments. 
 
Furthermore, we further verified the functional repression of PD-L1 
expression by also engineering CT26 cells expressing the full length PD-L1 
cDNA including the 3’UTR. As expected, these cells expressed lower levels 
of PD-L1 than the PD-L1∆3’UTR expressing cells (Figure 5.11).  
 
 
 
Figure 5.11 The endogenous 3’UTR of PD-L1 decreases expression of a 
PD-L1 transgene 
Representative histograms of flow cytometry analysis of PD-L1 expression in 
stable CT26 cell lines harbouring the indicated PD-L1 expression constructs. 
 
As expected, TTP transgene expression with doxycycline was associated 
with a decrease in PD-L1 mRNA stability, which was comparable to that 
mediated by MEK inhibition in this system (Figure 5.12A). Crucially, the 
growth rates of the stable cell lines in vitro did not significantly differ with the 
overexpression of PD-L1 ∆3’UTR cDNA (Figure 5.12B), or the induction of 
TTP transgene expression with doxycycline (Figure 5.12C). 
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Figure 5.12 TTP transgene induction reduces PD-L1 mRNA stability but 
does not reduce cell proliferation in vitro 
(A) Stability of murine PD-L1 mRNA measured by qPCR analysis. CT26 TTP 
(tetON) cells were pretreated with doxycycline (Dox.; 1 μg/ml) or vehicle for 
16 h and then MEK inhibitor (GSK1120212, trametinib; 25 nM) for an 
additional 30 min before actinomycin D (ActD; 10 μg/ml) was added. Data 
are normalized to time 0 h when ActD was added and represent the mean ± 
SEM of two independent experiments.  
(B) Confluency was measured using IncuCyte for CT26 parental and stable 
derivative cell lines. Data represent the mean ± SD of biological triplicates. 
(C) Confluency was measured using IncuCyte for CT26 stable derivative cell 
lines treated with the indicated concentrations of doxycycline or vehicle at t = 
0 h. Data represent the mean ± SD of biological triplicates and are 
representative of two independent experiments. 
 
Using these engineered CT26 cell lines, we performed subcutaneous 
transplantation experiments in mice and monitored tumour progression. In 
vivo, doxycycline treatment significantly reduced tumour growth in immune 
competent, syngeneic BALB/c mice (Figure 5.13A). Strikingly, the anti-
tumour effects mediated by doxycycline treatment were absent in 
immunocompromised nu/nu mice, implying an essential contribution from the 
adaptive immune system to this anti-tumour response (Figure 5.13A).  
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Tumour cells overexpressing PD-L1 ∆3’UTR grew significantly faster than the 
empty vector cells in BALB/c mice, but had no growth advantage in nu/nu 
mice. Moreover, expression of PD-L1 ∆3’UTR was able to rescue the growth 
inhibition mediated by doxycycline treatment in BALB/c mice, suggesting that 
suppression of tumour cell PD-L1 expression is an essential component of 
the anti-tumour effects mediated by TTP transgene induction. Consistently, 
tumours derived from mice treated with doxycycline had a greater degree of 
CD3+ lymphocyte infiltration than tumours from mice treated with vehicle, 
and this corresponding infiltration was abrogated in tumours derived from 
cells overexpressing PD-L1 ∆3’UTR (Figure 5.13B and Figure 5.13C ). 
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Figure 5.13 Restoration of tumour cell TTP enhances anti-tumour 
immunity 
(A) Tumour growth curves for the indicated CT26-derived cell lines 
subcutaneously transplanted into BALB/c mice (left panel, n = 8 per group) or 
nu/nu mice (right panel, n = 6 per group). Treatment with vehicle or 
doxycycline (Dox., 50 mg/kg) by oral gavage commenced from day three 
after tumour cell injection. Mean ± SEM. **P=0.0072, n.s., not significant; 
two-way ANOVA. 
(B) Histological analysis of subcutaneous tumours at the end-point from the 
experiment described in (A). Magnification is 4X. 
(C) Semi-automated quantification of CD3+ cell in the CT26 tumours as in (B) 
using NIS elements software. Five fields of view were quantified per mouse, 
with 5-6 mice per group. **P > 0.01. 
 
Collectively, these data highlight the functional importance of the regulation 
of PD-L1 expression by TTP in tumour progression, and demonstrate that 
this novel regulatory pathway may be exploited for the treatment of Ras-
mutant cancers. These findings support a model where tumour-specific 
suppression of TTP can foster PD-L1 upregulation, and ultimately, tumour 
immunoresistance. 
 
5.3 Conclusions 
 
In this chapter, we have verified the in vivo relevance of our findings on the 
regulation of PD-L1 expression in cancer by TTP and RAS. We have found 
that human lung tumours with high RAS pathway activity express increased 
levels of PD-L1 compared to low RAS activity tumours. It is the subject of on 
going work in our laboratory to further characterise the immune profile of RAS 
active lung tumours using bioinformatics approaches. 
 
We found that TTP expression is strikingly reduced in lung cancer versus 
normal lung tissue. We also confirmed that this downregulation of tumour 
TTP expression is evident in the KP mouse model. However, we did not find 
that TTP is significantly downregulated in human RAS active tumours 
Chapter 5. Results 3. Regulation of PD-L1 by RAS and TTP in vivo 
 184 
compared to RAS low activity tumours. This may be partly influenced by the 
complication of TTP’s ability to autoregulate expression of its own transcript 
through AREs in the 3’UTR of TTP (Tchen et al., 2004). Regardless, we 
speculate that remaining TTP protein in tumours is further suppressed by 
phosphorylation and inactivation in RAS active tumours.  
 
We note that acute activation of TTP expression can be achieved by growth 
factor stimulation of serum-starved cells; however, acute serum stimulation 
resulted in only a rapid and transient increase followed by a prolonged 
reduction in TTP expression. Concordantly, TTP expression was significantly 
suppressed in lung tumours from a genetically engineered mouse model of 
Kras-driven lung cancer, and in human patient lung adenocarcinoma 
samples relative to normal lung tissue. This is consistent with a tumour-
suppressive role for TTP in vivo (Rounbehler et al., 2012). We also noted an 
increase in time to first progression from surgery in lung adenocarcinoma 
patients with high TTP expression levels. Indeed, this may reflect 
suppression of immune evasion in these tumours.  
 
We reveal that TTP transgene expression can restrain tumour growth in an 
experimental CT26 tumour model, and demonstrate that this anti-tumour 
effect is predominantly non-cell autonomous, dependent on the adaptive 
immune system and suppression of tumour cell PD-L1 expression. We noted 
only minor reductions in tumour growth rates following TTP transgene 
induction in cells overexpressing PD-L1 ∆3’UTR, although these differences 
were not significant. TTP has been reported to have cell-autonomous tumour 
suppressive roles (Rounbehler et al., 2012) and other non-cell autonomous 
anti-tumour effects mediated by targeting VEGF and COX-2 mRNAs (Cha et 
al., 2011; Essafi-Benkhadir et al., 2007), which may contribute to some of 
these ostensibly PD-L1-independent effects, the magnitude of which are 
likely to be determined by the level of TTP overexpression in each system. 
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We also provide further evidence that targeting RAS effectors such as MEK 
and PI3K may elicit non-cell autonomous, anti-tumour effects in RAS-mutant 
tumours. Recently, the MEK inhibitor trametinib (used in this study) and PD-1 
blockade were shown to combine strongly in vivo in a syngeneic tumour 
model of Ras-mutant colon carcinoma (Liu et al., 2015). Therefore, our 
findings may inform the development of rational and effective combination 
therapies with immune checkpoint blockade in cancer. 
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6 Chapter 6. Discussion 
 
6.1 Immunogenicity of autochthonous GEMMs 
 
We reason that the KrasLSL-G12D/+; Trp53F/F mouse failed to recapitulate the 
positive clinical responses observed for anti-PD-L1 immunotherapy (Brahmer 
et al., 2012) due to the relatively poor immunogenicity of these murine 
tumours for the following reasons: (1) we administered the maximum dose of 
anti-PD-L1 antibody successfully used in patients in clinical trials (10 mg/kg; 
(Brahmer et al., 2012), (2) we confirmed that the therapeutic antibody was 
binding to the target lung tissue, and (3) we observed no significant 
difference in tumour growth dynamics in immunocompromised KrasLSL-G12D/+; 
Trp53F/F; Rag2-/- mice compared to their immunocompetent counterparts, 
suggesting that adaptive immunity plays little role in controlling tumour 
growth in KrasLSL-G12D/+; Trp53F/F mice. Concordantly, several recent studies 
demonstrate that, in the absence of carcinogens from cigarette smoke, lung 
tumours from GEMMs have a dramatically lower rate of point mutations in 
their genome than a smoker’s lung adenocarcinoma (McFadden et al., 
2014b); (Westcott et al., 2015a); (Rizvi et al., 2015a); Julian Downward’s 
laboratory, unpublished data). However, we cannot exclude possible 
immunosuppressive mechanisms from contributing to primary anti-PD-
L1/anti-CTLA-4 antibody resistance. Still, our findings together with published 
reports on the tumour somatic mutation rate in GEMMs of lung cancer 
indicate that there is a need for GEMMs that more closely mimic the mutation 
rate, and thus immunogenicity, of human NSCLC. 
 
Contrary to our results, other mouse models of KP-driven cancer have been 
shown to respond to immunotherapies. For example the LSL-KrasG12D/+; 
LSL-Trp53 R172H/+; Pdx1-Cre (KPC) model of pancreatic cancer has been 
shown to respond to a p110δ inhibitor, affecting Treg function (Ali et al., 
2014). However, the authors do not report on decreases in tumour volume 
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and we note that there are now concerns about the authenticity of this data 
(Ali et al., 2016). In addition, the KPC model has been demonstrated to 
respond to anti-PD-1 antibody treatment, but only in combination with a 
CXCR4 inhibitor, which promotes T cell infiltration into the pancreatic tumour 
(Feig et al., 2013). This inhibitor of the CXCR4 chemokine receptor partially 
reverses immunosuppression mediated by tumour-associated fibroblasts in 
the stroma of pancreatic cancers in this model. Also, Vonderheide and 
colleagues showed that KPC mouse tumours that were normally refractory to 
anti-PD-1 and anti-CTLA-4 combination therapy were rendered sensitive only 
when ICB antibodies were combined as a five-drug combination, with nab-
paclitaxel, gemcitabine and an agonistic anti-CD40 antibody (Winograd et al., 
2015). In line with our data, the authors report high levels of PD-L1 
upregulation on pancreatic tumour cells, a phenomenon that is not influenced 
by T cell depletion; this implies a degree of cell-intrinsic PD-L1 upregulation 
in RAS-mutant pancreatic tumour cells. Furthermore, CXCR2 inhibition has 
been shown to sensitise KPC pancreatic tumours to anti-PD-1 therapy by 
reversing immunosuppression by neutrophils and myeloid-derived 
suppressor cells in the tumour microenvironment and increasing T cell 
infiltration into tumours (Steele et al., 2016). Strikingly, inhibition of CXCR2 
signalling alone with the small molecule inhibitor AZ13381758 was sufficient 
to reduce the incidence of metastasis in the KPC model. Finally, the KP –
OVA lung cancer model ostensibly responded to anti-PD-1 and CTLA-4 ICB, 
but only when combined with the ICD-inducer oxaliplatin and the Treg-
depleting chemotherapy cyclophosphamide (Pfirschke et al., 2016). 
However, we note that the anti-tumour effects reported by Pfirschke et al 
mediated by the combination of oxaliplatin, cyclophosphamide and ICB are 
modest and only slightly better than chemotherapy alone. In addition, many 
of their analyses of anti-tumour responses were based on measurement of 
lung weight, which is a crude read-out of tumour-burden and easily 
confounded by immune infiltrates and other issues relating to the dynamic 
cellularity of the diseased lung. Moreover, this method does not give 
information on the behaviour of single tumour lesions over time.  
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In a study using a mouse cell line derived from a GEMM of melanoma, 
syngeneically engrafted tumours were essentially resistant to anti-PD-1 
therapy and grew similarly in immunodeficient mice (Zelenay et al., 2015). 
However, when COX-mediated production of immunosuppressive 
prostaglandins was disrupted in tumour cells, these tumours responded to 
PD-1 antibody therapy. This cell line is unlikely to harbour many potent neo-
antigens, although there are examples of tumours with lower mutational 
burden responding to ICB (Hugo et al., 2016). Finally, in a mouse model of 
BRAF-driven melanoma, tumours were resistant to PD-L1 ICB until CD103+ 
DC recruitment and expansion was initiated with FLT3L and poly(I:C) 
treatment (Salmon et al., 2016b). 
 
There is clearly a recurrent theme in the reports outlined above: RAS/RAF-
driven GEMMs of cancer have primary resistance to ICB treatments in 
isolation, and require additional therapies to remodel the tumour-
microenvironment in order to be efficacious. Although our data points 
towards unrealistically low levels of lung tumour immunogenicity, it remains 
possible that tumour-associated antigens are present that could facilitate 
tumour rejection if the immune-suppressive microenvironment is perturbed. 
One potentially important difference in the KPC mouse model is the 
expression of the mutant form of Trp53 (in contrast to Trp53 deletion, in our 
KP lung model), which could potentially act as a tumour neo-antigen. One 
might argue that these poorly immunogenic models could be used to model 
tumours lacking strong neo-antigens found in the clinic. 
 
By generating lung tumour cell lines from immunocompetent Rag1+/- or 
immunodeficient Rag1-/- hosts, we were able to show that most cell lines 
were not classically “immunoeditied” in vivo, that is, they grew comparably 
well when transplanted into wild-type or Rag1-/- recipient mice. However, we 
did identify one cell line that behaved as if it elicited a strong anti-tumour 
immune response. Mice that rejected this KPRag1-/- c cell line developed 
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immunological memory and could reject these tumour cells upon re-
challenge. Although further investigation is required to determine the nature 
of the tumour-rejection antigen, these are the first data to suggest that there 
are immunogenic clones in the tumours from this mouse model that could be 
selected against by the adaptive immune system. Theoretically, very few 
neo-antigens are actually necessary to evoke an immune response; 
regarding tumour neo-antigens, successful anti-tumour immunity seems to be 
more reliant on quality than quantity. For example, Ribas, Lo and colleagues 
found that tumour mutational burden alone could not reliably predict response 
to PD-1 therapy in melanoma patients, as several tumours with low 
mutational burden still responded (Hugo et al., 2016). Importantly, the 
comparable tumour progression we observed in KP;Rag2+/- and KP;Rag2-/- 
mice suggests that any immunoediting in this model is likely to be infrequent 
and has minimal impact on long-term tumour burden and latency of the 
disease. 
 
Several groups have introduced foreign antigens into GEMMs of cancer to 
more easily study host-tumour interactions, notably OVA (DuPage and Jacks, 
2013). The development of tetramer reagents to follow antigen specific T cell 
responses to tumours with known model antigens is a powerful advantage of 
this approach. Such studies have elucidated interesting, tissue-specific 
modes of immunosuppression in vivo. For example, the Tyler Jacks 
laboratory recently showed that Tregs play a significant role in supressing 
anti-tumour immune responses against a modified KP model, where tumour 
cells express OVA antigens (Joshi et al., 2015b). As mentioned in the 
Introduction, the evolution of a polyclonal tumour is likely to differ significantly 
from this monoclonal tumour model expressing potent foreign antigens. 
 
Using a spontaneous GEMM of NSCLC without the expression of exogenous 
tumour antigens, we found that numbers of APCs were significantly elevated 
in tumour-bearing lungs, but not healthy lungs, of mice treated with Carb/Tax 
chemotherapy. To delineate whether the increase in APC numbers is due to 
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local expansion of resident APCs or influx from neighbouring lymphoid 
structures, one could perform an adoptive transfer experiment using labelled 
APCs before treatment. Although increases in APC numbers in the lung did 
not lead to a detectable anti-tumour adaptive immune response, it would be 
interesting to examine the consequence of these effects in a more 
immunogenic mouse tumour model. Our laboratory is currently developing 
ways to increase tumour mutation rate and thus neo-antigen burden, for 
example, by introducing carcinogens. Urethane is a carcinogen found in 
tobacco smoke and can initiate lung tumours harbouring driving mutations in 
Kras as well as an average of 185 single nucleotide polymorphisms (SNVs) 
(Westcott et al., 2015a). Lung tumours from the KrasLA2 GEMM on the other 
hand (where the latent oncogenic Kras allele is spontaneously activated by 
recombination), only carried an average of 47 SNVs. We predict that mouse 
models of lung cancer initiated with urethane or MNU will be more 
immunogenic, although this remains to be demonstrated. Importantly, the 
carcinogen mouse models will overcome the requirement for tumour initiation 
by lentiviruses or adenoviruses. Viral infection and transient expression of the 
bacterial Cre-recombinase at the pre-neoplastic stage may have profound 
implications on anti-tumour immunity, and is unrepresentative of virus-
independent tumorigenesis in humans. A disadvantage of both tumour 
models (and perhaps a critique of mouse models of cancer in general) is that 
tumour progression is very rapid and occurs within months. This does not 
recapitulate tumour development in humans. In fact, there is evidence that 
lung cancer progression can take decades before becoming clinically overt 
(de Bruin et al., 2014). The accrual of other important genetic changes, and 
the co-evolution of host and tumour over this time-scale is not feasible in 
mouse models of cancer. 
  
Chapter 6. Discussion 
 191 
 
6.2 Regulation of PD-L1 expression by TTP and RAS 
 
In this report, we uncover an oncogenic KRAS-driven signalling network 
capable of driving cell intrinsic tumour PD-L1 expression, implying that this 
oncogenic program may uncouple tumour PD-L1 expression and the 
immunogenicity of the tumour. RAS controls PD-L1 mRNA expression partly 
through an unanticipated post-transcriptional mechanism, mediated by the 
AU-rich element binding protein TTP (Figure 6.1).  
 
We discovered that PD-L1 is encoded by an unstable transcript, from which 
gene expression can be controlled through functional AU-rich elements in the 
3’UTR of the mRNA. Immunomodulatory molecules such as cytokines are 
among the most frequently controlled genes by ARE-mediated decay, as 
their expression often requires rapid and dynamic regulation (Anderson, 
2008). For example, CD28 ligation on T cells results in the stabilisation of 
several ARE-containing cytokine mRNAs (Lindstein et al., 1989). Since PD-
L1 is upregulated on T cells following CD28/CD3 ligation and MAPK 
activation (Yamazaki et al., 2002), our results suggest that PD-L1 may also 
be upregulated through mRNA stabilisation in activated T cells.  
 
We show that endogenous levels of TTP and KSRP bind to the unstable PD-
L1 transcript. There are reports that these ARE-BPs work together to 
destabilise target transcripts (Linker et al., 2005), but we did not observe 
obvious signs of cooperation when we over-expressed TTP and KSRP 
together. However, there are limitations to experiments involving 
overexpression; for example, the maximum repression of PD-L1 mRNA or 
PD-L1 3’UTR luciferase reporter expression might have already been 
reached with the overexpression of TTP or KSRP alone, essentially leading 
to saturation of the mRNA degradation machinery.  
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Our finding that TTP binds to the 3’UTR of PD-L1 potentially explains why the 
3’UTR of PD-L1 is recurrently lost in cancer, including NSCLC (Kataoka et 
al., 2016). Here, we show that complete loss of PD-L1 3’UTR increases PD-
L1 expression (as in (Kataoka et al., 2016)) and furthermore, mutation of 
AREs increases expression of a PD-L1 3’UTR luciferase reporter. Kataoka 
and colleagues reveal that PD-L1 3’UTR loss is found in many different 
cancers, perhaps supporting the functional relevance of our findings across 
multiple tissue types and malignancies. We speculate that aberrant 
regulation of TTP is a more common mechanism of PD-L1 dysregulation, 
although presumably complete loss of the 3’UTR would lead to a more 
profound increase in PD-L1 expression, as miRNA-mediated regulation is 
also lost. Modulating TTP function using small molecule inhibitors of the 
appropriate pathways may be a therapeutic option in the majority of 
immunogenic cancers that have intact PD-L1 3’UTRs (Figure 6.1). 
 
Recently, several studies using RNA individual-nucleotide resolution 
crosslinking and immunoprecipitation (iCLIP) approaches have provided 
useful insights into the mRNA targets and binding sites of TTP and TTP 
family-members. In a comprehensive analysis of TTP binding partners in 
LPS-stimulated mouse macrophages, TTP was found to bind to PD-L1 
mRNA at AREs in the 3’UTR (Sedlyarov et al., 2016). Using genome-wide 
RNA sequencing, Sedlyarov and colleagues revealed that PD-L1 mRNA was 
more stable and more potently induced in response to LPS in TTP KO 
macrophages compared with wild-type macrophages. Using a similar 
approach, work on ARE-BP involvement in mouse B-cell development 
revealed that PD-L1 mRNA was among the many target transcripts of 
Zfp36l1, and moreover, PD-L1 mRNA expression was elevated in Zfp36l1 
and Zfp36l2 double-knockout B-cells (Hodson et al., 2010). These data imply 
a degree of redundancy within the TTP family. In lung cancer cells, we 
showed that siRNA-mediated knock-down of ZFP36L1 or ZFP36L2 did not 
significantly increase PD-L1 expression, perhaps reflecting tissue-specific 
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differences, and the obvious limitations of gene silencing by RNAi as 
compared with full genetic deletion.  
 
 
 
Figure 6.1 Regulation of PD-L1 mRNA stability through RAS and TTP 
signaling networks 
Proposed molecular model. RAS-mediated upregulation of PD-L1 is 
dependent on both MEK and PI3K effector pathways. MEK signalling 
stabilises the labile transcript, and PI3K-AKT signalling predominantly acts 
via upregulating translation of the mRNA (Parsa et al., 2007). PD-L1 mRNA 
is targeted by AUBPs including TTP and KSRP via AREs in the 3’UTR. 
Chronic oncogenic RAS-MEK signalling downregulates TTP activity, resulting 
in increased expression of PD-L1 in tumour cells. Signalling nodes are 
highlighted that may be targeted with drugs to modulate anti-tumour 
immunity. S52 and S178 represent MK2 target sites and numbering 
corresponds to mouse TTP. OA, Okadaic acid. 
 
Mechanistically, TTP expression is suppressed in human and mouse lung 
cancer. Remaining TTP function in RAS-mutant cancer cells is further 
downregulated by phosphorylation (Figure 6.2). TTP is phosphorylated by 
Chapter 6. Discussion 
 194 
ERK activation (Taylor et al., 1995) and, importantly, by MK2, at key 
inhibitory sites. Although mutation of ERK-consensus sites had no 
discernable effect on TTP function alone, it is possible that MK2 and ERK 
function together to strongly suppress TTP activity (Brook et al., 2006). In 
addition, RSK downstream of ERK may play a significant role in reducing 
TTP binding to deadenylase machinery, as this has been demonstrated for 
ZFP36L1 and ZFP36L2 (Adachi et al., 2014). This is concordant with our 
data showing that the RSK inhibitor BI-D1870 reduced PD-L1 mRNA 
expression in lung cancer cells. In vitro kinase assays initially demonstrated 
that S52 and S178 MK2 consensus sites are phosphorylated by active MK2 
protein (Chrestensen et al., 2004). Since these in vitro kinases assays do not 
formerly exclude the involvement of other regulators, it is possible that S52 
and S178 are also phosphorylated by other kinases activated downstream of 
RAS. Indeed, RSK has a similar phosphorylation consensus motif, requiring 
an arginine residue at the -3 position and -5 position (Cargnello and Roux, 
2012). Indeed, there are instances where AGC kinases such as AKT, S6K 
and RSK share phosphosite specificity (for example, glycogen synthase 
kinase 3) (Pearce et al., 2010). Nonetheless, our data strongly implicate a 
ROS-p38-MK2 signalling cascade in the inactivation of TTP because: (1) 
ROS promoted PD-L1 expression downstream of RAS, (2) ∆MEKK3-ER 
activity specifically elevated PD-L1 levels, and (3) MK2 inhibitors 
substantially reverse PD-L1 induction by RAS.  
 
Signalling nodes that regulate TTP activity that could be potential therapeutic 
targets to treat cancer are highlighted in Figure 6.1. Although p38 and MK2 
inhibitors are being developed for the treatment of inflammatory disorders 
such as arthritis, the use of these drugs in oncology is questionable, as the 
p38 pathway has predominantly been associated with growth arrest and 
tumour suppression (Xu et al., 2014b). There are some reports that p38 can 
promote tumour progression, but this seems to be context-dependent 
(Yoshizuka et al., 2012). Specifically, p38 activation by oncogenic signalling 
has been suggested to be initially tumour-suppressive by initiating growth 
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arrest, but once this stage has been overcome by the acquisition of additional 
oncogenic or epigenetic changes, p38 signalling can have a tumour-
promoting role in epithelial tumours by promoting angiogenesis (Yoshizuka et 
al., 2012). Pharmacological targeting of kinases or phosphatases regulating 
TTP in order to increase TTP activity may also affect the senescence 
associated secretory phenotype (SASP). SASP induced by chronic RAS 
activation was shown to depend on MK2-mediated phosphorylation and 
inactivation of ZFP36L1, which targets several SASP mRNAs under steady-
state conditions (Herranz et al., 2015). Thus, the regulatory pathway we 
describe in this thesis may also be pertinent to the biology of ageing in 
mammals. 
 
MEK inhibition may be a suitable alternative to directly inhibiting p38 or MK2 
signalling. MEK inhibitors have been shown to have clinical activity in NSCLC 
as monotherapies, but have also been used in preclinical studies in mice to 
augment anti-PD-1 responses (Ebert et al., 2016; Liu et al., 2015). Initially, 
there were concerns that inhibition of RAS effector pathways may profoundly 
compromise T cell activity as RAS is involved signalling through the TCR 
(Downward et al., 1990a). Crucially, MEK or RAF inhibition only transiently 
decreased T cell proliferation capacity in vitro (Liu et al., 2015). Moreover, in 
vivo, the specific MEK inhibitor trametinib was shown to combine with anti-
PD-1 antibody in a CT26 syngeneic tumour model, and this effect was 
associated with increased lymphocyte infiltration into regressing tumours (Liu 
et al., 2015). Mechanistically, although MEK inhibition reduces the efficiency 
of T cell priming, it spares chronically activated anti-tumour T cells from TCR 
activation-induced apoptosis, thus preserving a larger pool of anti-tumour T 
cells that can be subsequently activated with anti-PD-1 therapy (Ebert et al., 
2016). Our data also support the use of MEK inhibitors with PD-1 blockade in 
NSCLC. MEK inhibition is likely to induce tumour-cell death, which will help 
activate DCs and prime T cell responses. Secondly, assuming incomplete 
PD-1/PD-L1 pathway inhibition, decreases in tumour-cell PD-L1 expression 
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by inhibition of MEK will likely cause more profound activation of anti-tumour 
immunity.  
 
Comprehensive RNA sequencing analysis of melanoma patients receiving 
PD-1 ICB therapy revealed that intrinsic resistance to pembrolizumab or 
nivolumab was associated with a transcriptional programme analogous to 
that observed for melanomas following MAPK inhibitor treatment (Hugo et al., 
2016). Although, PD-L1 expression did not significantly correlate with anti-
PD-1 therapy response in this study, Hugo and colleagues’ PD-1 resistance 
signature has several corollaries regarding RAS regulation of PD-L1 in ICB 
response: firstly, it provides further evidence that tumours with highly active 
RAS signalling (i.e. the opposite of a MAPK inhibitor signature) may be more 
susceptible to PD-1 blockade. Secondly, since resistance to PD-1 is closely 
associated with a MAPK inhibitor-treated gene expression signature, it 
implies that dual resistance to both of these therapeutic agents may be easily 
achievable. Little is currently known about clinical resistance to 
immunotherapies, but Hugo et al. provide an important cautionary note for 
the clinical trials combining PD-1 and MEK inhibitors that are currently 
underway.  
 
One ambiguity in the mechanism described in this thesis relates to how PD-
L1 expression responds to MEK inhibition. Although it is clear from our data 
that RAS increases PD-L1 expression, and this process is expressly 
dependent on MEK activity, we have discovered that the level of PD-L1 
expression in response to MEK inhibition is more nuanced in some KRAS-
mutant cell lines. For example, in CT26 cells, PD-L1 mRNA expression 
initially falls rapidly following MEK inhibition at 2 h, and then recovers to 
baseline levels after 24 h (data not shown), suggesting that there is a 
compensatory signalling mechanism that leads to eventual recovery of PD-L1 
expression. In addition, from a panel of KRAS mutant human colon cancer 
cell lines, only 2/6 cell lines had reduced PD-L1 protein expression following 
24 of trametinib treatment, whereas others had unchanged levels of PD-L1 or 
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increased PD-L1 expression at 48 h. Moreover, a recent publication showed 
that prolonged exposure to trametinib at high doses could lead to increased 
PD-L1 expression in breast cancer cells (Loi et al., 2016). These data 
suggest that there may be some tissue specific and cell line specific 
differences governing the response of PD-L1 expression to MEK inhibitors. 
We speculate that chronic exposure to MEK inhibition in MEK-dependent 
cancer cells may trigger the activation of stress signalling, such as p38 
MAPK pathway stimulation and other pathways relating to apoptosis (Berra 
et al., 1998), especially at later time-points. Moreover, several MEK 
inhibitors, including trametinib, have been shown to increase STAT3 
phosphorylation in cancer cells (Lee et al., 2014; Zhao et al., 2015), which 
would then lead to potent transcriptional upregulation of PD-L1. This 
mechanism would also explain the biphasic response of PD-L1 expression in 
CT26 cells treated with trametinib. Although the mechanism responsible for 
STAT3 activation following MEK inhibition is unclear at this time, it is likely 
that it involves compensatory feedback to receptor tyrosine kinases and c-
Src activation (Girotti et al., 2013), the activation of JAK-STAT signalling 
through autocrine signalling (Lee et al., 2014), or a combination of these 
pathways. We are currently testing whether combining inhibitors of STAT 
pathway activation with MEK inhibitors can profoundly reduce PD-L1 
expression in cell lines that do not response to MEK inhibition alone. Further 
understanding of the molecular mechanisms behind the susceptibility to MEK 
inhibitors and immunotherapies should lead to insights into how these 
inhibitors can be successfully scheduled to maximise response and minimise 
drug resistance in lung and colon cancers.  
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Figure 6.2 Post-translational regulation of TTP activity in cancer 
Proposed molecular model. Oncogenic RAS activity leads to 
hyperphosphorylation, whereas PP2A activity promotes hypophosphorylation 
of TTP (Bourcier et al., 2011; Deleault et al., 2008; Essafi-Benkhadir et al., 
2007; Hardle et al., 2015; Rahman et al., 2015; Sun et al., 2007), constituting 
a rapid switch controlling TTP activity. Low TTP expression and activity in 
tumour cells represents a permissive context for PD-L1 expression and 
immune evasion. 
 
Using bioinformatics analysis, we discovered that PD-L1 expression was 
significantly higher in lung tumours with gene expression characteristics 
indicative of high RAS activity. This was not solely attributable to preferential 
T cell infiltration or an inflammatory phenotype as indicated by only modest 
changes in mRNA expression of CD3 or IFN-γ in RAS pathway active 
tumours. Therefore, RAS active human tumours may evade immune 
destruction partly by upregulating PD-L1. This poses the question: do 
patients with RAS mutant/active lung cancer have improved response rates 
to anti-PD-L1 or anti-PD-1 therapy? Although further large-scale trials of PD-
1 pathway-directed immunotherapies in lung cancer are required to 
definitively answer this question, there are early indications that KRAS-
mutant NSCLC patients respond better than KRAS-wild-type patients to 
nivolumab (Borghaei et al., 2015). It is worth noting that KRAS-mutant 
cancers are often associated with a history of smoking, and can therefore 
harbour hundreds of non-synonymous mutations (de Bruin et al., 2014; 
Matsushita et al., 2012). We must also consider the scenario where cell-
intrinsic KRAS signalling drives tumour PD-L1 expression in the absence of 
anti-tumour antigen expression. As immunotherapy success depends on 
tumour antigens (Gubin et al., 2014), ICB will fail in this setting. 
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We discovered that restoration of TTP expression could promote anti-tumour 
immunity and stall tumour growth in vivo. Although most of our work focussed 
on lung cancer we chose the CT26 colon carcinoma cell line as it is highly 
immunogenic and responds to PD-L1 antibody therapy and PD-L1 
expression modulation. There are very few cell lines available that are 
amenable to syngeneic cell transplantation experiments to test anti-tumour 
immune responses. The most common publically available cell lines used in 
publications pertaining to cancer immunology are MC38 and CT26 for 
modelling colon carcinoma, the EL4 and E.G7-OVA lymphoma cell line pair, 
4T1 and EMT-6 for breast cancer, the mildly immunogenic B16 melanoma 
cell line and the LLC1 Lewis lung carcinoma line for lung. However, we found 
that LLC1 did not show significant responses to anti-PD-L1 antibody therapy 
in vivo, and KPB6 tumour cells engineered to express the model antigen 
OVA proved too immunogenic in untreated mice. Therefore, once fully 
characterised, the immunogenic KPR c-/- cell line that we have generated, 
and the paired escape variant that has been passaged through an 
immunocompetent host, may serve as useful tools for the study anti-tumour 
immune responses in lung cancer. A possible advantage of using an 
immunogenic cell line derived from the KP GEMM rather than a carcinogen-
induced tumour is that the genetic driving events in this cell line are already 
well defined.  
 
Our in vivo experiments in Chapter 5 suggest that activation of TTP activity in 
tumour cells may have therapeutic potential in tumours wild-type for PD-L1 
3’UTR. This is supported by the observation that TTP expression is 
massively suppressed in many tumour types, especially in cancers with Myc 
involvement (Rounbehler et al., 2012). Interestingly, withdrawal of Myc 
expression from tumours addicted to oncogenic Myc has been associated 
with tumour microenvironment remodelling and tumour regression involving 
poorly defined immune cell involvement (Casey et al., 2016a)(Gerard Evan, 
unpublished). Although Myc has been involved in directly promoting PD-L1 
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transcription (Casey et al., 2016a), we speculate that this effect may also rely 
on de-repression of TTP expression and PD-L1 downregulation through 
decreasing PD-L1 mRNA stability. This would constitute a novel, non-cell 
autonomous mechanism of oncogene cooperation between RAS and Myc. 
However, our results from overexpressing c-Myc in NL-20 lung cells did not 
indicate Myc-driven expression of PD-L1 mRNA. 
 
6.3 Concluding remarks 
 
Immune checkpoint blockade already holds great promise for curing some 
cancers, but their maximum therapeutic potential is only just starting to be 
explored. Notably, approaches focussed on activating anti-tumour immune 
responses to clonal, non-essential passenger mutations may require further 
personalised peptide or RNA vaccines to achieve complete regressions 
(Schumacher and Schreiber, 2015). Tantalisingly, the unexpected discovery 
of tumour-infiltrating T cells specific for KrasG12D in a patient with 
gastrointestinal cancer suggests that common oncogenes can be 
immunogenic (Tran et al., 2015). Re-invigorating immune responses against 
essential driver mutations is likely to lead to more profound and durable 
tumour regressions, and even cures. Deeper understanding of how 
oncogenes such as RAS can manipulate the tumour-microenvironment, and 
how to reverse such signalling will undoubtedly play a central role in 
improving immunotherapies and patient stratification. 
 
Although mouse models of cancer are often key to understanding therapy 
responses, we show that the KP GEMM of lung cancer is refractory to ICB 
therapies targeting PD-L1 and CTLA-4. The intrinsically low tumour somatic 
mutation rate in GEMMs of cancer make them inappropriate for modelling 
smoker’s lung cancer, but perhaps well suited to model cancers with low 
somatic mutation rates such as glioblastoma and pancreatic cancer 
(Alexandrov et al., 2013); cancers that are yet to show clinical responses to 
ICB. Cancer immunologists may be forced to step back in time and revisit 
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early carcinogen induced models and move away from sophisticated 
conditional genetic animal models in order to account for the mutational 
complexity and heterogeneity observed in some human cancers. 
 
Inevitably, personalised and combinatorial treatment approaches including 
targeted therapies will have to be adopted for patients with poorly 
immunogenic tumours. In this thesis, we show that RAS can drive 
immunoresistance through PD-L1 upregulation, involving the modulation of 
TTP activity and increased PD-L1 mRNA stability. We hope that the 
mechanism of PD-L1 regulation described will inform the interpretation of PD-
L1 expression as a biomarker for treatment response in lung cancer, and 
eventually aid therapeutic advances against RAS-driven cancers. 
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